{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import numpy as np"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "from nltk import tokenize\n",
    "from operator import itemgetter\n",
    "import math\n",
    "from tqdm import tqdm\n",
    "import os\n",
    "import nltk\n",
    "from nltk.corpus import stopwords\n",
    "from nltk.tokenize import word_tokenize \n",
    "stop_words = set(stopwords.words('english'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['tdm1_metadf2.csv',\n",
       " 'genome wide association study_metadf2.csv',\n",
       " 'progression free survival_metadf2.csv',\n",
       " 'hormone therapy_metadf2.csv',\n",
       " 'overall survival_metadf2.csv',\n",
       " 'disease free survival_metadf2.csv',\n",
       " 'radiation_metadf2.csv',\n",
       " 'chemotherapy_metadf2.csv',\n",
       " 'neratinib_metadf2.csv',\n",
       " 'pertuzumab_metadf2.csv',\n",
       " 'pathologic complete response_metadf2.csv',\n",
       " 'surgery_metadf2.csv',\n",
       " 'polymorphism_metadf2.csv',\n",
       " 'neoadjuvant_metadf2.csv',\n",
       " 'adjuvant_metadf2.csv',\n",
       " 'trastuzumab_metadf2.csv',\n",
       " 'polygenic risk score_metadf2.csv',\n",
       " 'Breast Cancer_metadf2.csv']"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "kk = os.listdir(\"/home/amansinha/extractpubmed/papers/key_meta_all/\")\n",
    "kk"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 66,
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_keywords(doc, k):\n",
    "    total_words = doc.split()\n",
    "    total_word_length = len(total_words)\n",
    "    #print(total_word_length)\n",
    "    \n",
    "    total_sentences = tokenize.sent_tokenize(doc)\n",
    "    total_sent_len = len(total_sentences)\n",
    "    #print(total_sent_len)\n",
    "    \n",
    "    tf_score = {}\n",
    "    for each_word in total_words:\n",
    "        each_word = each_word.replace('.', '')\n",
    "        if each_word in tf_score:\n",
    "            tf_score[each_word] += 1\n",
    "        else:\n",
    "            tf_score[each_word] = 1\n",
    "            \n",
    "    tf_score.update((x, y/int(total_word_length)) for x,y in tf_score.items())\n",
    "    #print(tf_score)\n",
    "    \n",
    "    def check_sent(word, sentences): \n",
    "        final = [all([w in x for w in word]) for x in sentences] \n",
    "        sent_len = [sentences[i] for i in range(0, len(final)) if final[i]]\n",
    "        return int(len(sent_len))\n",
    "    \n",
    "    idf_score = {}\n",
    "    for each_word in total_words:\n",
    "        each_word = each_word.replace('.','')\n",
    "        if each_word not in stop_words:\n",
    "            if each_word in idf_score:\n",
    "                idf_score[each_word] = check_sent(each_word, total_sentences)\n",
    "            else:\n",
    "                idf_score[each_word] = 1\n",
    "\n",
    "    # Performing a log and divide\n",
    "    idf_score.update((x, math.log(int(total_sent_len)/y)) for x, y in idf_score.items())\n",
    "    #print(idf_score)\n",
    "    \n",
    "    tf_idf_score = {key: tf_score[key] * idf_score.get(key, 0) for key in tf_score.keys()}\n",
    "    #print(tf_idf_score)\n",
    "    \n",
    "    result = dict(sorted(tf_idf_score.items(), key = itemgetter(1), reverse = True)[:k]) \n",
    "    return result, tf_idf_score\n",
    "    \n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>pubmed_id</th>\n",
       "      <th>title</th>\n",
       "      <th>keywords</th>\n",
       "      <th>publication_date</th>\n",
       "      <th>abstract</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>33479246</td>\n",
       "      <td>Fibroblast growth factor receptor facilitates ...</td>\n",
       "      <td>[]</td>\n",
       "      <td>2021-01-23</td>\n",
       "      <td>Trastuzumab-emtansine (T-DM1) is an antibody-d...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>33259892</td>\n",
       "      <td>Third-line treatment of HER2-positive advanced...</td>\n",
       "      <td>[Breast cancer, HER2\\xa0+, Third line, Trastuz...</td>\n",
       "      <td>2020-12-02</td>\n",
       "      <td>Human epidermal growth factor receptor 2 posit...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>33238772</td>\n",
       "      <td>Margetuximab for the treatment of HER2-positiv...</td>\n",
       "      <td>[Margetuximab, breast cancer, her2, mgah22, so...</td>\n",
       "      <td>2020-11-27</td>\n",
       "      <td>No specific standard treatment is currently re...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>32737515</td>\n",
       "      <td>Post-neoadjuvant treatment with capecitabine a...</td>\n",
       "      <td>[Breast cancer, Capecitabine, Radiochemotherap...</td>\n",
       "      <td>2020-08-02</td>\n",
       "      <td>Following neoadjuvant chemotherapy for breast ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>32236828</td>\n",
       "      <td>Comparison of outcomes in a population-based c...</td>\n",
       "      <td>[Cardiotoxicity, Heart failure, Overall surviv...</td>\n",
       "      <td>2020-04-03</td>\n",
       "      <td>Little data exist for comparing cardiac safety...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>32192389</td>\n",
       "      <td>Safety of trastuzumab after trastuzumab emtans...</td>\n",
       "      <td>[Breast cancer, HER2, nodular regenerative hyp...</td>\n",
       "      <td>2020-03-21</td>\n",
       "      <td>Trastuzumab emtansine is an antibody-drug conj...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>32104023</td>\n",
       "      <td>Analysis of the Cost-Effectiveness of Liquid B...</td>\n",
       "      <td>[biomarkers, breast cancer, cost-effectiveness...</td>\n",
       "      <td>2020-02-28</td>\n",
       "      <td>Breast cancer is highly prevalent worldwide an...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>31949426</td>\n",
       "      <td>Recent advances and optimal management of huma...</td>\n",
       "      <td>[Breast cancer, TDM1, neratinib, pertuzumab, t...</td>\n",
       "      <td>2020-01-18</td>\n",
       "      <td>With the introduction of anthracycline-based r...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>31781874</td>\n",
       "      <td>When to Add Additional Anti-HER2 Therapy to Ad...</td>\n",
       "      <td>[Adjuvant, Early, HER2, Neoadjuvant, Neratinib...</td>\n",
       "      <td>2019-11-30</td>\n",
       "      <td>One year of trastuzumab dramatically improves ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>31449983</td>\n",
       "      <td>The evolving role of trastuzumab emtansine (T-...</td>\n",
       "      <td>[Brain metastases, Breast cancer, HER2, Trastu...</td>\n",
       "      <td>2019-08-27</td>\n",
       "      <td>Approximately 30-50% of advanced human epiderm...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>31230485</td>\n",
       "      <td>Investigational drugs in early stage clinical ...</td>\n",
       "      <td>[ADCs, HER2+ breast cancer, TKIs, bispecific a...</td>\n",
       "      <td>2019-06-25</td>\n",
       "      <td>Despite improvements in the management of HER2...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>30957209</td>\n",
       "      <td>Systemic Therapy of Central Nervous System Met...</td>\n",
       "      <td>[Brain metastases, Breast cancer, Chemotherapy...</td>\n",
       "      <td>2019-04-09</td>\n",
       "      <td>Historically, systemic treatment options for p...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>30833989</td>\n",
       "      <td>Post-neoadjuvant treatment and the management ...</td>\n",
       "      <td>[breast cancer, chemotherapy, pathologic compl...</td>\n",
       "      <td>2019-03-06</td>\n",
       "      <td>Achieving a pathologic complete response after...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>30595754</td>\n",
       "      <td>ASCO 2018: highlights in HER2-positive metasta...</td>\n",
       "      <td>[ASCO Annual Meeting 2018, HER2-positive disea...</td>\n",
       "      <td>2019-01-01</td>\n",
       "      <td>At the 2018 ASCO Annual Meeting, data from sev...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>30560092</td>\n",
       "      <td>Exceptional and Durable Responses to TDM-1 Aft...</td>\n",
       "      <td>[T-DM1, adotrastuzumab, emtansine, immune micr...</td>\n",
       "      <td>2018-12-19</td>\n",
       "      <td>Breast Cancer (BC) skin metastases represent a...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>30159132</td>\n",
       "      <td>Dual targeting of HER2-positive breast cancer ...</td>\n",
       "      <td>[HER2, TDM1, breast cancer, pertuzumab, trastu...</td>\n",
       "      <td>2018-08-31</td>\n",
       "      <td>Targeting of HER2-positive tumors with trastuz...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>30087853</td>\n",
       "      <td>Trastuzumab Emtansine for the Treatment of HER...</td>\n",
       "      <td>[brain metastases, carcinoma ex-pleomorphic ad...</td>\n",
       "      <td>2018-08-09</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>29721483</td>\n",
       "      <td>Practical consensus recommendations regarding ...</td>\n",
       "      <td>[Capecitabine, TDM1, combination systemic ther...</td>\n",
       "      <td>2018-05-04</td>\n",
       "      <td>Metastatic breast cancer (MBC) is cancer that ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>29721477</td>\n",
       "      <td>Practical consensus recommendations on Her2 +v...</td>\n",
       "      <td>[Herceptin, TDM1, WBCR, stereotactic radiosurg...</td>\n",
       "      <td>2018-05-04</td>\n",
       "      <td>Breast cancer is a common cause of brain metas...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>29719406</td>\n",
       "      <td>Cardiotoxic effects of the novel approved anti...</td>\n",
       "      <td>[breast cancer, immunotherapy, pertuzumab, ran...</td>\n",
       "      <td>2018-05-03</td>\n",
       "      <td>Pertuzumab, a novel anti-epidermal growth fact...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>29679630</td>\n",
       "      <td>High irisin levels are associated with better ...</td>\n",
       "      <td>[Bone remodeling, Irisin, Multiple daily injec...</td>\n",
       "      <td>2018-04-22</td>\n",
       "      <td>Irisin is a new peptide produced mainly by the...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>29215678</td>\n",
       "      <td>Decrease in Mandibular Cortical in Patients Wi...</td>\n",
       "      <td>[]</td>\n",
       "      <td>2017-12-08</td>\n",
       "      <td>In this study we analyzed the mandibular corti...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>27995546</td>\n",
       "      <td>Preliminary experience of the concurrent use o...</td>\n",
       "      <td>[Brain metastases, Concurrent treatment, Metas...</td>\n",
       "      <td>2016-12-21</td>\n",
       "      <td>This is preliminary study assessing the effica...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>27843589</td>\n",
       "      <td>Highlights from the San Antonio Breast Cancer ...</td>\n",
       "      <td>[Breast Cancer]</td>\n",
       "      <td>2016-11-16</td>\n",
       "      <td>A critical review on the practice changing stu...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>27342941</td>\n",
       "      <td>Preliminary results of the concurrent use of r...</td>\n",
       "      <td>[Concurrent treatment, Metastatic breast cance...</td>\n",
       "      <td>2016-06-28</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>27338847</td>\n",
       "      <td>Human epidermal growth factor antagonists and ...</td>\n",
       "      <td>[Ado-trastuzumab (T-DM1), Human epidermal rece...</td>\n",
       "      <td>2016-06-25</td>\n",
       "      <td>The Human Epidermal growth factor Receptor 2 (...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>27132096</td>\n",
       "      <td>Effects of DGAT1 K232A polymorphism and milkin...</td>\n",
       "      <td>[DGAT1, dairy cow, milk composition, once-dail...</td>\n",
       "      <td>2016-05-02</td>\n",
       "      <td>Milk spontaneous lipolysis (SL) of milk trigly...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>27114895</td>\n",
       "      <td>ACTIVITY OF TRASTUZUMAB-EMTANSINE (TDM1) IN HE...</td>\n",
       "      <td>[Adotrastuzumab, Brain Metastasis, Breast Canc...</td>\n",
       "      <td>2016-04-27</td>\n",
       "      <td>The incidence of breast cancer brain metastasi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>26871453</td>\n",
       "      <td>TDM1 Regulation Determines the Number of Meiot...</td>\n",
       "      <td>[]</td>\n",
       "      <td>2016-02-13</td>\n",
       "      <td>Cell cycle control must be modified at meiosis...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>26859680</td>\n",
       "      <td>Marked enhancement of lysosomal targeting and ...</td>\n",
       "      <td>[ErbB2, HSP90, Trastuzumab, breast cancer, tar...</td>\n",
       "      <td>2016-02-10</td>\n",
       "      <td>Targeted delivery of anticancer drugs to tumor...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>26557884</td>\n",
       "      <td>Safety and efficacy of the combination of T-DM...</td>\n",
       "      <td>[HER2-positive, TDM1, breast cancer, radiother...</td>\n",
       "      <td>2015-11-12</td>\n",
       "      <td>Approximately 35% of patients with confirmed H...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>26348709</td>\n",
       "      <td>The Chromatin Protein DUET/MMD1 Controls Expre...</td>\n",
       "      <td>[]</td>\n",
       "      <td>2015-09-09</td>\n",
       "      <td>Meiosis produces haploid cells essential for s...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>26276735</td>\n",
       "      <td>Mechanisms of lapatinib resistance in HER2-dri...</td>\n",
       "      <td>[Breast cancer, ErbB2/HER2, Lapatinib, Resista...</td>\n",
       "      <td>2015-08-16</td>\n",
       "      <td>Targeted therapies have been approved for vari...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>25908069</td>\n",
       "      <td>Long-term prognosis in patients with type 1 an...</td>\n",
       "      <td>[isolated CABG, major adverse coronary event, ...</td>\n",
       "      <td>2015-04-25</td>\n",
       "      <td>Patients with diabetes mellitus (DM) have an i...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>25937839</td>\n",
       "      <td>Insulin resistance and associated factors in p...</td>\n",
       "      <td>[Estimated glucose disposal rate formula, Insu...</td>\n",
       "      <td>2014-01-01</td>\n",
       "      <td>To assess the presence of insulin resistance (...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>22844260</td>\n",
       "      <td>OSD1 promotes meiotic progression via APC/C in...</td>\n",
       "      <td>[]</td>\n",
       "      <td>2012-07-31</td>\n",
       "      <td>Cell cycle control is modified at meiosis comp...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>22749531</td>\n",
       "      <td>Costs of treatment and complications of adult ...</td>\n",
       "      <td>[]</td>\n",
       "      <td>2012-07-04</td>\n",
       "      <td>Costs associated with diabetes represent a lar...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>21119056</td>\n",
       "      <td>Meiotic progression in Arabidopsis is governed...</td>\n",
       "      <td>[]</td>\n",
       "      <td>2010-12-02</td>\n",
       "      <td>Meiosis is a modified cell division that produ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>20877670</td>\n",
       "      <td>Immunological Approaches in the Treatment of M...</td>\n",
       "      <td>[]</td>\n",
       "      <td>2009-01-01</td>\n",
       "      <td>A better understanding of tumor biology has le...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>20578412</td>\n",
       "      <td>Thyroid autoimmunity and type 1 diabetes in ch...</td>\n",
       "      <td>[]</td>\n",
       "      <td>2009-01-01</td>\n",
       "      <td>The incidence of autoimmune thyroiditis in pat...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>2442724</td>\n",
       "      <td>A labile inhibitor blocks endo A gene transcri...</td>\n",
       "      <td>[]</td>\n",
       "      <td>1987-08-11</td>\n",
       "      <td>The endo A gene encoding for an intermediate f...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>16347085</td>\n",
       "      <td>Conjugal Transfer of Bacteriophage Resistance ...</td>\n",
       "      <td>[]</td>\n",
       "      <td>1986-06-01</td>\n",
       "      <td>Agar surface conjugal matings were used to int...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>42</th>\n",
       "      <td>7158680</td>\n",
       "      <td>The significance of natural killer activity in...</td>\n",
       "      <td>[]</td>\n",
       "      <td>1982-12-01</td>\n",
       "      <td>A number of mouse strains of known F9 resistan...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "    pubmed_id                                              title  \\\n",
       "0    33479246  Fibroblast growth factor receptor facilitates ...   \n",
       "1    33259892  Third-line treatment of HER2-positive advanced...   \n",
       "2    33238772  Margetuximab for the treatment of HER2-positiv...   \n",
       "3    32737515  Post-neoadjuvant treatment with capecitabine a...   \n",
       "4    32236828  Comparison of outcomes in a population-based c...   \n",
       "5    32192389  Safety of trastuzumab after trastuzumab emtans...   \n",
       "6    32104023  Analysis of the Cost-Effectiveness of Liquid B...   \n",
       "7    31949426  Recent advances and optimal management of huma...   \n",
       "8    31781874  When to Add Additional Anti-HER2 Therapy to Ad...   \n",
       "9    31449983  The evolving role of trastuzumab emtansine (T-...   \n",
       "10   31230485  Investigational drugs in early stage clinical ...   \n",
       "11   30957209  Systemic Therapy of Central Nervous System Met...   \n",
       "12   30833989  Post-neoadjuvant treatment and the management ...   \n",
       "13   30595754  ASCO 2018: highlights in HER2-positive metasta...   \n",
       "14   30560092  Exceptional and Durable Responses to TDM-1 Aft...   \n",
       "15   30159132  Dual targeting of HER2-positive breast cancer ...   \n",
       "16   30087853  Trastuzumab Emtansine for the Treatment of HER...   \n",
       "17   29721483  Practical consensus recommendations regarding ...   \n",
       "18   29721477  Practical consensus recommendations on Her2 +v...   \n",
       "19   29719406  Cardiotoxic effects of the novel approved anti...   \n",
       "20   29679630  High irisin levels are associated with better ...   \n",
       "21   29215678  Decrease in Mandibular Cortical in Patients Wi...   \n",
       "22   27995546  Preliminary experience of the concurrent use o...   \n",
       "23   27843589  Highlights from the San Antonio Breast Cancer ...   \n",
       "24   27342941  Preliminary results of the concurrent use of r...   \n",
       "25   27338847  Human epidermal growth factor antagonists and ...   \n",
       "26   27132096  Effects of DGAT1 K232A polymorphism and milkin...   \n",
       "27   27114895  ACTIVITY OF TRASTUZUMAB-EMTANSINE (TDM1) IN HE...   \n",
       "28   26871453  TDM1 Regulation Determines the Number of Meiot...   \n",
       "29   26859680  Marked enhancement of lysosomal targeting and ...   \n",
       "30   26557884  Safety and efficacy of the combination of T-DM...   \n",
       "31   26348709  The Chromatin Protein DUET/MMD1 Controls Expre...   \n",
       "32   26276735  Mechanisms of lapatinib resistance in HER2-dri...   \n",
       "33   25908069  Long-term prognosis in patients with type 1 an...   \n",
       "34   25937839  Insulin resistance and associated factors in p...   \n",
       "35   22844260  OSD1 promotes meiotic progression via APC/C in...   \n",
       "36   22749531  Costs of treatment and complications of adult ...   \n",
       "37   21119056  Meiotic progression in Arabidopsis is governed...   \n",
       "38   20877670  Immunological Approaches in the Treatment of M...   \n",
       "39   20578412  Thyroid autoimmunity and type 1 diabetes in ch...   \n",
       "40    2442724  A labile inhibitor blocks endo A gene transcri...   \n",
       "41   16347085  Conjugal Transfer of Bacteriophage Resistance ...   \n",
       "42    7158680  The significance of natural killer activity in...   \n",
       "\n",
       "                                             keywords publication_date  \\\n",
       "0                                                  []       2021-01-23   \n",
       "1   [Breast cancer, HER2\\xa0+, Third line, Trastuz...       2020-12-02   \n",
       "2   [Margetuximab, breast cancer, her2, mgah22, so...       2020-11-27   \n",
       "3   [Breast cancer, Capecitabine, Radiochemotherap...       2020-08-02   \n",
       "4   [Cardiotoxicity, Heart failure, Overall surviv...       2020-04-03   \n",
       "5   [Breast cancer, HER2, nodular regenerative hyp...       2020-03-21   \n",
       "6   [biomarkers, breast cancer, cost-effectiveness...       2020-02-28   \n",
       "7   [Breast cancer, TDM1, neratinib, pertuzumab, t...       2020-01-18   \n",
       "8   [Adjuvant, Early, HER2, Neoadjuvant, Neratinib...       2019-11-30   \n",
       "9   [Brain metastases, Breast cancer, HER2, Trastu...       2019-08-27   \n",
       "10  [ADCs, HER2+ breast cancer, TKIs, bispecific a...       2019-06-25   \n",
       "11  [Brain metastases, Breast cancer, Chemotherapy...       2019-04-09   \n",
       "12  [breast cancer, chemotherapy, pathologic compl...       2019-03-06   \n",
       "13  [ASCO Annual Meeting 2018, HER2-positive disea...       2019-01-01   \n",
       "14  [T-DM1, adotrastuzumab, emtansine, immune micr...       2018-12-19   \n",
       "15  [HER2, TDM1, breast cancer, pertuzumab, trastu...       2018-08-31   \n",
       "16  [brain metastases, carcinoma ex-pleomorphic ad...       2018-08-09   \n",
       "17  [Capecitabine, TDM1, combination systemic ther...       2018-05-04   \n",
       "18  [Herceptin, TDM1, WBCR, stereotactic radiosurg...       2018-05-04   \n",
       "19  [breast cancer, immunotherapy, pertuzumab, ran...       2018-05-03   \n",
       "20  [Bone remodeling, Irisin, Multiple daily injec...       2018-04-22   \n",
       "21                                                 []       2017-12-08   \n",
       "22  [Brain metastases, Concurrent treatment, Metas...       2016-12-21   \n",
       "23                                    [Breast Cancer]       2016-11-16   \n",
       "24  [Concurrent treatment, Metastatic breast cance...       2016-06-28   \n",
       "25  [Ado-trastuzumab (T-DM1), Human epidermal rece...       2016-06-25   \n",
       "26  [DGAT1, dairy cow, milk composition, once-dail...       2016-05-02   \n",
       "27  [Adotrastuzumab, Brain Metastasis, Breast Canc...       2016-04-27   \n",
       "28                                                 []       2016-02-13   \n",
       "29  [ErbB2, HSP90, Trastuzumab, breast cancer, tar...       2016-02-10   \n",
       "30  [HER2-positive, TDM1, breast cancer, radiother...       2015-11-12   \n",
       "31                                                 []       2015-09-09   \n",
       "32  [Breast cancer, ErbB2/HER2, Lapatinib, Resista...       2015-08-16   \n",
       "33  [isolated CABG, major adverse coronary event, ...       2015-04-25   \n",
       "34  [Estimated glucose disposal rate formula, Insu...       2014-01-01   \n",
       "35                                                 []       2012-07-31   \n",
       "36                                                 []       2012-07-04   \n",
       "37                                                 []       2010-12-02   \n",
       "38                                                 []       2009-01-01   \n",
       "39                                                 []       2009-01-01   \n",
       "40                                                 []       1987-08-11   \n",
       "41                                                 []       1986-06-01   \n",
       "42                                                 []       1982-12-01   \n",
       "\n",
       "                                             abstract  \n",
       "0   Trastuzumab-emtansine (T-DM1) is an antibody-d...  \n",
       "1   Human epidermal growth factor receptor 2 posit...  \n",
       "2   No specific standard treatment is currently re...  \n",
       "3   Following neoadjuvant chemotherapy for breast ...  \n",
       "4   Little data exist for comparing cardiac safety...  \n",
       "5   Trastuzumab emtansine is an antibody-drug conj...  \n",
       "6   Breast cancer is highly prevalent worldwide an...  \n",
       "7   With the introduction of anthracycline-based r...  \n",
       "8   One year of trastuzumab dramatically improves ...  \n",
       "9   Approximately 30-50% of advanced human epiderm...  \n",
       "10  Despite improvements in the management of HER2...  \n",
       "11  Historically, systemic treatment options for p...  \n",
       "12  Achieving a pathologic complete response after...  \n",
       "13  At the 2018 ASCO Annual Meeting, data from sev...  \n",
       "14  Breast Cancer (BC) skin metastases represent a...  \n",
       "15  Targeting of HER2-positive tumors with trastuz...  \n",
       "16                                                NaN  \n",
       "17  Metastatic breast cancer (MBC) is cancer that ...  \n",
       "18  Breast cancer is a common cause of brain metas...  \n",
       "19  Pertuzumab, a novel anti-epidermal growth fact...  \n",
       "20  Irisin is a new peptide produced mainly by the...  \n",
       "21  In this study we analyzed the mandibular corti...  \n",
       "22  This is preliminary study assessing the effica...  \n",
       "23  A critical review on the practice changing stu...  \n",
       "24                                                NaN  \n",
       "25  The Human Epidermal growth factor Receptor 2 (...  \n",
       "26  Milk spontaneous lipolysis (SL) of milk trigly...  \n",
       "27  The incidence of breast cancer brain metastasi...  \n",
       "28  Cell cycle control must be modified at meiosis...  \n",
       "29  Targeted delivery of anticancer drugs to tumor...  \n",
       "30  Approximately 35% of patients with confirmed H...  \n",
       "31  Meiosis produces haploid cells essential for s...  \n",
       "32  Targeted therapies have been approved for vari...  \n",
       "33  Patients with diabetes mellitus (DM) have an i...  \n",
       "34  To assess the presence of insulin resistance (...  \n",
       "35  Cell cycle control is modified at meiosis comp...  \n",
       "36  Costs associated with diabetes represent a lar...  \n",
       "37  Meiosis is a modified cell division that produ...  \n",
       "38  A better understanding of tumor biology has le...  \n",
       "39  The incidence of autoimmune thyroiditis in pat...  \n",
       "40  The endo A gene encoding for an intermediate f...  \n",
       "41  Agar surface conjugal matings were used to int...  \n",
       "42  A number of mouse strains of known F9 resistan...  "
      ]
     },
     "execution_count": 41,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df = pd.read_csv('/home/amansinha/extractpubmed/papers/key_meta_all/tdm1_metadf2.csv')\n",
    "df['keywords'] = df['keywords'].str.strip('[]').str.split(',')\n",
    "df['keywords'] = df['keywords'].apply(lambda x: [xx.strip().strip(\"''\") for xx in x])\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "columns = [f'key{i+1}' for i in range(10)]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 88,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "tdm1- {'post-neoadjuvant', 'her2-positive', 'breast', 'cancer', 't-dm1', 'trastuzumab', 'cancer:', 'a', 'safety'}\n",
      "tdm1- {'her2-positive', 'her2', 'we', 'trastuzumab', 'the', 'tdm1', 'egdr', 'trastuzumab/pertuzumab', '=', '<'}\n",
      "******************************\n",
      "\n",
      "\n",
      "genome wide association study- {'mendelian', 'genome-wide', \"parkinson's\", 'randomization', 'risk', 'with', 'variants', 'study', 'genetic', 'gwas'}\n",
      "genome wide association study- {'ci:', 'genome-wide', 'the', '95%', '(gwas)', 'in', 'risk', '=', 'we', 'gwas'}\n",
      "******************************\n",
      "\n",
      "\n",
      "progression free survival- {'neck', 'patients', 'neoadjuvant', 'efficacy', 'squamous', 'lung', 'with', 'a', 'study', 'without'}\n",
      "progression free survival- {'(pfs)', 'the', '<', 'pfs', 'nsclc', 'os', '=', '±', 'survival', 'we'}\n",
      "******************************\n",
      "\n",
      "\n",
      "hormone therapy- {'breast', 'cancer', 'growth', 'the', 'review', 'hormone', 'with', 'a', 'therapy'}\n",
      "hormone therapy- {'abi', 'dna', 'the', '95%', 'pfs', 'in', '=', 'a', 'we', 'therapy'}\n",
      "******************************\n",
      "\n",
      "\n",
      "overall survival- {'microbubble', 'new', 'the', 'review', 'patients]', 'outcomes', 'risk', 'covid-19', 'covid-19:', 'a'}\n",
      "overall survival- {'the', 'sars-cov-2', '95%', 'que', 'risk', 'covid-19', '=', '±', 'major', 'we'}\n",
      "******************************\n",
      "\n",
      "\n",
      "disease free survival- {'cancer', 'patients', 'prognostic', 'neoadjuvant', 'efficacy', 'outcomes', 'lung', 'with', 'squamous', 'study'}\n",
      "disease free survival- {'dfs', 'the', '<', 'expression', '95%', 'risk', 'os', '=', 'survival', 'we'}\n",
      "******************************\n",
      "\n",
      "\n",
      "radiation- {'a', 'dna', 'using', 'feasibility', 'qa', 'with', 'tgf-', 'quality', 'ionizing', 'squamous'}\n",
      "radiation- {'dna', 'the', 'qa', 'imrt', 'vmat', 'in', 'circ-ptk2', '=', '5-ala', 'a'}\n",
      "******************************\n",
      "\n",
      "\n",
      "chemotherapy- {'breast', 'cancer', 'new', 'hiv-1', '2021', 'covid-19', 'with', 'treatment', 'a', 'therapy'}\n",
      "chemotherapy- {'af', 'the', 'и', 'in', 'wif1', 'os', '=', '±', 'в', 'we'}\n",
      "******************************\n",
      "\n",
      "\n",
      "neratinib- {'breast', 'her2-positive', 'cancer', 'kinase', 'growth', 'trastuzumab', 'her2+', 'neratinib', 'a'}\n",
      "neratinib- {'her2+', 'her2-positive', 't-dm1', 'trastuzumab', 'the', 'adjuvant', '+', 'in', '=', 'we'}\n",
      "******************************\n",
      "\n",
      "\n",
      "pertuzumab- {'breast', 'her2-positive', 't-dm1', 'her2+', 'cancer', 'trastuzumab', 'neoadjuvant', 'with', 'a'}\n",
      "pertuzumab- {'her2-positive', 't-dm1', 'her2', 'we', 'trastuzumab', 'the', '95%', '+', '=', 'pertuzumab'}\n",
      "******************************\n",
      "\n",
      "\n",
      "pathologic complete response- {'breast', 'her2-positive', 'neoadjuvant', '1', 'mri', 'cancer:', 'with', 'a'}\n",
      "pathologic complete response- {'however,', 'her2-positive', 'the', '<', '95%', 'neoadjuvant', 'in', '=', 'we'}\n",
      "******************************\n",
      "\n",
      "\n",
      "surgery- {'microbubble', 'the', 'examination', 'outcomes', 'long-term', 'curettage', 'squamous', 'knee', 'use', 'histopathological'}\n",
      "surgery- {'the', '<', 'yap1', 'mri', 'in', '=', '±', 'dex', 'pvi', 'we'}\n",
      "******************************\n",
      "\n",
      "\n",
      "polymorphism- {'the', '(snps)', 'covid-19', 'subjects', 'frequency', 'mthfr', 'japanese', 'genetic', 'characterization', 'rs671'}\n",
      "polymorphism- {'however,', 'the', 'sars-cov-2', '95%', 'in', 'risk', 'covid-19', '=', 'snp', 'we'}\n",
      "******************************\n",
      "\n",
      "\n",
      "neoadjuvant- {'breast', 'cancer', 'pd-l1', 'neoadjuvant', 'squamous', 'gemcitabine', 'resectable', 'a'}\n",
      "neoadjuvant- {'pd-l1', 'the', '<', '95%', 'neoadjuvant', 'os', '=', '(hr', 'we'}\n",
      "******************************\n",
      "\n",
      "\n",
      "adjuvant- {'breast', 'cancer', 'review', 'adjuvant', 'squamous', 'covid-19', 'cancer:', 'a', 'study', 'therapy'}\n",
      "adjuvant- {'the', 'adjuvant', '95%', 'ddx5', 'in', 'covid-19', 'os', '=', 'a', 'we'}\n",
      "******************************\n",
      "\n",
      "\n",
      "trastuzumab- {'breast', 'her2-positive', 'her2', 'myl-1401o', 'cancer', 'trastuzumab', 'neoadjuvant', 'with', 'a'}\n",
      "trastuzumab- {'her2-positive', 't-dm1', 'her2', 'the', 'trastuzumab', '(week', 't-dxd', '=', 'we'}\n",
      "******************************\n",
      "\n",
      "\n",
      "polygenic risk score- {'biobank', 'the', 'disease:', 'uk', 'long-term', 'risk', 'polygenic', 'genetic', \"alzheimer's\", 'major'}\n",
      "polygenic risk score- {'prs', 'ad', 'the', 'uk', 'in', 'risk', '=', 'major', 'we', 'gwas'}\n",
      "******************************\n",
      "\n",
      "\n",
      "Breast Cancer- {'breast', 'cancer', 'using', 'cancer]', 'neoadjuvant', '2021', 'triple-negative', 'cancer:', 'm2'}\n",
      "Breast Cancer- {'breast', 'the', 'expression', 'kpna2', '95%', 'in', 'mri', 'wif1', '=', 'hormad1'}\n",
      "******************************\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "for k in kk:\n",
    "    \n",
    "    df = pd.read_csv(f'/home/amansinha/extractpubmed/papers/key_meta_all/{k}')\n",
    "    df['keywords'] = df['keywords'].str.strip('[]').str.split(',')\n",
    "    df['keywords'] = df['keywords'].apply(lambda x: [xx.strip().strip(\"''\") for xx in x])\n",
    "    \n",
    "    \n",
    "    name = k.split('_')[0]\n",
    "\n",
    "    akeys, amkeysdict, all_text = set(),[], []\n",
    "    for t in ['title', 'abstract']:\n",
    "        text = []\n",
    "        for i, (key, abst) in enumerate(zip(df['keywords'], df[t])):\n",
    "            if len(key)>1  and (not pd.isna(abst)):\n",
    "                    keylist = set(list(map(str.lower, key)))\n",
    "\n",
    "                    amkeysdict.append(d)\n",
    "                    text.append(abst)\n",
    "                    akeys |= keylist\n",
    "            if i == 100:\n",
    "                break\n",
    "                \n",
    "        all_text.append(' '.join(text))\n",
    "        mkd,d =  get_keywords(' '.join(all_text), 10)\n",
    "        manual_keylist = set(list(map(str.lower,mkd.keys() )))\n",
    "        \n",
    "        print(f'{name}- {manual_keylist}')\n",
    "        \n",
    "    #print(f'\\n all_keys: {akeys}')\n",
    "        \n",
    "    print('*'*30)\n",
    "    print('\\n')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 87,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "tdm1- {'post-neoadjuvant', 'her2-positive', 'breast', 'cancer', 't-dm1', 'trastuzumab', 'cancer:', 'a', 'safety'}\n",
      "tdm1- {'her2-positive', 'her2', 'we', 'trastuzumab', 'the', 'tdm1', 'egdr', 'trastuzumab/pertuzumab', '=', '<'}\n",
      "\n",
      " all_keys: {'post-neoadjuvant', 'her2-positive', 'her2-positive disease', 'neratinib', 'surgery', 'targeted therapies', 'cost-effectiveness', 'type 1 diabetes', 'trastuzumab', 'metastatic breast cancer', 'trastuzumab emtansine', 'dairy cow', 'mgah22', 'immunotherapy', 'trastuzumab-dm1', 'her2+ breast cancer', 'tucatinib', 'residual disease', 'tkis', 'biomarkers', 'ranolazine', 'immune microenvironment', 'combination systemic therapy', 'revascularization', 'toxicity', 'herceptin', 'highlights', 'hsp90', 'pathologic complete response', 'metastatic her2\\\\u2009+\\\\u2009breast cancer', 'emtansine', 'radiotherapy', 'treatment', 'heart failure', 'insulin resistance', 'trastuzumab deruxtecan', 'isolated cabg', 'brain metastases', 'concurrent treatment', 'capecitabine', 'breast cancer', 'bispecific antibodies', 'once-daily milking', 'adotrastuzumab', 'lapatinib', 'ds8201a', 'radiochemotherapy', 'third line', 'cardiotoxicity', 'spontaneous lipolysis', 'overall survival', 'major adverse coronary event', 'milk composition', 'nodular regenerative hyperplasia', 'adjuvant', 'erbb2', 'estimated glucose disposal rate formula', 'adcs', 'asco annual meeting 2018', 'sophia trial', 'carcinoma ex-pleomorphic adenoma', 'pertuzumab', 'personalized modification', 'docetaxel', 'early', 'review', 'prognosis', 'left ventricular ejection fraction (lvef)', 'subcutaneous infusion of insulin (csii)', 'her2\\\\xa0+', 'human epidermal receptor 2 (her2)', 'liquid biopsy', 'ado-trastuzumab (t-dm1)', 'her2', 'margetuximab', 'neoadjuvant', 'multiple daily injections (mdi)', 'targeted drug delivery', 'brain metastasis', 'skin metastasis', 'kadcyla', 't-dm1', 'stereotactic radiosurgery', 'resistance', 'trastuzumab emtansine (tdm1)', 'chemotherapy', 'tdm1', 'bone remodeling', 'wbcr', 'irisin', 'insulin sensitivity score', 'erbb2/her2', 't‑dm1', 'dgat1'}\n",
      "******************************\n",
      "\n",
      "\n",
      "genome wide association study- {'mendelian', 'genome-wide', \"parkinson's\", 'randomization', 'risk', 'with', 'variants', 'study', 'genetic', 'gwas'}\n",
      "genome wide association study- {'ci:', 'genome-wide', 'the', '95%', '(gwas)', 'in', 'risk', '=', 'we', 'gwas'}\n",
      "\n",
      " all_keys: {'candidate genes', 'psychosocial environment', 'chronic kidney disease', 'germans', 'gout', 'edn2', 'expression quantitative trait locus', 'myc', 'therapy efficacy and safety', 'immunoassay', 'data collection protocols', 'uk-pbc', 'psen2', 'smoking', 'fusarium wilt', 'plant domestication', 'genetic variation', 'extensive whole-genome sequencing', 'bivariate gwas', 'phenylpropanoid metabolism', 'aptamers', 'snp', 'mendelian randomization.', 'bantu', 'duck', 'genome-wide', 'alspac', 'trem2', 'gge', 'self- and informant-reports', 'phenotypes', 'hi-host', 'bottle gourd', 'uk biobank', 'bace1', 'glucose', 'breast cancer', 'metabolic-associated fatty liver disease (mafld)', 'proteomics', 'the cancer genome atlas', 'novel genomic regions', 'transcriptome', 'beta power', 'fruit flavor', 'cnv', 'qpcr', 'microglia', 'genotoxic adaptation', 'hla', 'vascular biology', 'qtl', 'association mapping', '\\\\npopulus\\\\n', 'luxi gamecock', 'lung cancer', 'standard measures', 'selenium', 'parkinson’s disease', 'facets', 'genome-wide association studies (gwas)', 'genome-wide association (gwas)', 'gene polymorphism', 'locus', 'micronutrient', 'obsessive-compulsive symptoms', 'phewas', 'children', 'egg quality', 'zinc', 'apoe', 'ptsd', 'orofacial cleft(s)', 'gastric cancer', '\\\\n          akr1c4\\\\n        ', 'nonalcoholic fatty liver disease (nafld)', 'mendelian randomization analysis', 'cancer', 'developmental biology', 'cytokinin biosynthesis pathway', 'atrial fibrillation', 'host-parasite coevolution', 'ad', 'drosophila suzukii', 'generalist pathogen', 'octoploid strawberry', 'heritable covariate', 'drosophila', 'ld-score', '\"alzheimer\\'s disease\"', 'trans-ethnic meta-analysis', 'signatures of selection', '\\\\nghnsltpsa10\\\\n', 'gene', 'pediatric longitudinal research', 'splicing', 'ern rare liver', 'cacna1b', 'mta1', 'prevalence', 'taiwan biobank', 'gwas catalog', 'chromatin', 'bilirubin', 'sedentary', 'rs505922', 'genes', 'poolseq', 'exposure assessment', 'o-glcnac', 'genetics', 'biased', 'gc-mass', 'precision medicine', 'inflammation', 'trauma', 'molecular genetics', 'craniofacial anomalies', 'ffm personality traits', '\\\\napoe\\\\n', 'replication', 'association study', 'genome-wide association (gwa)', 'vibrio harveyi', 'cvd', 'atopic dermatitis', 'neuroticism', 'qrt-pcr', 'functional assays', 'family history', 'autoimmune blistering skin diseases', 'genetic diversity', 'snp array', 'gingivitis', 'eqtn mapping', 'reprogen consortium', 'macular telangiectasia', 'vitamin c', 'body composition', 'de novo mutations', 'strenuous sports or other exercises', 'histone modifications', 'nutrigenetics', 'tauopathy', 'plasma amyloid beta levels', 'caa', 'sex differences', 'leptin', 'craniofacial biology/genetics', 'amyotrophic lateral sclerosis', 'network-based in silico drug efficacy screening', 'asthma', 'myopia', 'circadian rhythms', 'genome-wide association study', 'morningness-eveningness', 'mast4health', 'lipid', 'thermoregulation', 'reference genome comparison', 'inverse-variance weighted', 'generalized epilepsy', 'bovine', 'prediction model', 'genetic association study', 'capsicum spp.', 'functional variant', 'populations', 'cleft palate', 'cnvs', 'qtls', 'transcription factor motif', 'mta3 (metastasis associated 1 family member 3)', 'han chinese', 'age at first birth', 'mendelian randomization', 'genomic co-localization', 'hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13)', 'candidate gene', 'genetic', 'telomere length', 'adiponectin', 'recessive white feather broiler', 'mastiha', 'summary association statistics', 'transposable elements', 'genome-wide association analysis', 'calcium imaging', 'severe covid-19', 'colocalization', 'transcriptomic', 'bioinformatics', 'randomized clinical trial', 'memory', 'common somatic symptoms', '\\\\ntnfsf15\\\\n', 'epidemiology', 'alt serial test', 'cerebral amyloid angiopathy', 'physical activity', 'oscillations', 'cacna1a', 'allergic sensitization', 'sensitive skin', 'heterogeneity', 'severe early childhood caries', 'eeg', 'childhood obesity', 'linc-pint', 'survival', 'eqtl', 'broad-spectrum resistance', '\\\\ngossypium hirsutum\\\\n', 'genome wide association study', 'serum uric acid', 'domains', 'balancing selection', 'molecular markers', 'cross-phenotype association', 'endophenotype', 'epigenetics', 'major depressive disorder', 'prognosis', 'pharmacogenomics', 'sleep', 'multi-marker analysis', 'single nucleotide polymorphism (snp)', 'ca(v)2', 'cytokinin signal transduction pathway', 'fungus', 'botrytis cinerea', 'multifactorial disease', 'summary mendelian randomization', 'environmental exposures', 'alzheimer’s disease', 'minors', 'transcription factor', 'quantitative trait', 'cynoglossus semilaevis', 'chip-seq', 'biological invasion', 'c44857t', 'inflammaging', 'plant-pathogen interactions', 'epigenetic', 'genotyping-by-sequencing', 'high-resolution melting marker', 'snps', 'metabolism', 'immune defense', 'african', 'cardiovascular diseases', 'sequence variants', 'c-reactive protein', 'estimated glomerular filtration rate', 'blood pressure', 'preclinical biomarkers', 'genome-wide association studies', 'haplotype', 'gtex', 'sexual dimorphism', 'age at menarche', 'oxidative stress', 'plasma biomarkers', 'positive selection', 'polygenic risk score analysis', 'cardiometabolic traits', 'host genetics', 'chromatin accessibility', 'genome-wide association study; gwas', 'polygenic risk score', 'alignment quality', 'idiopathic pulmonary fibrosis', 'performance', 'cardiac aging', 'biomarkers', 'copy number variation', 'linkage disequilibrium', 'caqtl', 'voltage-gated calcium channel', 'rs12610495', 'schizophrenia', 'early childhood caries (ecc)', 'nafld', 'cacophony', 'inference', 'heat stress', 'bullous pemphigoid', 'nucleotide', 'genetic pleiotropy', 'adaptation', 'functional annotation', 'items', 'risk factors', 'rs2869462', 'prs', 'non-alcoholic fatty liver disease', 'longitudinal research', 'animal model', 'rcsprf1l', 'dairy (cows)', 'atac-seq', 'host specificity', 'hepatocellular carcinoma', 'genetic drift', 'polygenic virulence', 'methylation', ' cytochrome p450', 'rna', 'pleiotropy', 'lcorl/ncapg', 'blood coagulation factors', 'app', 'gwas', 'rheumatoid arthritis', 'chronotype', 'ion', 'chile peppers', 'single nucleotide polymorphism markers', 'venous thrombosis', 'ldlr rs1433099', 'polygenic scores', 'paratubercolosis', 'population structure', 'genomics', 'genetic epidemiology', 'osteoporosis', 'obsessive-compulsive disorder', 'dairy cattle', 'connective tissue biology'}\n",
      "******************************\n",
      "\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "progression free survival- {'neck', 'patients', 'neoadjuvant', 'efficacy', 'squamous', 'lung', 'with', 'a', 'study', 'without'}\n",
      "progression free survival- {'(pfs)', 'the', '<', 'pfs', 'nsclc', 'os', '=', '±', 'survival', 'we'}\n",
      "\n",
      " all_keys: {'osimertinib', 'nonnegative matrix factorization', 'egfr', 'endocrine toxicity', 'sdhb', 'pathological complete response', 'pan-cancer', 'non-randomized confirmatory trial', 'chemoradiotherapy', 'renal cell carcinoma', 'bone metastasis', 'pemetrexed', 'systematic review', 'cancer of unknown primary (cup)', 'anti pd-1', 'sox12', 'immunosuppression status', 'tumor-infiltrating macrophages', 'small cell lung cancer', 'sarcopenic obesity', 'lung adenocarcinoma', 'real-world effectiveness', 'japan', 'immunomodulatory activity', 'clinical manifestations', 'soft tissue sarcoma', 'enzalutamide', 'dyskerin pseudouridine synthase 1', 'pharmacokinetics', 'radiotherapy', 'watchful waiting', 'urothelial carcinoma of the upper urinary tract', 'rs671', 'cancer stem cells', 'extracapsular extension of neck nodes (ece)', 'breast cancer', 'hepatic metastases', 'partitioned survival analysis', 'mek1/2', 'the cancer genome atlas', 'diffuse large b-cell lymphoma', 'relapsed', 'supportive therapies', 'imrt', 'upper aerodigestive tract', 'trifluridine', 'microwave ablation', 'atezolizumab', 'glioblastoma multiform', 'ganciclovir', 'free flap', 'genomic biomarkers', 'organ preservation', 'mortality', 'without sdhb', 'neoadjuvant therapy', 'angioimmunoblastic t-cell lymphoma', 'g8', 'hormone-sensitive', 'newly diagnosed ovarian cancer', 'foxd1', 'pembrolizumab', 'geriatric assessment', 'high-risk', 'immune checkpoint inhibitor', 'chemosaturation', 'chordoma', 'proton beam therapy (pbt)', 'prognostic value', 'progression-free survival', 'intensity modulated radiation therapy', 'gastric cancer', 'tumor budding', 'retrospective analysis', 'second allogeneic stem cell transplantation', 'sites of metastasis', 'tumor doubling time', 'cancer', 'tipiracil', 'outcome research', 'late acute gvhd', 'non-small cell lung cancer (nsclc)', 'anti-androgen', 'head and neck squamous cell carcinoma (hnscc)', 'mrpl15', 'prior chemotherapy', 'hnsc', 'locally advanced rectal cancer', 'm2bpgi', 'erbb-2', 'tumor-infiltrating lymphocytes', 'abiraterone', 'neratinib', 'hypersensitivity reactions', 'invasion', 'symptomatic progression', 'anemia', 'gata6', 'neutrophils', 'non-small-cell lung', 'combination therapy', 'castration-resistant prostate cancer', 'efficacy', 'head and neck cancer (hnc)', 'esophageal carcinoma', 'immunotherapy', 'prognostic factor', 'cervical squamous cell cancer', 'laparoscopic distal gastrectomy', 'recurrent gvhd', 'non-small-cell lung cancer', 'survey', 'programmed death-1', 'precision medicine', 'inflammation', 'hr+/her2- abc', 'pancreatoduodenectomy', 'sigmoid colon cancer', 'maximal removal', 'epidermal growth factor receptor', 'brain', 'capecitabine', 'doxorubicin', 'pheochromocytoma', 'local radiation therapy', 'nsclc', 'lapatinib', 'translational medical research', 'chimeric antigen receptor', 'paraganglioma', 'plasma concentration', 'overall survival', 'smarca4-dts', 'pneumonitis', 'drug-eluting beads', 'androgen', 'theranostics', 'radiologically non-invasive cancer', 'body composition', 'platinum', 'gene therapy', 'pediatrics', 'tyrosine kinase inhibitor', 'carboplatin desensitization', 'adrenal metastasis', 'apatinib', 'computed tomography', 'down staging', 'upfront chemotherapy', 'radical nephroureterectomy', 'iran', 'cdk4/6 inhibitor', 'abiraterone acetate', 'linc00680', 'transsphenoidal approach', 'alk rearrangements', 'gain (1q21)', 'volumetric analysis', 'aldh2', 'robot-assisted surgery', 'egfr-tki', 'nasopharyngeal carcinoma', 'head and neck squamous cell carcinoma', 'meta-analysis', 'immuno-oncology', 'upfront therapy', 'chronic gvhd', 'poly (adenosine diphosphate [adp]–ribose) polymerase (parp) inhibitors', 'ptch1', 'cavitary', 'metastatic', 'prognostication', 'transarterial chemoembolization (tace)', 'isatuximab', 'tumor microenvironment', 'reirradiation', 'cost-effectiveness', 'prognostic model', 'ribociclib', 'first-line treatment', 'rectal neoplasms', 'refractory', 'positron-emission tomography', 'relapsed/refractory multiple myeloma', 'pre/perimenopausal', 'callispheres® beads', 'dangle protocol', 'rucaparib', 'paclitaxel', 'afatinib', 'immune checkpoint inhibitors', 'asymptomatic meningioma', 'urothelial carcinoma', 'intraductal papillary mucinous neoplasm', 'toxicity', 'bioinformatics', 'ground-glass opacity', 'hap score', 'caudate lobe', 'uveal melanoma', 'veliparib', 'targeted therapy', 'central nervous system neoplasms', 'olaparib', 'arising from endometriosis', 'suicidal gene', 'metastasis', 'natural history', 'tumour microenvironment', 'heterogeneity', 'survival', 'tam infiltration', 'tcga', 'non-small cell lung cancer', 'particle therapy', 'tumor load', 'alternative lengthening of telomeres', 'tepotinib', 'neck dissection (nd)', 'cisplatin-based postoperative radio-chemotherapy', 'microbiota', 'epigenetics', 'carcinoma', 'malignant gliomas', 'testosterone level', 'durvalumab', 'prognostic factors', 'prognosis', 'review', 'switch-maintenance', 'biomarker', 'cancers', 'lorlatinib', 'cetuximab', 'immune infiltration', 'neoadjuvant chemoradiotherapy', 'dependency protocol', 'synchronous liver metastasis', 'lower limb reconstruction', 'metastatic castration sensitive prostate cancer (mcspc)', 'smarca4-dtst', 'mesenchymal stem cell', 'ovarian cancer', 'prognostic', 'outcomes', 'parp inhibitors', 'immunotherapy response', 'prognostic biomarkers', 'liquid biopsy', 'sarcoma', 'thymic tumors', 'ribosomal protein', 'circular rna', 'immunoadjuvant', 'minimally-invasive surgery', 'niraparib', 'young', 'perioperative outcomes', 'brca', 'functional network analysis', 'splenic artery', 'immunophenotype', 'clinicopathologicalfeatures', 'acquired resistance', 'palbociclib', 'docetaxel (doc)', 'dnlr', 'pyrazofurin', 'pediatric oncology', 'lymphoma', 'cisplatin', 'biomarkers', 'short course radiotherapy', 'albumin-globulin ratio', 'radiation therapy', 'cell cycle', 'biochemical recurrence', 'pancreatic cancer', 'treatment outcome', 'epstein–barr virus', 'syndecan', 'psma', 'quadruple-modality therapy', 'brain metastases', 'cytogenetics', 'thoracic malignancy', 'protein kinase inhibitors', 'checkpoint kinase 1 inhibitor', 'sarcopenia', 'psa progression-free survival', 'hepatocellular carcinoma (hcc)', 'whipple procedure', 'proto-oncogene proteins c-met', 'lung neoplasms', 'major pathologic response', 'incidentally discovered meningioma', 'chromophobe', 'hepatocellular carcinoma', 'subtype', 'trametinib', 'splenic vein', 'coexisting with endometriosis', 'docetaxel', 'receptor', 'natural killer/t cell lymphoma', 'bladder cancer', 'methylation', 'gene mutation', 'rising prostate-specific antigen', 'castration sensitive', 'clinical trial', 'talazoparib', 'metastatic colorectal cancer', 'intra-arterial therapy', 'abiraterone (aa)', 'her2', 'piggybac transposon', 'nonmetastatic', 'acute myeloid leukemia', 'parp inhibitor', 'disease-specific survival', 'gamma knife radiosurgery', 'prostate cancer', 'colorectal cancer', 'hpv16', 'non-small-cell-lung-cancer', 'pd-l1 protein', 'castration-resistant', 'visceral disease', 'nf-κb signalling', 'postoperative protocol', 'resistance', 'chemotherapy', 'pleural dissemination', 'tumor response', 'bevacizumab', 'oropharynx', 'cabozantinib', 'microvascular reconstruction', 'non-small-cell lung carcinoma'}\n",
      "******************************\n",
      "\n",
      "\n",
      "hormone therapy- {'breast', 'cancer', 'growth', 'the', 'review', 'hormone', 'with', 'a', 'therapy'}\n",
      "hormone therapy- {'abi', 'dna', 'the', '95%', 'pfs', 'in', '=', 'a', 'we', 'therapy'}\n",
      "\n",
      " all_keys: {'glutamine', 'growth hormone', 'dementia', 'vasculitis', 'coping strategies', 'breast fibroadenoma', 'gender-affirming genital surgery', 'spinal cord', 'cardiovascular disease', 'individualized surgery', 'idiopathic sexual precocity', 'pco', 'subcutaneous progesterone supplementation', 'systematic review', 'acute respiratory distress syndrome (ards)', 'protein', 'beta cells', 'levothyroxine', 'oocytes', 'trappc2 gene', 'central precocious puberty', 'infantile spasm (is)', 'enzalutamide', 'thyroid function', 'testosterone', 'radiotherapy', 'riesenzellarteriitis', 'breast cancer', 'estrogen metabolism', 'partitioned survival analysis', 'pediatric growth disorders', 'cervical cancer', 'future therapies', 'low volume', 'serum progesterone', 'metabolic adaptivity', 'immunology', 'eligibility criteria', 'selenium', 'immunosuppression and health', 'letrozole', 'alexithymia', 'axillary complete response', 'clinical node-positive', 'hormone-sensitive', 'tocilizumab', 'nsd1', 'pembrolizumab', 'cell therapy', 'cyproterone acetate', 'pregnenolone', 'chronic nonbacterial osteomyelitis', 'anti-müllerian hormone (amh)', 'quality of life', 'luteal phase rescue', 'alpelisib', 'food intake', 'critical illness', 'retrospective analysis', 'x-linked spondyloepiphyseal dysplasia tarda', 'stereotactic radiotherapy', 'clinical', 'probiotics', 'recombinant human growth hormone therapy', 'infertility', 'triamcinolone acetonide', 'cadmium', 'ovulation induction therapy', 'cancer', 'prothrombotic states', 'oligometastatic breast cancer', 'puberty status', 'parathyroid hormone', 'case report', 'paediatric endocrinology', 'progestin', 'ventilator strategies', 'definition', 'locoregional therapy', 'prior chemotherapy', 'cardiovascular risk', 'complications', 'neratinib', 'steroid', 'animals', 'anemia', 'retina', '\"alzheimer\\'s disease\"', 'patient-specific modeling', 'lh', 'myocarditis', 'melatonin', 'acromegaly', 'hormone status', 'sotos syndrome', 'meta-analyses', 'survey', 'twins', 'o-glcnac', 'brca mutation', 'neurodevelopmental disorder', 'precision medicine', 'inflammation', 'hr+/her2- abc', 'anti-müllerian hormone', 'emotional functioning', 'thyroid hormones', 'endometrium', 'neoadjuvant endocrine therapy', 'brain', 'age‐associated neurodegenerative diseases', 'molecular chaperons', 'ovarian stimulation', 'ehealth', 'liver', 'statin', 'coronary artery diseases', 'quality of health care', 'hypothyroidism', 'resident education', 'intratumoral heterogeneity', 'personalized medicine', 'overall survival', 'drug therapy', 'cortisol', 'phyllodes tumor', 'craniopharyngioma', 'menarche', 'thecoma', 'hormone replacement therapy', 'pediatrics', 'computed tomography', 'obesity', 'cdk4/6 inhibitor', 'abiraterone acetate', 'adrenal adenoma', 'hyperkalemia', 'metabolic fingerprint', 'portal vein thrombosis', 'mandible', 'stem cells', 'publication bias', 'thyroidectomy', 'hyperlipidemia', 'ongoing pregnancy', 'intestinal microbiota', 'ovarian tissue cryopreservation', 'avascular bone necrosis', 'pregnancy', 'asthma', 'physical functioning', 'growth deficiency', 'primary chronic osteomyelitis', 'crmo', 'superior mesenteric vein thrombosis', 'upfront therapy', 'testosterone implant', 'breast neoplasms', 'cancer morbidity', 'acute kidney injury', 'congenital anomaly of kidney and urinary tract (cakut)', 'workshop discussions', 'appetite', 'diabetes', 'ovarian hyperstimulation syndrome', 'kidney-tonifying traditional chinese medicine', 'thyrotropin', 'precocious puberty', 'cost-effectiveness', 'feeding behavior', 'ribociclib', 'delay', 'human unrestricted somatic stem cells', 'maturation', 'giant cell arteritis', 'pre/perimenopausal', 'evolutionary biology', 'ob-gyn', 'recurrence', 'estrogen receptor status', 'scheimpflug imaging system', 'hyperthyroidism', 'gonadotropin-releasing hormone', 'immune checkpoint inhibitors', 'hormone receptor', 'thyroid cancer', 'addison disease', 'dna methylation', 'sexual health education', 'three-tesla mri', 'ferutinin', 'insulin resistance', 'hyponatremia', 'cardiovascular event', 'human epidermal growth factor receptor 2', 'steroidogenesis', 'cushing syndrome', 'lens opacity', 'cyp11a1', 'luteinizing hormone', 'antioxidants', 'central nervous system', 'coronary artery disease', '\"turner\\'s syndrome\"', 'magnetic resonance imaging', 'ferula species', 'case control study', 'pituitary adenoma', 'follicle-stimulating hormone (fsh)', 'redox status', 'thyroxine', 'pseudohypoaldosteronism', 'epigenetics', 'adherence to treatment', 'molecular subtypes', 'endometrial cancer', 'prognosis', 'adrenal cortex hormones', 'dose-response relationship', 'auricular keloid', 'metachronous', 'referral and diagnosis', 'drugs: respiratory system', 'iodine', 'desiccated thyroid extracts', 'pcos', 'continuous renal replacement therapy', 'set point', 'rare disease', 'fertility preservation', 'covid-19', 'biotin', 'follitropin delta', 'oligoprogressive breast cancer', 'estrogen replacement therapy', 'choline metabolism', 'precision hormone therapy', 'serine biosynthesis', 'hormone replacement therapy (hrt)', 'ovarian cancer', 'clinical genetics', 'lactation', 'thyroid', 'o. japonicus', 'ovulation', 'islet transplantation', 'menopausal hormone therapy', 'resident physicians', 'metabolism', 'growth hormone deficiency', 'decreased ovarian reserve', 'rathke cleft cyst', 'glycolytic upregulation', 'thyroid dysfunction', 'type 2 diabetes', 'fsh', 'estrogen', 'allergic rhinitis', 'clomiphene citrate', 'cytochrome p450', 'neurosteroids', 'pik3ca', 'type 1 diabetes', 'receptivity', 'metastatic breast cancer', 'inciting events', 'functional gastrointestinal disease', 'metastatic hormone-sensitive prostate cancer', 'palbociclib', 'liothyronine', 'cold stress', 'pediatric oncology', 'inflammatory cytokines', 'gastrointestinal peptides', 'thyroid neoplasms', 'parameter', 'insulin', 'vaskulitis', 'dermatology', 'remission', 'endoscopic surgery', 'ovarian reserve', 'treatment', 'gastrointestinal microbiome', 'pharmacology', 'chronic recurrent multifocal osteomyelitis', 'risk factors', 'vitrified–warmed embryo transfer', 'free thyroxine', 'transsexualism', 'therapy', 'growth hormone therapy', 'social functioning', 'surgeon experience', 'medical conditions', 'follicle stimulating hormone', 'ovarian response', 'adrenocorticotropic hormone', 'ldl-cholesterol', 'urinary tract infection', 'pi3k', 'subacute thyroiditis', 'osteogenesis', 'growth failure', 'fdg-pet/ct', 'real-world experience', 'penile inversion vaginoplasty', 'learning and memory', 'controlled ovarian stimulation', 'postmenopausal bleeding and menopause', 'prostate cancer', 'radioactive iodine', 'intensive care', 'visceral disease', 'gender dysphoria', 'osteoporosis', 'testicular tissue cryopreservation', 'ehealth tools', 'ct', 'amino acid', 'surgical outcome', 'estrogens', 'diagnostic criteria'}\n",
      "******************************\n",
      "\n",
      "\n",
      "overall survival- {'microbubble', 'new', 'the', 'review', 'patients]', 'outcomes', 'risk', 'covid-19', 'covid-19:', 'a'}\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "overall survival- {'the', 'sars-cov-2', '95%', 'que', 'risk', 'covid-19', '=', '±', 'major', 'we'}\n",
      "\n",
      " all_keys: {'microbubble', ' grade', 'older adults', 'neurotoxicity', 'chronic kidney disease', 'diabetic foot', 'remember-know procedure', 'aterectomía', 'negative', 'nosocomial infections', 'favipiravir', 'household crowding', 'immune system', 'culture', 'porcine retina', 'rock2', 'edwardsiella piscicida', 'fontan', 'myeloid-derived suppressor cells', 'nuclear factor kappa b', 'pregnancy outcome', 'mammograms', 'multiple pregnancy', 'ez-albi score', 'mortalidad', 'streptococcus pyogenes', 'brentuximab vedotin', 'mortalidad en amputación mayor', 'near-infrared spectroscopy', 'qualitative', 'falls', 'salmonids', 'virulence', 'acute myocardial infarction', 'liver resection', 'breast cancer screening', 'bleeding', 'innate immunity', 'survival analysis', 'co-infection', 'restrictions', 'secondary hyperparathyroidism', 'pim1', 'social isolation', 'disease management', 'atherectomy', 'coronary intervention', 'mortality', 'hígado', 'amputación supracondílea', 'drug-eluting balloon', 'canada', 'mechanical ventilation', 'total parathyroidectomy with autotransplantation', 'suppressive neutrophil', 'risk factor', 'hcc recurrence', 'immune checkpoint inhibitor', 'xist', 'herida', 'dyslipidemia prevention', 'sars-cov-2 infection', 'in-hospital mortality', 'lesiones', 'colecistitis aguda', 'adcetris', 'world', 'probiotics', 'mortality in major amputation', 'cancer', 'atrial fibrillation', 'aged', 'guidelines', 'immune related adverse event', 'debridement', 'adjustment', 'covid-19 pandemics', 'kidney transplant', 'housing', 'infectious diseases', 'collective action', 'implementation', 'wedge resection', 'pie diabético', 'cardiovascular risk', 'magnesium depletion score', ' low molecular weight heparin', 'hypersensitivity reactions', 'infracondylar amputation', 'xbp1v1', 'immunoinformatics', 'ecuador', 'xbp1', 'myocarditis', 'mir-362', 'diagnosis', 'mucormycosis', 'bacteriophages', 'stroke', 'inorganic arsenic', 'outcome', 'directed forgetting', 'mitochondrial dynamics', 'non-small-cell lung cancer', 'survivorship', 'sex', 'advanced hepatocellular carcinoma', 'cancer cell survival', 'acidic stress', 'trauma', 'neurological symptoms', 'pancreatoduodenectomy', 'older people', 'xv1', 'magnesium tolerance test', 'hemorrhage', 'neuro-covid-19', 'tracheostomy', 'laparoscopic cholecystectomy', 'response', 'autologous stem cell transplantation', 'infective endocarditis', 'myocardial infarction', 'drug-resistant bacteria', 'choep', ' social determinants of health', 'liver', 'abdomen', 'covid 19', 'injury', 'autophagy', 'violencia', 'pleural infection', 'paciente anciano', 'clinical practice', ' antipsychotics', 'alectinib', 'rate-of-ageing', 'utilization', 'colecistectomía laparoscópica', 'enucleation', 'aquaculture', 'post-operative right ventricular assist device', 'tracheotomy', 'gemcitabine', ' latin america', 'health beliefs model', 'postoperative hypocalcemia', 'chronic disease', 'predictive', 'blood cultures', 'sars-cov-2', 'carboplatin desensitization', 'the multisystem inflammatory syndrome in children', 'intensive care unit', 'and vaccine', 'melanoma', 'anticoagulation', 'apoptosis', 'abdominal', 'rho kinase', 'akt', 'intestinal microbiota', 'cardiovascular mortality', 'head and neck squamous cell carcinoma', 'selective reduction', 'survival processing', 'primary pci', 'cone repair', 'pmn-mdsc', 'bone pain', '16s rrna pcr', 'radiomic', 'receptor binding proteins', 'sepsis', 'memory inhibition', 'diabetes', 'segmentectomy', 'prognostication', 'necrotizing fasciitis', 'empyema', 'changes in lifestyle', 'chop', 'left ventricular assist device', 'amputación infracondílea', 'lrinec score', 'irae', 'recurrence', 'pre-operative atrial fibrillation', 'magnetic nanoparticles', 'nutritional epidemiology', 'adverse birth outcomes', 'paclitaxel', 'post-operative right ventricular failure', 'nhanes', 'large animal model', 'microrna', ' cancer', 'mental disorder', 'nadph oxidase', 'delirium', 'breast cancer self-examination', 'intraoperative brachytherapy', 'metabolic syndrome', 'heart failure', 'host-microbe interactions', 'metastasis', 'expertise', 'field knowledge', ' hospitalized patients', 'multi-epitope', 'coping', 'nonproportional hazards', 'antimicrobial activity', 'md simulation', 'atherogenic lipid abnormalities', 'enfermedad arterial periférica', 'ebstein’s anomaly', 'influenza', 'needle insertion angle', 'mathematical modeling of covid-19', 'psycho-oncology', 'clostridium perfringens', 'fontan association liver disease', 'mir-96-5p', 'shock', 'cardiac resynchronization therapy', 'mental health', 'prognosis', 'care pathways', 'stents', 'interdisciplinarity', 'percutaneous and open tracheostomy', 'p-i strategy', 'ampk', 'race/ethnicity disparity', 'single-cell rna sequencing', 'pretreatment', 'lcmv', 'necrotizing soft tissue infection', 'radiofrequency ablation', 'ultra-processed food', 'syrian refugee women', 'covid-19', 'antithrombotic therapy', 'transplantation', 'cervical', 'suicide', 'pediatric', 'chronic viral infection', 'prognostic', 'ovarian cancer', 'infection', 'outcomes', 't cell function', 'host-pathogen interaction', 'portal vein invasion', 'dynamic prediction', 'dental', 'metabolism', 'consensus', 'indigenous health', 'arginase-1', 'c-reactive protein', ' thromboembolic disease', 'ultrasound', 'perioperative outcomes', 'oxidative stress', 'liver disease', 'context reinstatement', 'multidisciplinary collaboration', 'time-dependent covariates', 'receptor for advanced glycation endproducts', 'inducible nitric oxide synthase', 'disease modification', 'sublobar resection', 'prospective cohort study', 'troponin', 'magnetic resonance imaging (mri)', 'portal thrombectomy', 'albumin-globulin ratio', 'direct oral anticoagulants', 'pancreatic cancer', 'gender', ' epistemonikos', 'endovascular procedures', 'lung', 'pancreaticoduodenectomy', 'supracondylar amputation', 'peripheral arterial disease', 'catastrophic financial loss', 'public policy', 'hybrid peptide', 'wound', 'trypsin stability', 'hepatocellular carcinoma (hcc)', 'risk factors', 'whipple procedure', 'cardiotoxicity', 'docking', 'acute cholecystitis', 'vaccine', 'conditional restricted mean survival time', ' review', 'leishmania', ' atypical antipsychotics', 'long-term', 'hepatocellular carcinoma', 'balón liberador de fármacos', 's100 calcium binding proteins', 'transphosphatidylation', ' risk factors', 'peritoneal dialysis', 'injuries', 'prostate cancer', 'intensive care', 'magnetoresistive sensors', 'cerebral ischemia/reperfusion', 'elderly patient', 'radiation exposure', 'nir', 'guch', 'cardiometabolic risk', 'violence'}\n",
      "******************************\n",
      "\n",
      "\n",
      "disease free survival- {'cancer', 'patients', 'prognostic', 'neoadjuvant', 'efficacy', 'outcomes', 'lung', 'with', 'squamous', 'study'}\n",
      "disease free survival- {'dfs', 'the', '<', 'expression', '95%', 'risk', 'os', '=', 'survival', 'we'}\n",
      "\n",
      " all_keys: {'splenic flexure', 'osimertinib', 'disease free survival', 'sex hormone', 'lipid metabolite', 'egfr', 'diabetic foot', 'pan-cancer', 'pathological complete response', 'liver metastasis', 'germ cell cancer', 'chemoradiotherapy', 'renal cell carcinoma', 'bone metastasis', 'immunologic', 'primary sclerosing cholangitis', 'pemetrexed', 'relapse', 'immunosuppression status', 'tumor-infiltrating macrophages', 'small cell lung cancer', 'amputation', 'coronary atherosclerosis', 'real-world effectiveness', 'lung adenocarcinoma', 'standard deviation', 'ci', 'coronary heart disease', 'immunomodulatory activity', 'prolactin', 'enzalutamide', 'pharmacokinetics', 'radiotherapy', 'liver resection', 'glioblastoma', 'cancer stem cells', 'breast cancer', 'hepatic metastases', 'partitioned survival analysis', 'the cancer genome atlas', 'relapsed', 'asymptomatic', 'etoposide', 'trifluridine', 'cd19 car t-cell therapy', 'chronic limb threatening ischaemia', 'gc', 'laparoscopic surgery', 'genomic biomarkers', 'lung cancer', 'mortality', 'primary prophylaxis', 'hr', 'neoadjuvant therapy', 'azathioprine', 'g8', 'neuroendocrine tumors', 'foxd1', 'geriatric assessment', 'immune checkpoint inhibitor', 'children', 'micropapillary pattern', 'chemosaturation', 'head-and-neck carcinoma', 'hyperaldosteronism', 'antineutrophil cytoplasmic antibody-associated vasculitis', 'proton beam therapy (pbt)', 'hepatic resection', 'prognostic value', 'progression-free survival', 'gastric cancer', 'tumor budding', 'retrospective analysis', 'first-line', 'second allogeneic stem cell transplantation', 'sites of metastasis', 'cd19', 'lactate dehydrogenase', 'tipiracil', 'late acute gvhd', 'non-small cell lung cancer (nsclc)', 'dendrimer', 'coronary imaging', 'mrpl15', 'wedge resection', 'prior chemotherapy', 'hnsc', 'erbb-2', 'tumor-infiltrating lymphocytes', 'neratinib', 'patient and graft survival', 'invasion', 'combination therapy', 'hoxa5 protein', 'digital ureteroscopy', 'efficacy', 'esophageal carcinoma', 'immunotherapy', '(1)h nmr spectroscopy', 'colon carcinoma', 'laparoscopic distal gastrectomy', 'antidepressant', 'proton beam', 'recurrent gvhd', 'non-small-cell lung cancer', 'human papillomavirus', 'advanced hepatocellular carcinoma', 'chimeric antigen receptor t (car-t)', 'precision medicine', 'inflammation', 'hr+/her2- abc', 'pancreatoduodenectomy', 'histological subtype', 'clinically significant incidental prostate cancer', 'epidermal growth factor receptor', 'interleukin 6 soluble receptor', 'capecitabine', 'targeted delivery', 'lymphocyte', 'nsclc', 'lapatinib', 'chimeric antigen receptor', 'plasma concentration', 'orthopedic oncology', 'utilization', 'ajcc', 'overall survival', 'confidence interval', 'vertigo', 'theranostics', 'breast surgery', 'incidental prostate cancer', 'platinum', 'predictive', 'tyrosine kinase inhibitor', 'adrenal metastasis', 'apatinib', 'estradiol', 'cdk4/6 inhibitor', 'geo', 'neutrophil-to-lymphocyte ratio', 'melanoma', 'alk rearrangements', 'thyroidectomy', 'bayesian statistics', 'akt', 'sd', 'locally advanced colon cancer', 'tumor‐associated macrophage', 'carcinoids', 'early stage', 'nasopharyngeal carcinoma', 'head and neck squamous cell carcinoma', 'conservative therapy', 'meta-analysis', 'myocardial perfusion imaging', 'immuno-oncology', 'breast neoplasms', 'pegfilgrastim', 'adult surgery', 'interleukin 6', 't4 colon cancer', 'radiomic', 'prognosis\\\\u2029', 'anal cancer', 'chronic gvhd', 'neutrophil', 'nomogram', 'upper tract urothelial carcinoma', 'neoadjuvant chemotherapy', 'segmentectomy', 'prognostication', 'disease recurrence', 'roc', 'tumor microenvironment', 'milan criteria', 'thyrotropin', 'reirradiation', 'decision curve analysis', 'cost-effectiveness', 'vestibular migraine', 'ribociclib', 'rectal neoplasms', 'refractory', 'pre/perimenopausal', 'programmed death-ligand 1', 'recurrence', 'squamous cell carcinoma', 'descending colon cancer', 'relapse/refractory b cell acute lymphoblastic leukemia', 'ectopic acth production syndrome', 'rucaparib', 'surgical oncology', 'afatinib', 'immune checkpoint inhibitors', 'urothelial carcinoma', 'bioinformatics', 'caudate lobe', 'uveal melanoma', 'veliparib', 'intraoperative brachytherapy', 'targeted therapy', 'central nervous system neoplasms', 'olaparib', 'arising from endometriosis', 'receiver operating characteristic', 'bfgf', 'albumin', 'poor outcomes', 'cancer risk factors', 'human', 'heterogeneity', 'cushing syndrome', 'survival', 'tam infiltration', 'tcga', 'central nervous system', 'non-small cell lung cancer', 'coronary artery disease', 'chronic cholecystitis', 'vascular quality initiative', 'tumor load', 'magnetic resonance imaging', 'interleukin-21', 'platelet-to-lymphocyte ratio', 'thyroxine', 'villoglandular adenocarcinoma', 'epigenetics', 'image 1-s', 'malignant gliomas', 'dfs', 'acute lymphoblastic leukemia', 'endometrial cancer', 'review', 'prognosis', 'peritoneal metastases', 'radiological complete response', 'switch-maintenance', 'ifosfamide and cisplatin', 'biomarker', 'cancers', 'narrow-band imaging', 'pretreatment', 'transverse colon cancer', 'lorlatinib', 'oncological outcomes', 'dual antiplatelet therapy', 'chronic limb threatening ischemia', 'immune infiltration', 'neoadjuvant chemoradiotherapy', 'ct angiography', 'clinical trials as topic', 'radiofrequency ablation', 'gastrointestinal tumours', 'elderly patients', 'end-stage renal disease', 'metastatic castration sensitive prostate cancer (mcspc)', 'transcription factor', 'dca', 'prognostic', 'infection', 'parp inhibitors', 'portal vein invasion', 'ewing sarcoma', 'prognostic biomarkers', 'mibc', 'head and neck cancer', 'tumour infiltrating lymphocytes', 'c-reactive protein', 'lung large cell neuroendocrine carcinoma', 'immunoadjuvant', 'adjuvants', 'niraparib', 'young', 'perioperative outcomes', 'brca', 'surgery', 'choline containing phospholipid', 'hematopoietic stem-cell transplantation', 'functional network analysis', 'adrenocortical carcinoma', 'the gene expression omnibus', 'hazard ratio', 'clinicopathologicalfeatures', 'palbociclib', 'docetaxel (doc)', 'depression', 'tils', 'anal squamous cell carcinoma', 'sublobar resection', 'lymphoma', 'prognostic signature', 'cervix', 'biomarkers', 'portal thrombectomy', 'magnetic resonance imaging (mri)', 'thyroid neoplasms', 'albumin-globulin ratio', 'clinically significant incidental prostate cancer in radical cystectomies', 'pancreatic cancer', 'stage ia', 'systemic', 'polyp', 'pelvis', 'fatty liver disease', 'epstein–barr virus', 'syndecan', 'fiber optic ureteroscopy', 'psma', 'allogeneic hematopoietic cell transplantation', 'quadruple-modality therapy', 'brain metastases', 'immunogenicity', 'propensity score matching', 'wound', 'cancer related symptoms', 'checkpoint kinase 1 inhibitor', 'sarcopenia', 'hpv', 'hepatocellular carcinoma (hcc)', 'whipple procedure', 'vaccine', 'radical cystectomy', 'regulatory t cells', 'major pathologic response', 'hepatocellular carcinoma', 'coexisting with endometriosis', 'adenocarcinoma', 'receptor', 'bladder cancer', 'methylation', 'clinically significant incidental prostate cancer in high risk nmibc', 'gamma-glutamyltransferase', 'clinical trial', 'aldo-keto reductase family 1 member b10', 'talazoparib', 'abiraterone (aa)', 'her2', 'the american joint committee on cancer', 'surgical resection', 'piggybac transposon', 'liver transplantation', 'postmenopausal woman', 'gallbladder cancer', 'acute myeloid leukemia', 'parp inhibitor', 'disease-specific survival', 'prostate cancer', 'colorectal cancer', 'hpv16', 'non-small-cell-lung-cancer', 'castration-resistant', 'visceral disease', 'resistance', 'mycophenolate mofetil', 'tumor response', 'irtks', 'bevacizumab', 'colorectal surgery', 'cabozantinib', 'proliferation', 'oropharynx', 'surgical outcome', 'immune gene', 'invasive therapy'}\n",
      "******************************\n",
      "\n",
      "\n",
      "radiation- {'a', 'dna', 'using', 'feasibility', 'qa', 'with', 'tgf-', 'quality', 'ionizing', 'squamous'}\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "radiation- {'dna', 'the', 'qa', 'imrt', 'vmat', 'in', 'circ-ptk2', '=', '5-ala', 'a'}\n",
      "\n",
      " all_keys: {'gene set enrichment analysis', 'financial planning', 'financial toxicity', 'mcnp', 'flash', 'pixelated semiconductor', 'risk analysis', 'coordination', 'endocrine toxicity', 'cyanobacteria', 'tumor microenvironment', 'conversion efficiency', 'radiation monitoring', 'hypertrophic olivary degeneration', 'paraneoplatic pemphigus', 'chemoradiotherapy', 'catalysis', 'double strand breaks (dsbs)', 'chemoradiation therapy', 'accelerator', 'dual-ended readout', 'rectal neoplasms', 'anastrazole', 'proton detection', 'anti pd-1', 'flattening filter-free (fff) beams', 'electron beam', 'thermophotovoltaics', 'recurrence', 'objective functions', 'critical-sized bone defects', 'pdsapi', 'hydrogel spacer', 'subglottic small cell carcinoma', 'immune checkpoint inhibitors', 'single-strand annealing', 'ultraviolet radiation', 'caudate lobe', 'picket fence test', 'vascular endothelial growth factor receptor-2 inhibitor', 'mitochondrial membrane potential', 'pdgf', 'radiotherapy', 'radiolabeling', 'osteoinductive membrane', 'external-beam radiation therapy', 'amyloid', 'anatomical variations', 'radiation', 'white', 'breast cancer', 'brachium pontis', 'qa automation', 'cumulative dose effects', 'imrt qa', 'peptidylarginine deiminase', 'the cancer genome atlas', 'aortic aneurysm', 'auto immune', 'fluence-to-dose conversion coefficients', 'silicon detector', 'radon analysis', 'bayesian', 'bone morphogenetic proteins', 'ir', 'potassium-ion batteries', 'magnetic resonance imaging', 'linac', 'printed circuit board', 'igf-1', 'iron chelator', 'small-angle x-ray', 'monte-carlo simulations', 'ureasil-polyether materials', 'coastal area', 'oral vinorelbine', 'metal artifact', 'autoantibodies', 'villoglandular adenocarcinoma', 'teeth', 'neoadjuvant therapy', 'silicon photomultiplier (sipm)', 'chinese', 'advanced', 'quality specifications', 'dna model', 'scandium radionuclides', 'review', 'prognosis', 'dosimetry', 'utilization for treatment', 'reimbursement', 'esophageal cancer', 'inverse planning', 'foxc1', 'prognostic factors', 'colorectal neoplasms', 'proton therapy', 'bone', 'electromechanical impedance', 'snout', 'children', 'dose–volume histogram', 'geant4', 'chordoma', 'pretreatment', 'high-altitude adaptation', 'aorta', '\\\\n          18f fluoro-2 deoxy-d-glucose (18f -fdg)', '5-amino levulinic acid', 'proton beam therapy (pbt)', 'tgf-β', 'squamous cell', 'flavonol', 'neoadjuvant chemoradiotherapy', 'phytochemical', 'cancer immunotherapy', 'dna damage', 'error curve method', 'intensity modulated radiation therapy', 'medical imaging', 'gamma passing rates', 'absorption', 'dna double-strand break repair', 'stent-graft', 'api', 'microcystin', 'cancer', 'clinical goals', 'endovascular repair', 'pediatric', 'prognostic', 'cardiomyocyte', 'passive scattering', 'oncotype', 'ovarian cancer', 'lovo cell', 'circbanp', 'p53', 'commissioning', 'desmoglein', 'insurance', 'case report', 'bio-monitoring', 'geant4-dna', 'head and neck cancer', 'radiocesium', 'gamma irradiation', 'thymic tumors', 'mussel watch', 'synergistic', 'fukushima', 'germinoma', 'aperture', 'mlc', 'scattered protons', 'measurement protocols', 'health expenditure', 'young', 'surgery', 'ciprofloxacin', 'piezo-device', 'ionizing irradiation', 'thoracoabdominal aortic aneurysm', 'autoantigens', 'icrp', 'm. aeruginosa', 'metastatic breast cancer', 'clinicopathologicalfeatures', 'concurrent chemoradiotherapy', 'multileaf collimator', 'goal based', 'photo-dynamic therapy (pdt)', 'positron emission tomography/computed tomography (pet/ct)', 'immunotherapy', 'range compensator', 'smooth approximation', 'carbon nanotube', 'structural health monitoring', 'cervix', 'p21', 'radiosensitivity', 'dosimeter', 'magnetic resonance imaging (mri)', 'imrt qa tolerances', 'survey', 'radiation therapy', 'effective dose', 'maximum entropy method', 'quality assurance', 'radiation impact', 'dose perturbation', 'molecular breast imaging', 'trauma', 'monte carlo', 'nanoscale', 'megavoltage ct', 'tissue expander', '5-ala', 'coated', 'biomechanics', 'long-term tumor vascular normalization', 'angiogenesis', 'rich-edge defects', 'gamma comparison sensitivity', 'dbscan', 'depth-of-interaction (doi)', 'quadruple-modality therapy', 'esapi', 'log file-based qa', 'delta-like 1', 'doxorubicin', 'homologous recombination', 'local radiation therapy', 'radiation protection', 'enhance', 'p97', 'in vivo studies', 'sarcopenia', 'unconditional death probability rate', 'mre11', 'bollous autoimmune diseases', 'hepatocellular carcinoma (hcc)', 'neutron radiation', 'recombination loss', '3d porous structure', 'maresin 1', 'dna repair', 'radiation dosimeters', 'overall survival', 'mir-338-3p', 'mouse dermal fibroblast', 'lung neoplasms', 'local skin dose', 'committed dose', 'radon risk', 'laryngeal cancer', 'qa', 'major pathologic response', 'epithelial–mesenchymal transition', 'conservatism', 'intravenous immunoglobulins (ivig)', 'time-of-flight (tof)', 'visceral arteries', 'ctdna', 'long-read sequencing', 'bladder cancer', 'implantable cardiac pacemaker (icp)', 'plasmapheresis', 'fff beams', 'predictive', 'apatinib', 'thermal radiation', 'cell cycle phase', 'hypertrophy', 'tumorigenesis', 'antimicrobial', 'mean-tail-dose', 'mir-639', 'chest', 'palliative care', 'light-emitting diode', 'trajectory log file', 'structural variation', 'apoptosis', 'cb-5083', 'failure', 'mitochondrial depolarization', 'reactive oxygen species', 'lungs', 'prostate cancer', 'tibetan', 'pemphigus vulgaris', 'head and neck squamous cell carcinoma', 'conservative therapy', 'brachytherapy', 'internal exposure', 'radiation exposure', 'accelerator- and nuclear reactor production', 'monte carlo simulation', 'pulmonary', 'scintillation detector', 'smad 3', 'pleural dissemination', 'ionizing radiation', 'reducing agent', 'pipspro software', 'carbon nanosheets', 'physiology', 'fluka', 'circ-ptk2', 'radiomic', 'ozone-mediated mechanism', 'ultrastable cyclability', 'motivation', 'theory of planned behaviour', '8-ohdg', 'hospitals', 'invasive therapy'}\n",
      "******************************\n",
      "\n",
      "\n",
      "chemotherapy- {'breast', 'cancer', 'new', 'hiv-1', '2021', 'covid-19', 'with', 'treatment', 'a', 'therapy'}\n",
      "chemotherapy- {'af', 'the', 'и', 'in', 'wif1', 'os', '=', '±', 'в', 'we'}\n",
      "\n",
      " all_keys: {'microbubble', 'machine learning', 'matrix-assisted laser desorption ionization time-of-flight mass spectrometry', 'gout', 'advanced breast cancer', 'mycobacterium bovis', 'aterectomía', 'hcc', 'favipiravir', 'non-tuberculous mycobacteria', 'pulmonary drug delivery', 'data integration', 'augmentation therapy', 'multivariate analysis', 'pd: direct surgery', 'weight loss', 'radiology', 'brentuximab vedotin', 'hif-1α', 'near-infrared spectroscopy', 'exercise', 'family caregiver', 'chemoresistance', 'ranitidine', 'capsaicin', 'hypertension treatment', 'andrology', 'enzalutamide', 'wnt inhibitor factor-1', 'radiotherapy', 'oncology', 'tdm', 'glioblastoma', 'circrnas', 'cancer stem cells', 'white', 'breast cancer', 'antacid', 'pulmonary function test', 'idsa', 'ireland', 'mycobacteria growth indicator tube', 'auricular acupressure', 'erg3', 'diffuse large b-cell lymphoma', 'auto immune', 'ramucirumab', 'mycobacterium avium', 'sarscov-2', 'delayed speech development', 'tuberculosis', 'atherectomy', 'ntm', 'iron chelator', 'mortality', 'drug-eluting balloon', 'muscle wasting', 'neoadjuvant therapy', 'data harmonisation', 'chinese', 'afb', 'tb', 'mechanobullous diseases and treatment', 'esophageal cancer', 'tetrahedral framework nucleic acid', 'pembrolizumab', 'drug delivery', 'progressive multifocal leukencephalopathy', 'relapsed acute myeloid leukemia', 'fda', 'gastroesophageal junction adenocarcinoma (g/gea)', 'children', 'ecg', 'immune checkpoint inhibitor', 'chordoma', 'dyslipidaemia', 'loop recorder', 'chronic obstructive pulmonary disease', 'atrial fibrillation burden', 'adcetris', 'gastric cancer', 'pneumatic dilation', 'chemotherapy-associated insomnia', 'nursing', 'flow cytometry', 'polymerase chain reaction', 'cancer', 'fat metabolism', 'atrial fibrillation', 'early breast cancer', 'hypertrophic cardiomyopathy', 'desmoglein', 'case report', 'pre-operative biliary drainage', 'percutaneous ablation', 'infectious diseases', 'assay performance', 'ebs', 'bioactive drugs', 'cytotoxic agent', 'prior chemotherapy', 'neurotrophic therapy', 'protein therapeutics formulation', 'anemia', 'ciprofloxacin', 'somatostatin analog', 'osteosarcoma', 'human immunodeficiency virus', 'antihypertensive', 'end of life decisions (palliative care)', 'healthcare utilization database', 'anti-inflammatory', 'antimicrobial-susceptibility testing', 'thc', 'africa', 'diagnosis', 'drug addiction', 'immunotherapy', 'ats', 'peroral endoscopic myotomy', 'outcome', 'endocrine cancer', 'infliximab', 'interferon- γ', 'sirna-pd-l1', 'hr+/her2- abc', 'cancer research', 'monotherapy', 'var2csa malaria protein', 'clsi', 'triple-negative breast cancer', 'nanocapsulation.', 'stereotactic navigation', 'clinical and laboratory standards institute', 'bacille calmette-guerin', 'sulfobutyl cyclodextrin', 'polyphenol compounds', 'immunohistochemistry', 'autologous stem cell transplantation', 'copd', 'education', 'infectious disease society of america', 'choep', 'bollous autoimmune diseases', 'paraneoplastic neurologic syndrome', 'bcg', 'overall survival', 'modular response analysis', 'drug therapy', 'intravesical bcg treatment', 'chemotherapy and bullous diseases', 'gemcitabine', 'cell-free dna', 'virtual patient', 'signaling networks', 'erg11', 'neuromuscular', 'american thoracic society', 'plasmapheresis', 'clofarabine', 'sars-cov-2', 'percutaneous electrochemotherapy', 'right upper quadrant', 'qualitative research', 'bempedoic acid', 'iran', 'abiraterone acetate', 'mavacamten', 'raf inhibitors', 'nutrition', 'emb', 'achalasia', 'inh', 'botulinum toxin a', 'sumoylation', 'isoniazid', 'ast', 'epidermolysis bullosa simplex', 'breast neoplasms', 'hiv-1 drug resistance testing', 'molecular-targeted agent', 'liposomes', 'diabetes', 'iron', 'dietary supplements', 'tumor', 'neutrophil elastase', 'oxaliplatin', 'chronic inflammatory demyelinating polyneuropathy', 'nanoparticles', 'chop', 'paraneoplatic pemphigus', 'therapeutics', 'irgd', 'mycobacterium abscessus', 'nanoformulation', 'drug synergy', 'cardiophrenic lymph node', 'epidermolysis bullosa simplex (ebs) and cisplatin', 'interventional oncology', 'placental site trophoblastic tumor', 'refractory', 'cyclosporine', 'irinotecan (cpt-11)', 'efflux pumps', '\"pediatric crohn\\'s disease\"', 'hrct', 'sipuleucel-t', 'crispr-cas13', 'pcr', 'paclitaxel', 'surgical oncology', 'cost-effectiveness analysis', 'toxicity', 'bioinformatics', 'exosomes', 'multi-omics', 'debulking surgery', 'continuing medical education', 'follow-up', 'targeted therapy', 'medical oncology', 'cannabis', 'platelet membrane', 'drug resistance', 'enfermedad arterial periférica', 'therapeutic drug monitoring', 'senp1', 'non-small cell lung cancer', 'drug sensitivity', 'magnetic resonance imaging', 'mic', 'autoantibodies', 'marijuana', 'cytoreductive surgery', 'inf-γ', 'pdac', 'review', 'prognosis', 'ulcerative colitis', 'cortexin', 'maldi-tof', 'embolic stroke of undetermined source', 'digital medicine', '5-amino levulinic acid', 'glioma', 'penectomy', 'wait-list controlled', 'hiv', 'heller myotomy', 'pancreatic neuroendocrine tumors', 'statins', 'mgit', 'covid-19', 'pd-1', 'treatment strategy', 'antihypertensive therapy', 'non-hodgkin lymphoma', 'china', 'novel coronavirus', 'colectomy', 'targeted cancer therapy', 'cannabinoid hyperemesis syndrome', 'pediatric', 'ovarian cancer', 'questionnaire', 'omics', 'oncotype', '(2-hydroxy)propyl cyclodextrin', 'ebs with mottled pigmentation treatment', 'il-8', 'liquid biopsy', 'nutrition therapy', 'head and neck cancer', 'gastroenteropancreatic neuroendocrine neoplasms', 'pediatric ulcerative colitis', 'craving', 'ultrasound', 'fenofibrate', 'proton pump inhibitor', 'electrocardiogram', 'hyperemesis', 'surgery', 'palliative systemic chemotherapy', 'myeloid protocell', 'lymph node biopsy', 'autoantigens', 'kinase inhibitors', 'histone deacetylase inhibitor (hdaci)', 'metastatic breast cancer', 'kinetic models', 'palbociclib', 'photo-dynamic therapy (pdt)', 'vertebral osteomyelitis', 'pandemic', 'cisplatin', 'biomarkers', 'survival curve', 'pd-l1kd', 'heparanase', 'targeted treatment', 'erm', 'tumour treating fields (ttfields)', 'mac', 'caregiving burden', 'pancreatic cancer', 'adherence', 'c. albicans', 'schizophrenia', 'neoplasms', 'dermatology', 'remission', 'pancreaticoduodenectomy', '5-ala', 'mapk pathways', 'treatment', 'peripheral arterial disease', 'peripheral neuropathy', 'eb', 'acid fast bacilli', 'septal reduction therapy', 'minimum inhibitory concentrations', 'pan-degenerate amplification and adaptation', 'food and drug administration', 'cancer precision medicine', 'high resolution computed tomography', 'sarcopenia', 'epidermolysis bullosa', 'castration resistant prostate cancer', 'therapy', 'centralisation', 'azole resistance', 'rheumatologist', 'dual diagnosis', 'computational systems biology', 'electroacupuncture', 'adr', 'erythromycin ribosomal methylase', 'alpha 1-proteinase inhibitor', 'hdaci prodrug', 'combination treatment', 'simulation training', 'intravenous immunoglobulins (ivig)', 'docetaxel', 'balón liberador de fármacos', 'management', 'bladder cancer', 'tumor penetrating peptide', 'methylation', 'growth', 'pancreatic ductal adenocarcinoma', 'transphosphatidylation', 'alpha 1-antitrypsin', 'anvifen', 'non-thermal ablation', 'ethambutol', 'asthenic disorders', 'health-related quality of life', 'implantable cardiac monitor', 'atypical antipsychotics', '\"chuang\\'s prognostic scale\"', 'primary and metastatic cancer', 'crispr diagnostics', 'oncogenic ras', 'prevention', 'dox', 'acute myeloid leukemia', 'complication', 'mediator complex subunit 19', 'colorectal cancer', 'overexpression', 'dna damage response (ddr)', 'cdk4', 't lymphoblastic lymphoma', 'adverse drug reactions', 'pemphigus vulgaris', 'hipec', 'visceral disease', 'atherosclerotic cardiovascular disease', 'ghana national health insurance scheme', 'nir', 'chemotherapy', 'randomized', 'penile cancer', 'remdesivir', 'castration-resistant prostatic cancer', 'pft', 'mycobacterium avium complex', 'synthetic lethality', 'drug interactions'}\n",
      "******************************\n",
      "\n",
      "\n",
      "neratinib- {'breast', 'her2-positive', 'cancer', 'kinase', 'growth', 'trastuzumab', 'her2+', 'neratinib', 'a'}\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "neratinib- {'her2+', 'her2-positive', 't-dm1', 'trastuzumab', 'the', 'adjuvant', '+', 'in', '=', 'we'}\n",
      "\n",
      " all_keys: {'hr+/her2+', 'covalent binding', 'temperature effect on protein binding', 'egfr', 'c-met', 'advanced breast cancer', 'cdk4/6 inhibitors', 'her2 low expression', 'spontaneous metastasis', 'free fraction', 'competition', 'trastuzumab', 'antibody-drug conjugates.', 'drug discovery', 'mouse array', 'second-line treatment', 'immune therapy', 'tucatinib', 'unstable drugs', 'diarrhea', 'extended adjuvant treatment', 'plasma protein binding', 'hormone receptor', 'protein kinase structure', 'neo-antigen', 'michael acceptor', 'toxicity', 'hydrophobic interaction', 'quinoline', 'lobular', 'central nervous system neoplasms', 'targeted therapy', 'metastasis', 'trastuzumab deruxtecan', 'cyclin d1', 'bispecific antibodies', 'breast cancer', 'her2 positive', 'covalent inhibitors', 'intact rb', 'cxcl8', 'human epidermal growth factor receptor 2', 'cholangiocarcinoma', 'cervical cancer', 'transcriptome', 'drug resistance', 'imatinib', 'hospitalized', 'hdac inhibitor', 'irreversible', 'esr1', 'her2-positive brain metastases', 'gefitinib (pubchem cid: 123631)', 'molecular oncology', 'catalytic spine', 'adjuvant', 'α-acid glycoprotein', 'erbb2', 'nitroalkylation', 'molecular docking', 'lung cancer', 'sequential treatment', 'her2 positivity', 'ppb', 'pyrotinib', 'artificial intelligence', 'neoadjuvant therapy', 'pertuzumab', 'human epidermal growth factor', 'metastatic', 'prognosis', 'explainable machine learning', 'structure-activity relationship', 'feline mammary carcinoma', 'human epidermal growth factor receptor 2 positive', 'pembrolizumab', 'in silico screening', 'covalent tyrosine kinase inhibitors', 'covalent modulators', 'digital medicine', 'cancers', 'zanubrutinib (pubchem cid: 135565884)', 'erlotinib (pubchem cid: 176870)', 'her2+', 'osimertinib (pubchem cid: 71496458)', 'quality of life', 'breast', 'behavioral variant frontotemporal dementia', 'covid-19', 'post-translational modifications', 'neuropsychology', 'cell invasion', 'ulcer', 'mechanisms of action', 'molecular dynamic simulation', 'cancer', 't-dm1', 'acalabrutinib (pubchem cid: 71226662)', 'mutation', 'early breast cancer', 'expression profiling', 'her2(+)', 'rutin', 'locally advanced', 'orthotopic model', 'equilibrium dialysis', 'therapeutic biomarker', 'her2-positive', 'episodic memory', 'genetic frontotemporal dementia', 'erbb-2', 'adverse event', 'her2-positive disease', 'neratinib', 'fgfr', 'her3', 'anti-her2 treatments', 'breast cancer stem cells', 'targeted therapies', 'pik3ca', 'molecular determinant', 'combination therapy', 'dacomitinib (pubchem cid: 11511120)', 'basket clinical trial', 'phase ii trial', 'metastatic breast cancer', 'her2 resistance', 'protein kinase inhibitor classification', 'trastuzumab emtansine', 'ado-trastuzumab emtansine', 'efficacy', 'btk', 'carg toxicity risk score', 'monoclonal\\\\nantibodies', 'immunotherapy', 'biomarkers', 'triple-positive', 'hnscc', 'luminal her2', 'jak', 'quercetin', 'immune response', 'labile compounds', 'kinase', 'mass spectrometry', 'clinical trials', 'regulatory spine', 'fluorescence quenching', 'chromatography', 'cns disease', 'epidermal growth factor receptor', 'hormonal receptor', 'brain metastases', 'randomised controlled trial', 'binding interaction', 'capecitabine', 'neratinib (pubchem cid: 9915743)', 'electrophilic fatty acids', 'network meta-analysis', 'lapatinib', 'shell residues', 'ds8201a', 'distant disease-free survival', 'autophagy', 'ds-8201', 'organoids', 'ibrutinib (pubchem cid: 24821094)', 'third line', 'therapy', 'overall survival', 'master protocol trial', 'anticancer', 'her2-positive metastatic breast cancer', 'src-kinase', 'brca1/2', 'drug-drug interactions', 'endoplasmic reticulum (er) stress', 'combination treatment', 'prodromal disease', 'covalent drugs', 'her4', 'permutation test', 'receptor', 'tyrosine kinase inhibitors', 'targeted dendrimer', 'c-met/erbb1 axis', 'imatinib (pubchem cid: 5291)', 'covalent targeted kinase inhibitors', 'wnt5a', 'tyrosine kinase inhibitor', 'her', 'adjuvant treatment', 'adjuvant therapy', 'copositive', 'gut microbiota', 'her2-positive breast cancer', 'axis blockade', 'health-related quality of life', 'metabolites', 'her2\\\\xa0+', 'disease-free survival', 'linear modeling', 'sorafenib', 'diarrhea prophylaxis', 'inhibitor', 'rat model', 'larotrectinib', 'clinical trial', 'biomatrices', 'novel therapy', 'gpr116', 'her2', 'serum albumin', 'margetuximab', 'afatinib (pubchem cid: 10184653)', 'triple-positive breast cancer', 'molecular simulation', 'her2 mutant', 'neoadjuvant', 'quantitative calculations', 'estrogen receptors', 'trastuzumab duocarmazine', 'protocol', 'brain metastasis', 'early stage', 'human serum albumin', 'systemic therapy', 'meta-analysis', 'disease surveillance', 'cdk', 'emerging therapeutics', 'breast neoplasms', 'triple negative breast cancer', 'feline her2 tk mutations', 'cabozantinib', 'vorinostat', 'hormone receptor–positive', 'species difference', 'mutation burden', 'trastuzumab-emtansine', 'expert consensus', 'famotidine'}\n",
      "******************************\n",
      "\n",
      "\n",
      "pertuzumab- {'breast', 'her2-positive', 't-dm1', 'her2+', 'cancer', 'trastuzumab', 'neoadjuvant', 'with', 'a'}\n",
      "pertuzumab- {'her2-positive', 't-dm1', 'her2', 'we', 'trastuzumab', 'the', '95%', '+', '=', 'pertuzumab'}\n",
      "\n",
      " all_keys: {'her2-targeted therapy', 'enhertu', 'hr+/her2+', 'dual blockade', 'nlr', 'neoadjuvant chemotherapy', 'disease recurrence', 'real-world', 'advanced breast cancer', 'endocrine therapy', 'pathological complete response', 'cdk4/6 inhibitors', 'expanded access', 'neoadjuvant treatment', '89zr-immunopet', 'population-based', 'cost-effectiveness', 'antitumor effect', 'systematic review', 'trastuzumab', 'anti‐inflammatory activity', 'her2-positive receptors', 'dosage', 'breast cancer outcomes', 'hyaluronidase', 'synergistic antitumor activity', 'second-line treatment', 'haemodialysis', 'nact', 'immune therapy', 'tucatinib', 'her2+ breast cancer', 'bispecific antibody', 'diarrhea', '99mtc', 'paclitaxel', 'cost-effectiveness analysis', 'herceptin', 'vinorelbine', 'trastuzumab + pertuzumab', 'vascular access', 'targeted therapy', 'salivary duct carcinoma', 'a', 'radiotherapy', 'trastuzumab/pertuzumab blockade', 'cell internalization', 'trastuzumab deruxtecan', 'residual invasive early breast cancer', 'carcinoma ex pleomorphic adenoma', 'left ventricular dysfunction', 'breast cancer', 'cancer vaccines', 'her-2-positive mbc', 'predictive markers', 'intact rb', 'skbr3 cells', 'heterogeneity', 'partitioned survival analysis', 'essential amino acid', 'human epidermal growth factor receptor 2', 'drug resistance', 'lysosome targeting drug', 'flex care', 'survival', 'metastases', 'fdg-pet', 'trastuzumab-dkst', 'lichenoid drug eruption', 'myeloma', 'adjuvant', 'biosimilar', 'ductal carcinoma in situ', 'ct-p6', 'her2/erbb2', 'her2 positivity', 'prognostic markers', 'pyrotinib', 'neoadjuvant therapy', 'logistic regression', 'pertuzumab', 'chinese', 'human epidermal growth factor', 'monoclonal antibody', 'dosage adjustment', 'prognosis', 'early-stage breast cancer', 'brain tumor', 'feline mammary carcinoma', 'human epidermal growth factor receptor 2 positive', 'tatibody', 'mlr', 'blockades', 'cardiac safety', 'digital medicine', 'her-2 positive', 'tat-ptd', 'biosimilars', 'adverse effect', 'fam-trastuzumab deruxtecan', 'xeloda', 'her-2', 'cancer immunotherapy', 'modeling', 'gastric cancer', 'toxicités', 'eribulin mesylate', 'first-line', 'tukysa', 'cancer du sein', 'bsrem', 'ontruzant', 'adverse effects', 'radiothérapie', 'molecular imaging', 'flow cytometry', 'a10', 'china', 'antipoliferation', 'reconstruction algorithms', 't-dm1', 'cancer', 'ovarian cancer', 'lactation', 'a19', 'early breast cancer', 'positron emission tomography', 'h2-18', 'q.clear', 'immune checkpoints', 'phesgo', 'indication-specific pricing', 'taxane', 'head and neck cancer', 'first-line treatment patterns', 'amplification', 'lichen planus', 'route of administration', 'her2-positive', 'non-essential amino acid', 'herzuma', 'her2-positive disease', 'monoclonal antibodies', 'neratinib', 'value-based pricing', 'signal peptide', 'metastatic breast cancer (mbc)', 'osem', 'tdm-1', 'feline her2 mutations', 'treatment.', 'combination therapy', 'thrombocytopenia', 'neoadjuvant systemic treatment', 'metastatic breast cancer', 'her2 resistance', 'ado-trastuzumab emtansine', 'trastuzumab emtansine', 'efficacy', 'immunotherapy', 'parotid', 'a1', 'molecular targeted therapy', 'population pharmacokinetics', 'piv', 'subcutaneous trastuzumab', 'drug multipurposing', 'hemodialysis', 'maldi mass-spectrometry', 'human epidermal growth factor receptor 2 (her2)', 't-aml', 'peripheral neuropathy', 'safety', 'systhers', 'baseline characteristics', 'carboplatin', 'diffuse large b-cell lymphoma of central nervous system', 'brain metastases', 'response', 'pegylated monoclonal antibodies', 'capecitabine', 'dvd-ig', 'network meta-analysis', 'lapatinib', 'anti-erbb2 antibody', 'infusion-related reaction (irr)', 'new drugs', 'antibody drug conjugate', 'cardiotoxicity', 'therapy', 'overall survival', 'tchp', 't-dm1 efficacy', 'antibody leaders', 'cardioprotective medications', 'invasive growth', 'plr', 'anti-her2', 'tumor spheroid', 'home administration', 'annular atrophic lichen planus', 'docetaxel', 'real world', 'tyrosine kinase inhibitors', 'real-life', 'retrospective real-world data study', 'adjuvant therapy', 'pathology', 'her2-positive breast cancer', 'axis blockade', 'dosing', 'dialysis', 'cost-efficiency', 'cardiac dysfunction', 't-mds', 'ado-trastuzumab', 'perjeta', 'toxicities', 'her2', 'dual targeted therapy', 'margetuximab', 'neoadjuvant', 'recombinant production', 'invasive pleomorphic lobular breast carcinoma', 'colorectal cancer', 'tumor organoid', 'overexpression', 'pregnancy', 'combined therapies', 'meta-analysis', 'antibody families', 'kadcyla', 'resistance', 'chemotherapy', 'breast neoplasms', 'sb3', 'hersintuzumab', 'target therapy', 'duct carcinoma', 'patient perspectives', 'trastuzumab-emtansine', 'rash', 'drug interactions', 'cyclin d1', 'long survival', 'eribulin', 'metastatic'}\n",
      "******************************\n",
      "\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "pathologic complete response- {'breast', 'her2-positive', 'neoadjuvant', '1', 'mri', 'cancer:', 'with', 'a'}\n",
      "pathologic complete response- {'however,', 'her2-positive', 'the', '<', '95%', 'neoadjuvant', 'in', '=', 'we'}\n",
      "\n",
      " all_keys: {'pathologic response', 'quality of life (qol)', 'neoadjuvant chemotherapy', 'nigeria', 'restricted mean survival times', 'serous carcinoma', 'pathological complete response', 'pathologic complete response (pcr)', 'neoadjuvant treatment', 'chemoradiotherapy', 'kit d816v', 'systematic review', 'rectal neoplasms', 'major pathological response', 'tumor regression grade', 'residual tumour', 'recurrence', 'her2+ breast cancer', 'prostatectomy', 'neoadjuvant immunotherapy', 'triple-negative breast cancer (tnbc)', 'bone lymphoma', 'car-t cells', 'sample size', 'completepathologicalresponse', 'neoadjuvanttherapyinbreastcancer', 'trial design', 'qualitative', 'urothelial carcinoma', 'nduction chemotherapy', 'esmo congress 2020', 'pancreatic neoplasms', 'mir-378a-3p', 'soft tissue sarcoma', 'adult oncology', 'mitomycin c', 'pathologic complete response', 'ripretinib', 'targeted therapy', 'olaparib', 'watchful waiting', 't4 breast cancer', 'radiotherapy', 'intestinal microbial', 'liver resection', 'post-neoadjuvant therapies', 'gastro-oesophageal adenocarcinoma', 'radiation', 'breast cancer', 'petct', 'wingless-related integration site (wnt)/β-catenin pathway', 'apalutamide', 'survival analysis', 'human epidermal growth factor receptor 2', 'triple-negative breast carcinoma', 'cervical cancer', 'flex care', 'postmastectomy radiotherapy', 'β-catenin', 'atezolizumab', 'lymphocyte-to-monocyte ratio', 'magnetic resonance tumor regression grading', 'immunology', 'rtog 0529', 'residual cancer burden', 'chimiothérapie', 'adjuvant', 'ascent', 'mixture model', 'magnetic resonance imaging', 'clinical and pathologic features', 'axillary lymph node', 'organ preservation', 'gastrointestinal stromal tumor (gist)', 'ductal carcinoma in situ', 'adverse events', 'platelet-to-lymphocyte ratio', 'chemo-resistance', 'neo-adjuvant', 'neoadjuvant therapy', 'neoadjuvant systemic therapy (nast)', 'randomized controlled trial', 'neoadjuvant chemotherapy and radiotherapy', 'combined modality treatment', 'avapritinib', 'iwg-mrt-ecnm', 'endometrial cancer', 'review', 'prognosis', 'cystectomy', 'androgen deprivation therapy', 'secondaire', 'pembrolizumab', 'ucb', 'esophageal squamous cell carcinoma', 'rectal', 'primitif', 'digital medicine', 'germline sequencing', 'atypical endometrial hyperplasia', 'immune-check point inhibitors', 'midostaurin', 'cancer stemness', 'neoadjuvant chemoradiotherapy', 'tak-228', 'cochrane protocol', '5-fluorouracil', '16s rrna gene sequencing', 'calcification', 'axilla', 'chemotherapy resistance', 'radiothérapie', 'pallas', 'intensity-modulated radiation therapy', 'molecular switches', 'ovarian cancer', 'programmed cell death 1 (pd-1)', 'nigro regimen', 'mir-378d', 'outcomes', 'early breast cancer', 'complete response', 'nac', 'axillary lymph node dissection', 'treatment personalization', 'locally advanced', 'case report', 'apparent diffusion coefficient', 'non-small cell lung cancer (nsclc)', 'locally-advanced breast cancer', 'folfirinox', 'her2-positive', 'uterine cervical neoplasms', 'upper tract urothelial cancer', 'ultrasound', 'diagnostic', 'tumor-infiltrating lymphocytes', 'physiologic', 'surgery', 'concordance', 'hypofractionated radiotherapy', 'neoadjuvant systemic treatment', 'mtor inhibitor', 'trimodality therapy', 'hypoxia', 'chemotherapy-elicited exosomes', 'efficacy', 'esophagectomy', 'esophageal adenocarcinoma', 'programmed death ligand 1', 'extremity soft tissue sarcoma', 'immunotherapy', 'diagnosis', 'locoregional recurrence', 'lobular carcinoma', 'lumpectomy omission', 'tumor-associated lymphocytes', 'fertility-sparing treatment', 'biomarkers', 'toxicity management', 'aquaporin 1', 'locally advanced breast cancer', 'axillary surgery', 'brca mutation', 'sp142 pd-l1', 'secondary', 'biochemical recurrence', 'pancreatic cancer', 'neoadjuvant chemoimmunotherapy', 'highlights', 'lung squamous cell carcinoma (lusc)', 'alk-tki', 'high dose-intensity chemotherapy', 'clinical trials', 'sigmoid colon cancer', 'sacituzumab govitecan', 'treatment', 'triple-negative breast cancer', 'non-small-cell lung cancer (nsclc)', 'monarche', 'thoracic surgery', 'adjuvant alectinib', 'locoregional radiotherapy', 'complete', 'pd-l1', 'germline alterations', 'response', 'urinary bladder neoplasms;neoadjuvant therapy', 'imaging', 'resistant mutation', 'recurrence-free survival', 'neoadjuvant chemoradiation therapy', 'dna damage repair', 'neo-adjuvant therapy', 'network meta-analysis', 'global oncology', 'intralesional therapy', 'wound complications', 'indomethacin', 'inflammatory breast cancer', 'de-escalation', 'lung neoplasms', 'hormone therapy', 'radical cystectomy', 'conservativebreastcancersurgery', 'programmed cell death 1', 'sentinel lymph node biopsy', 'muscle invasive bladder cancer', 'home administration', 'locally advanced rectal cancer (larc)', 'bladder cancer', 'complete resection', 'pathology', 'her2-positive breast cancer', 'down staging', 'breast cancer therapy expert group', 'tumor regression grading', 'tumour response', 'abiraterone acetate', 'radiotherapy dose', 'prevention', 'pathological complete response (pcr)', 'melanoma', 'neutrophil-to-lymphocyte ratio', 'patterns of failure', 'her2', 'total neoadjuvant therapy (tnt)', 'remote controlling', 'lymphome osseux', 'm2 macrophage', 'complete pathologic response', 'multidetector computed tomography', 'neoadjuvant', 'parp inhibitor', 'breast cancer imaging', 'prostate cancer', 'colorectal cancer', 'hormone receptor-positive', 'cost effectiveness analysis', 'pathologic', 'systemic therapy', 'meta-analysis', 'primary', 'chemotherapy', 'rectal cancer', 'advanced nodal disease', 'platinum-based chemotherapy', 'target therapy', 'patient perspectives', 'cytotoxic t cells', 'systemic mastocytosis', 'circulating tumor dna', 'nomogram', 'supraclavicular radiation', 'neoadjuvant alectinib'}\n",
      "******************************\n",
      "\n",
      "\n",
      "surgery- {'microbubble', 'the', 'examination', 'outcomes', 'long-term', 'curettage', 'squamous', 'knee', 'use', 'histopathological'}\n",
      "surgery- {'the', '<', 'yap1', 'mri', 'in', '=', '±', 'dex', 'pvi', 'we'}\n",
      "\n",
      " all_keys: {'microbubble', 'dna methyltransferases (dnmts)', 'older adults', 'neurotoxicity', 'chronic kidney disease', 'coping strategies', 'negative', 'hcc', 'motor unit number estimation', 'mycoplasma', 'experimental study', 'fenton reaction', 'streptococcus pyogenes', 'huntington’s disease (hd)', 'flexibility of the incudo-malleal joint', 'exercise', 'ice hockey', 'youth athletes', 'genome-wide', 'segmental motion', 'breast mri', 'falls', 'diet-induced obesity', 'corneal ulcer', 'liver resection', 'lower extremity', 'elderly', 'breast cancer', 'fibroblast', 'epigenetic-based therapy', 'microglia', 'nlrp3 inflammasome', 'thoracolumbar fracture', 'secondary hyperparathyroidism', 'cancer du nasopharynx', 'burst fracture', 'vascular biology', 'patient management', 'sufentanil', ' grade.', 'mortality', 'glucagon-like peptide-1', 'endoscopic retrograde cholangiopancreatography', 'total parathyroidectomy with autotransplantation', 'oxidative phosphorylation', 'nonviable pregnancy', 'hcc recurrence', 'dynamic head rotation', 'bromodomain-containing protein 7', 'critical care', 'cesarean section', 'stem cell niche', 'football (soccer)', 'participatory', 'adipose tissue', 'bilateral primary tumor', 'oral cancer', 'world', 'abdominal surgery', 'thermogenesis', 'injection drug use', 'next-generation sequencing (ngs)', 'serine\\\\\\\\threonine protein kinase 24', 'vocal fold', 'anterior cruciate ligament', 'cervical segments', 'alignment', 'aged', 'hypertrophic cardiomyopathy', 'guidelines', 'leak', 'glp-1', 'return to sport', 'complications', 'opioid epidemic', '3d surface scan', 'surgical site infection', 'moral distress', 'steroid-induced avascular necrosis of femoral head', 'cisplatine', 'adaptation to static pressure changes', 'drug screening', 'diagnosis', 'eye', 'inorganic arsenic', 'acute traumatic central cord syndrome', 'miz1', 'stent', 'mu-opioid receptor', 'genetics', 'advanced hepatocellular carcinoma', 'inflammation', 'trauma', 'histopathological examination', 'pancreatoduodenectomy', 'mitochondrial supercomplexes', 'mir-206', 'boxing', 'laparotomy', 'sports psychology', 'implantable cardioverter-defibrillator', 'mor', 'single-cell rna-seq', 'infective endocarditis', 'association study', 'syria', 'molar pregnancy', 'breast volume', 'transfer function of the middle ear', 'astrocytes', 'injury', 'magnetic resonance cholangiopancreatography', 'autophagy', 'wechat platform', 'clinical practice', 'lipid peroxidation', 'tp53 c.475g>c', 'scrna-seq', 'dexamethasone', 'transvesical radical prostatectomy', 'in vivo', 'exercise training', 'gemcitabine', 'sebt', 'robotic radical prostatectomy', 'postoperative hypocalcemia', 'blood cultures', 'predictive', 'gut microbiota', 'head-neck complex', 'intensive care unit', 'palliative care', 'hepatocyte nf-κb', 'mavacamten', 'visceral traction pain', 'apoptosis', 'navigation', 'akt', 'pseudocyst', 'gestational trophoblastic disease', 'surgical treatment', 'pregnancy', 'hydatidiform mole', 'metadherin', 'head and neck squamous cell carcinoma', 'groin pain', 'hip pain', 'plc injury', 'attenuation of the middle-ear transfer function', 'bacteria', 'bone pain', 'spinal anesthesia', 'radiomic', 'clival chordomas', 'lymphatic endothelial cells', 'stk24', 'knee injury', 'genetic association study', 'prognostication', 'pancreatitis', 'polymer', 'incomplete pancreatic divisum', 'load-sharing classification', ' incarceration', 'rp11-51o6.1', 'lrinec score', 'recurrence', 'yes-associated protein 1', 'protein complexes', 'paclitaxel', 'compliance', 'obesity-associated metabolic disorder', 'microrna', 'neurodegeneration', 'bioinformatics', 'leptin sensitivity', 'epidemiology', 'heart failure', 'iron-based nanomaterials', 'metastasis', 'physical activity', 'middle-ear ossicular joints', 'pacemaker', 'voice', 'single port', 'chloroquine', 'heterogeneity', 'anembryonic pregnancy', 'ntsr2', 'anterior tibial displacement', 'endoscopic approach', ' brace', 'methylnaltrexone', 'magnetic resonance imaging', 'randomized control trial', 'static pressure', 'clostridium perfringens', 'mir-96-5p', 'cardiac resynchronization therapy', 'nerve excitability', 'vitreous substitute', 'compensatory lateral curvature', 'epigenetic regulation', 'mitochondrial respiratory complexes', 'cardiac surgery', 'knee osteoarthritis', 'fungal keratitis', 'rehabilitation', 'foreign body', 'health behaviour', 'ampk', 'pretreatment', 'corneal infection', 'effusion', 'frailty', 'neurotensin', 'covid-19', 'necrotizing soft tissue infection', 'cardiac implantable electronic devices', 'endoplasmic reticulum stress', 'reconstruction', 'pediatric', 'prognostic', 'outcomes', 'portal vein invasion', 'wrist', 'fiducial', 'consensus', 'head and neck cancer', 'rostral mucosa', 'ultrasound', 'lung squamous carcinoma', 'general imaging and radiography', 'perioperative outcomes', 'spinal cord injury', 'surgery', 'knee surgery', 'anterior tibial translation', 'multidisciplinary collaboration', 'tamponade', 'hypothalamic inflammation', 'continuous care', 'hip', 'genomic profiling', 'cisplatin', 'portal thrombectomy', 'magnetic resonance imaging (mri)', 'albumin-globulin ratio', 'transcription', 'nasopharyngeal cancer', 'organoid', 'pancreatic cancer', ' epistemonikos', 'treatment outcome', 'lung', 'treatment', 'steroids', 'ferroptosis', 'septal reduction therapy', 'alveolosphere', 'mtdh', 'shivering', 'military training', 'hepatocellular carcinoma (hcc)', 'risk factors', 'whipple procedure', 'computer-assisted surgery', 'tlics', 'bone marrow mesenchymal stem cells', 'competitive endogenous rna', 'therapy', 'intervertebral disc degeneration', 'complexome', 'hepatocellular carcinoma', 'vestibular schwannoma', '3d computed tomography (ct) analysis', 'transphosphatidylation', 'hydrogel', ' geriatric surgery inguinal hernia', 'refugee', 'tumorigenesis', 'incudo-malleal joint', 'cardiac rehabilitation', 'autophagie', 'mntx', 'prevention', 'total knee arthroplasty', 'adipose tissue macrophages', 'addiction', 'phosphatidylinositol 3-kinase', 'feline', 'hne1/ddp', 'family function', 'reactive oxygen species', 'prostate cancer', 'colorectal cancer', 'health disparity', 'intensive care', 'lncrnas', 'oprm1 gene', 'radiation exposure', '\"mccormack-gaine\\'s index\"', 'bowel obstruction', ' older people', 'endotherapy', 'iassist', 'dynamic balance'}\n",
      "******************************\n",
      "\n",
      "\n",
      "polymorphism- {'the', '(snps)', 'covid-19', 'subjects', 'frequency', 'mthfr', 'japanese', 'genetic', 'characterization', 'rs671'}\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "polymorphism- {'however,', 'the', 'sars-cov-2', '95%', 'in', 'risk', 'covid-19', '=', 'snp', 'we'}\n",
      "\n",
      " all_keys: {'chrysophrys auratus', 'in-situ analytics', 'growth hormone', 'associational effects', 'chronic kidney disease', 'homocysteine', 'hemophagocytic lymphohistiocytosis', 'raman spectroscopy', 'susceptibility', 'atlastin-1', 'cyp19a1', 'genetic variation', 'selective pressure', 'mastitis', 'swine leukocyte antigen', 'supersaturation', 'snp', 'near-infrared spectroscopy', 'world war ii', 'enzymatic activity', 'fat mass', 'ndm-1', 'glyceroneogenesis', 'amomum tsao-ko', 'posttranscription regulation', 'rs671', 'obesity-associated gene protein', 'polymorphic variants', 'cooperation', 'phenotype', 'cancer stroma', 'poorly water-soluble drugs', 'energy framework', 'otc gene', 'plasmids', 'fruit flavor', 'pea', 'hypotension', 'sequence-specific primers pcr', 'epithelial ovarian cancer', 'supra\\\\xadmolecular framework', 'art', 'vo2max test', 'pyrazine', 'tuberculosis', 'theoretical model', 'trichophyton equinum', 'mortality', 'genetic modifiers', 'renin-angiotensin system', 'mlst', 'aldehyde dehydrogenase 2', 'alcohol abstinence', 'opportunities', 'somatic diversification', 'freeze-drying', 'pediatric non-hodgkin lymphoma', 'molecular biology', 'gene polymorphism', 'next-generation sequencing', 'apai', 'pgt-sr (structural rearrangement)', 'cryptococcus neoformans species complex', 'transcription regulation', 'genetic affinity', 'coronavirus', 'apoe', 'cesarean section', 'real-time pcr', 'vim-2', 'self incompatibility', 'genetic sex determination', 'hla polymorphism', 'biological sciences', 'prognostic/predictive markers', 'genetic vulnerability', 'polymerase chain reaction', 'thermogenesis', 'ctx-m-2', 'methylenetetrahydrofolate reductase', 'periodontal disease', 'milk traits association', 'pneumocystis jirovecii', 'assortment', 'amorphous solid dispersions', 'epr effect', 'host-parasite coevolution', 'rs10204525', 'glandular trichomes', 'fiber tracking', 'kidney transplant', 'artemether-lumefantrine', 'microevolution', 'age-related cognitive impairment', 'rs1046872', 'cosmo-rs model', 'lysophosphatidic acid receptor', 'aggregation intermediates', 'cast therapy', 'octoploid strawberry', 'chagas disease', 'cancer specificity', 'discriminant function analysis', 'genetic polymorphism', 'protein aggregation', 'microsatellites', 'niveoscincus', 'single-nucleotide polymorphism', 'functional amyloids', 'adaptive immune system evolution', 'spg3a', 'epitopes', 'susceptible genes', 'atherosclerosis', 'genetics', 'gc-mass', 'inflammation', 'regions of interest', 'single nucleotide variations', 'discrimination power', 'gdh', 'malaria', 'real time monitoring', 'angiogenesis', 'prostate specific antigen', 'genetic heterogeneity', 'acute respiratory distress syndrome', 'polymorphism', 'behavioural symptoms', 'dairy cows', 'immunohistochemistry', 'tumor size', 'nonalcoholic fatty liver disease', 'ovarian stimulation', 'single nucleotide polymorphisms', 'therapeutic efficacy', 'atopic dermatitis', 'nod factor', 'mdh gene', 'sulf1', 'family history', 'ameloblastoma', 'process analytical technology (pat)', 'genotyping', 'snp array', 'hsp', 'niche diversity', 'epithelial–mesenchymal transition', 'st-elevation myocardial infarction', 'mthfr c677t polymorphism', 'tsd', 'saudi', 'ursus', 'avian ucp', 'gjb2 protein', 'sars-cov-2', 'horticulture', 'tp53 rs28934571', 'altruism', 'hepatitis c virus (hcv)', 'sex chromosome', 'leishmania tropica', 'potassium-organic framework', 'aldh2', 'bdnf', 'duplex-specific nuclease', 'base sequence', 'carboxyl\\\\xadate', 'gsd', 'neonatal outcome', 'third-generation sequencing', 'cystatin c', 'pregnancy', 'asthma', 'protein kinase', 'panstrongylus megistus', 'klebsiella pneumoniae', 'meta-analysis', 'genome-wide association study', 'primary pci', 'triatominae', 'quasispecies', 'outbreak', 'constraints', 'structural modelling', 'insoluble fibrin', 'alkali metal', 'bovine', 'prediction model', 'alpha-lactalbumin (lalba)', 'degenerative lumbar spinal stenosis', 'factor vii', 'spinal', 'blood coagulation', 'carbapenemases', 'molecular dynamics', 'gluconeogenesis', 'lykx', 'sym2', 'evolutionary history', 'high-sensitivity c-reactive protein', 'gene mutations', 'sensitivity and specificity', 'chicks', 'cd93', 'nonalcoholic steatohepatitis', 'hiv-1', 'evolutionary biology', 'evolutionary models', 'plant–herbivore interactions', 'hras', 'genetic', 'fruit tree', 'cultural evolution', 'mthfr polymorphism', 'bc28.1 gene', 'genome-wide association analysis', 'immune checkpoint inhibitors', 'microrna', 'stable polymorphism', 'horse dermatophytosis', 'alcoholism', '\\\\nsus scrofa\\\\n', 'polymorphism of htra1 gene', 'lumbar disc herniation', 'intra- and interpopulation variability', 'neuropathic pain', 'cst3 gene expression', 'gene frequency', 'klebsiella oxytoca', 'moisture content', 'oxa-23', 'ivf/icsi', 'human', 'phenotypic plasticity', 'pcsk9 gene polymorphism ', 'mthfr', 'survival', 'sustainable intensification', 'balancing selection', 'molecular markers', 'coronary artery disease', 'serotonin', 'toll-like receptor 4', 'rnai', 'salivary levels', 'hydrogen bonding', 'atl1', 'precipitation', 'single-nucleotide polymorphism (snp)', 'major adverse cardio-cerebrovascular events', 'clonal population', 'antibody drug resistance', 'milk somatic cells', 'oprd', 'platinum resistance', 'epigenetic regulation', 'hereditary spastic paraplegia', 'pfge', 'multiniche polymorphism', 'vegetative incompatibility', 'single nucleotide polymorphism (snp)', 'child', 'cytochrome p450 2e1', 'sequence covariation', 'bleeding disorders', 'genetic variance', 'sensorineural', 'lumbar disc degeneration', 'enhanced management', 'genetic probability', 'hakka', 'sars-cov-2 covid-19', 'pd-1', 'val66met polymorphism', 'klotho', 'covid-19', 'genetic improvement and crosses', 'pediatric obesity', 'prisoner’s dilemma', 'genome-based prediction', 'mutation', 'genetic susceptibility', 'high-resolution melting marker', 'babesia canis', 'metabolism', 'hearing loss', 'hirshfeld surface', 'cardiovascular diseases', 'tnf-alpha', 'tetra\\\\xadkis\\\\xad', 'mrna level', 'fsh', 'disease sites', 'human identification', 'allergic rhinitis', 'recovery and repatriation', 'oxidative stress', 'positive selection', 'cytokines', 'bsmi', 'ibuprofen', 'japanese war dead', 'temperature‐dependent sex determination', 'plasmodium falciparum', 'crystal structure', 'markers', 'chemotherapy-induced peripheral neuropathy', 'relationship', 'whole-exome sequencing', 'partial least square regression (pls)', 'cold stress', 'surfactant protein a', 'indigenous village chickens', 'adc', 'biomarkers', 'pathogenic replacements', 'alcoholic liver cirrhosis', 'belatacept', 'virulence genes', 'plasminogen activator inhibitor-1', 'epstein-barr virus', 'racemosae', 'interleukin-4', 'thrombin generation', 'inference', 'promoter polymorphism', 'anaplasma phagocytophilum', 'thoracic malignancy', 'endothelin-1', 'aurora kinase a (aurka)', 'oocytes retrieved', 'anesthesia', 'cryptococcus gattii species complex', 'hepatocellular carcinoma (hcc)', 'rs5370', 'gene flow', 'pgt-m (monogenic disease)', 'plant-rhizobia symbiosis', 'psoriasis', 'hepatocellular carcinoma', 'hypertension', 'genetic drift', 'cytokine', 'ammonia stress', 'diabetes mellitus', 'sinonovacula constricta', 'a1298c', 'growth', 'phosphoenolpyruvate carboxykinase (pck)', 'cst3 gene polymorphism', 'white matter', 'convergent evolution', 'recurrent implantation failure', 'tumorigenesis', 'antibody', 'alzheimer disease', 'issr polymorphism', 'spirit bear', 'competitive dna probe systems', 'plant breeding', 'taqi', 'controlled ovarian stimulation', 'kin recognition', 'prostate cancer', 'nitride oxide synthase', 'gene expression', 'host adaptation', 'diffusion tensor imaging (dti)', 'population structure', 'cholesterol', 'genomics', 'neovascular amd', 'morocco', 'connexin 26', 'resistance', 'chemotherapy', 'single nucleotide polymorphism', 'cutaneous leishmaniasis', 'allele-specific gene expression', 'interaction', 'intra-host single nucleotide variation (isnv)', 'genetic counselling', 'salmonella serotypes'}\n",
      "******************************\n",
      "\n",
      "\n",
      "neoadjuvant- {'breast', 'cancer', 'pd-l1', 'neoadjuvant', 'squamous', 'gemcitabine', 'resectable', 'a'}\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "neoadjuvant- {'pd-l1', 'the', '<', '95%', 'neoadjuvant', 'os', '=', '(hr', 'we'}\n",
      "\n",
      " all_keys: {'sphincter-saving surgery', 'neoadjuvant chemotherapy', 'intermittent', 'pathological complete response', 'endocrine therapy', 'collusion', 'tumor microenvironment', 'lymph nodes', 'borderline resectable', 'neoadjuvant treatment', 'conversion surgery', 'esophageal neoplasms', 'chemoradiotherapy', 'pemphigoïde bulleuse', 'renal cell carcinoma', 'signet cell adenocarcinoma', 'presentations: presented as a virtual poster presentation at the society of surgical oncology annual cancer symposium', 'multi-vendor', 'peritoneal staging', 'rectal neoplasms', 'placental site trophoblastic tumor', 'sarcome', 'enhanced recovery after surgery', 'locally advanced pancreatic cancer', 'radiodermite', 'her2+ breast cancer', 'pd-1 pathway', 'abdominoperineal resection', 'thyroid autoimmunity', 'immune checkpoint inhibitors', 'compliance', 'urothelial carcinoma', 'august 17-20th', 'pancreatic ductal', 'major hepatectomy', 'immunomodulatory activity', 'rectal bleeding', 'pathologic complete response', 'feature reduction', 'targeted therapy', 'radiotherapy', 'metastasis', 'colorectal cancer (crc)', 'breast cancer', 'survival analysis', 'human epidermal growth factor receptor 2', 'triple-negative breast carcinoma', 'sigmoid cancer', 'decision-making', 'programmed death 1', 'cervical cancer', 'survival', 'radiation lobectomy', 'psychological distress', 'residual cancer burden', 'total pain', 'psycho-oncology', 'magnetic resonance imaging', 'organ preservation', 'nectin-4', 'cutaneous disorders', 'neoadjuvant therapy', 'perioperative', 'axillary complete response', 'clinical node-positive', 'transurethral resection', 'prognosis', 'androgen deprivation therapy', 'cystectomy', 'total mesorectal excision', 'radiological complete response', 'laparoscopic', 'esophageal squamous cell carcinomas', 'pembrolizumab', 'infections', 'esophageal squamous cell carcinoma', 'variant histology', 'immune checkpoint inhibitor', 'sterilized lymph nodes', 'digital medicine', 'dynamic change', 'xelox', 'prognostic value', 'neoadjuvant chemoradiotherapy', 'cancer immunotherapy', 'gastric cancer', 'external environment', 'induction chemotherapy', 'stage iv', 'radiothérapie', 'regional hyperthermia', 'cancer', 'troubles cutanés', 'cell communication', '2020.', 'ovarian cancer', 'programmed-death ligand 1', 'radioembolization', 'early breast cancer', 'treatment personalization', 'case report', 'upper abdominal disease', 'consensus', 'non-small cell lung cancer (nsclc)', 'rectosigmoid cancer', 'sarcoma', 'neoadjuvant systemic therapy', 'gastrectomy', 'pancreas cancer', 'resectable pancreatic cancer', 'radiodermatitis', 'post hepatectomy liver failure (phlf)', 'locally advanced rectal cancer', 'young', 'complications', 'surgery', 'radiomics', 'neutrophils', 'combination therapy', 'crispr/cas9‐based library screening', 'kras', 'clinicopathologicalfeatures', 'nab-paclitaxel', 'concurrent chemoradiotherapy', 'efficacy', 'peritoneal disease', 'immunotherapy', 'tumor-associated lymphocytes', 'biomarkers', 'urinary division', 'survey', 'gynecologic surgical procedures', 'radiation therapy', 'pancreatectomy', 'locally advanced breast cancer', 'survivorship', 'axillary surgery', 'precision medicine', 'pancreatic cancer', 'non-pathological complete response', 'gender', 'adherence', 'sigmoid colon cancer', 'pancreas', 'late anastomotic leak', 'antibody–drug conjugate', 'treatment', 'triple-negative breast cancer', 'eras', 'borderline resectable pancreatic cancer', 'adolescents and young adult(aya)s', 'quadruple-modality therapy', 'neoadjuvant endocrine therapy', 'greater omentum', 'pd-l1', 'immunological status', 'immune regulation', 'triple-negative<bold></bold>breast cancer', 'bullous pemphigoid', 'stage migration', 'therapeutic efficacy', 'transanal', 'tumor mutational burden', 'hypothyroidism', 'adjuvant chemotherapy', 'bcg', 'muscle-invasive bladder cancer', 'urinary bladder neoplasms', 'nomograms', 'radical cystectomy', 'lung neoplasms', 'staging laparoscopy', 'major pathologic response', 'charlson comorbidity index', 'hemophagocytic lymphohistiocytosis (hlh)', 'gemcitabine', 'hepatocellular carcinoma', 'muscle invasive bladder cancer', 'breast surgery', 'adenocarcinoma', 'immunonutrition', 'long-term outcomes', 'tyrosine kinase inhibitors', 'bladder cancer', 'lymph node yield', 't cell exhaustion', 'tyrosine kinase inhibitor', 'predictive factors', 'postoperative complications', 'adjuvant treatment', 'adjuvant therapy', 'pathology', 'personalised medicine', 'down staging', 'vascular resection', 'palliative care', 'prevention', 'stage iii n2 lung cancer', 'surgical resection', 'her2', 'm2 macrophage', 'neoadjuvant', 'prostate cancer', 'colorectal cancer', 'clinical complete response', 'breast cancer microenvironment', 'genomics', 'recurrent/non-resectable cancer', 'nodal status', 'whole exon sequencing', 'meta-analysis', 'anterior rectal resection', 'chemotherapy', 'breast neoplasms', 'rectal cancer', 'bevacizumab', 'stomach neoplasms', 'cabozantinib', 'survey research', 'cytotoxic t cells', 'circulating tumor dna', 'interval cytoreductive surgery', 'advanced ovarian cancer', 'venous tumor thrombi', 'total neoadjuvant therapy'}\n",
      "******************************\n",
      "\n",
      "\n",
      "adjuvant- {'breast', 'cancer', 'review', 'adjuvant', 'squamous', 'covid-19', 'cancer:', 'a', 'study', 'therapy'}\n",
      "adjuvant- {'the', 'adjuvant', '95%', 'ddx5', 'in', 'covid-19', 'os', '=', 'a', 'we'}\n",
      "\n",
      " all_keys: {'older adults', 'periurethral', 'endometrial stromal cell', 'menopausal status', 'risk stratification', 'degradation', 'clostridial vaccine', 'lumbar', 'chemoradiotherapy', 'combination immunotherapy', 'existential issues', 'immunologic', 'non-drug therapy', 'relapse', 'hif-1α', 'exercise', 'design', 'epitope', 'streptococcus suis', 's-1', 'cauda equina', 'pain', 'molecular mechanisms', 'vaginal microbiota', 'radiotherapy', 'helicobacter pylori', 'breast cancer', 'radiosensitization', 'pili', 'metformin', 'gene signature', 'toxic nodule’ toxic multinodular goiter', 'nlrp3 inflammasome', 'bone regeneration', 'glioblastoma multiform', 'ganciclovir', 'n-dimethyltryptamine', 'iron chelator', 'mortality', 'sex cord-stromal tumor', 'ehpvo', 'neoadjuvant therapy', 'mechanical ventilation', 'fertility-sparing surgery', 'concomitant', 'androgen deprivation therapy', 'molecular diagnosis', 'early-stage breast cancer', 'methadone', 'pembrolizumab', 'health-care provider', 'anti-müllerian hormone (amh)', 'chordoma', 'rcbv', 'endometriosis', 'zinc', 'fusion protein', 'angiotensin', 'gastric cancer', 'intensity modulated radiation therapy', 'pcqn', 'oestrogen receptor status', 'pyridoxal', '16s rrna', 'probiotics', 'cancer', 'adoptive immunotherapy', 'hygiene hypothesis', 'early breast cancer', 'case report', 'upper gum', 'complications', 'neratinib', 'forkhead box l2 mutation', 'pancreatic ipmn', 'ciprofloxacin', 'osteosarcoma', 'kidney & urinary tract disorders', 'uterine carcinosarcoma', ' p2x7 receptor', 'neuromodulation', 'diagnosis', 'immunotherapy', 'melatonin', 'acromegaly', 'stroke', 'colon carcinoma', 'outcome', 'th2-adjuvant', 'life coaching', 'lithium', 'ctxb', 'kidney', 'supramolecular hydrogels', 'inflammation', 'psychometrics', 'uterus', 'cerebral ischemia', 'angiogenesis', 'genomic signature', 'immunohistochemistry', 'pd-l1', 'hospital length of stay', 'metabolomics', 'epicatechin', 'antigens', 'perinatal asphyxia', 'lymphocyte', 'nsclc', 'paraganglioma', 'adjuvant chemotherapy', 'utilization', 'neuroendocrine tumor', 'overall survival', 'predict tool', 'zoledronate', 'autoimmunity', 'hgg', 'obstetric outcome', 'curcumin', 'histopathology', 'gene therapy', 'adjuvant treatment', 'uric acid', 'sars-cov-2', 'right upper quadrant', 'cd8-positive t-lymphocytes', ' lung damage', 'gut microbiota', 'hepatocyte', 'iran', 't4 prostate cancer', 'scalp squamous cell carcinoma', 'palliative care', 'neonatal encephalopathy', 'melanoma', 'neuroendocrine', 'pcnsl', 'granulosa cell tumor of the ovary', 'dendritic cells', 'locally advanced colon cancer', 'lower gum', 'breast neoplasms', 'serum human chorionic gonadotrophin', 'carcinosarcoma', 't4 colon cancer', 'cavernous transformation', 'neutrophil', 'interferon-alpha', 'opioid', 'oncologic rehabilitation', 'neoadjuvant chemotherapy', 'emt', 'total flavonoids', 'intermittent', 'endocrine therapy', 'tumor microenvironment', 'psma pet imaging', 'microbial exposures', 'hepatitis b', 'n', 'sacral', 'cardiophrenic lymph node', 'therapeutic hypothermia', 'prognostic model', 'rectal neoplasms', 'placental site trophoblastic tumor', 'papillary thyroid cancer', 'kynurenine', 'ivig', 'recurrence', 'behavior', 'rectum', 'squamous cell carcinoma', 'hyperthyroidism', 'surgical oncology', 'psr', 'hypofractionation', 'spreading depolarization', 'orthopaedic implant', 'immune checkpoint inhibitors', 'hormone receptor', 'intraductal papillary mucinous neoplasm', 'person-centered communication', 'thyroid cancer', 'debulking surgery', 'targeted therapy', 'uterine cancer', 'epidemiology', 'neuroprotection', 'patterns of metastasis', 'metastasis', 'oncological outcome', 'physical activity', 'medical oncology', 'albumin', 'suicidal gene', 'whole person care', 'bacterial diversity', 'mucosal immunity', 'extranodal metastasis', 'non-inferiority rct', 'rag2', 'human epidermal growth factor receptor 2', 'clear margins', 'survival', 'central nervous system', 'allograft', 'follicle-stimulating hormone (fsh)', 'intradural', 'microbiota', 'carcinoma', 'cpt-11', 'pvt', 'adenoid cystic carcinoma', 'neonatology', 'skeletal muscle', 'tumour control', 'self‐assembled peptides', 'prognosis', 'adjuvanticity', 'end stage renal failure', 'peritoneal metastases', 'multiparametric mri', 'melittin', 'pbi', 'immunoregulation', 'endopredict®', 'graves’ disease', 'tips', 'tracheal-bronchial cancer', 'digital medicine', 'braf mutations', 'oncological outcomes', '5-amino levulinic acid', 'neoadjuvant chemoradiotherapy', 'clinical trials as topic', 'brain injury', 'neurology', 'covid-19', 'prognostic nutritional indicator', 'host-direct therapies', 'mesenchymal stem cell', 'ovarian cancer', 'prognostic', 'radiobiology', 'vibrio cholerae', 'outcomes', 'local chemotherapy', 'chronic stress', 'ace2', 'head and neck cancer', 'multicenter study', 'perfusion imaging', 'pancreas cancer', 'c-reactive protein', '3d-printed titanium alloy', 'adjuvants', ' tuberculosis', 'young', 'oxidative stress', 'gallbladder', 'glycyrrhiza uralensis', 'micrometastasis', 'splenic artery', 'type 1 diabetes', 'matrine', 'clinicopathologicalfeatures', 'photo-dynamic therapy (pdt)', 'biomarkers', 'radiation therapy', 'bone metastases', 'hygiene', 'pancreatic cancer', 'gestational throphoblastic disease', 'lymph node metastases', 'biochemical progression', 'remission', 'endoscopic surgery', '5-ala', 'ovarian reserve', 'metabolite', 'treatment', 'quadruple-modality therapy', 'invasive ipmn', 'evolution', 'leptomeningeal spread', 'interviews', 'immunogenicity', 'pleomorphic rhabdomyosarcoma', 'medullary thyroid cancer', 'sarcopenia', 'tcpa', 'adjuvant arthritis', 'vaccine', 'choroid plexus carcinoma', 'close margins', 'surgeon experience', 'major pathologic response', 'echinococcosis', 'unexplained recurrent spontaneous abortion', 'cell migration', 'new therapies', 'hepatocellular carcinoma', 'cytokine', 'vagus nerve stimulation', 'splenic vein', 'carcinoembryonic antigen', 'betel chewing', 'pancreatic ductal adenocarcinoma', 'adjuvant therapy', 'hydrogel', 'cytokine storm', 'anhedonia', 'extramural tumor deposits', 'sigma-1 receptor', 'non cirrhotics', 'rat', 'dialysis', 'prevention', 'antibody', 'prostate cancer with bladder invasion', 'cancer registry', 'lung squamous cell carcinoma', 'sbp2’', 'prostate cancer', 'colorectal cancer', 'radioactive iodine', 'knowledge', 'brachytherapy', 'mir-199a-5p', 'hysterectomy'}\n",
      "******************************\n",
      "\n",
      "\n",
      "trastuzumab- {'breast', 'her2-positive', 'her2', 'myl-1401o', 'cancer', 'trastuzumab', 'neoadjuvant', 'with', 'a'}\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "trastuzumab- {'her2-positive', 't-dm1', 'her2', 'the', 'trastuzumab', '(week', 't-dxd', '=', 'we'}\n",
      "\n",
      " all_keys: {'her2-targeted therapy', 'selenium (se)', 'surrogate subtyping', 'hr+/her2+', 'dual blockade', 'neoadjuvant chemotherapy', 'somatic mutations', 'antibody drug conjugate (adc)', 'nlr', 'egfr', 'advanced breast cancer', 'endocrine therapy', 'pathological complete response', 'expanded access', 'conversion surgery', 'antibodies', 'neoadjuvant treatment', 'auger electron therapy', 'lyophilization', 'guideline concordance', 'population-based', 'competition', 'trastuzumab', 'adalimumab', 'anti‐inflammatory activity', 'registries', 'bispecific antibody', 'extended adjuvant treatment', 'pcr', 'reduced glutathione (gsh)', 'medicine', 'hydrophobic surface', 'systemic treatment', 'toxicity', 'vinorelbine', 'trastuzumab + pertuzumab', 'her2 amplification', 'salivary duct carcinoma', 'perioperative treatment', 'oncologics', 'a', 'oncology', 'passive adsorption', 'trastuzumab deruxtecan', 'radiotherapy', 'monomethyl auristatin-f', 'non-medical shift', 'kadcyla® (t-dm-1)', 'residual invasive early breast cancer', 'her2 positive', 'breast cancer', 'biological', 'n-terminal conjugation', 'cancer vaccines', 'bispecific antibodies', 'heterogeneity', 'short duration', 'the netherlands', 'tcr mimic antibodies', 'human epidermal growth factor receptor 2', 'lysosome targeting drug', 'microwave-assisted reduction', 'serum human epidermal growth factor receptor 2 (her2)', 'sustainability', 'graphene oxide', 'microsatellite instability (msi)', 'wistar rats', 'trastuzumab-dkst', 'adjuvant', 'krt19', 'erbb2', 'biosimilar', 'ductal carcinoma in situ', 't-tubules', 'herceptin®', 'cardio-oncology', 'her2/erbb2', 'neo-adjuvant', 'necrotizing cellulitis', 'pyrotinib', 'cutaneous lesion', 'neoadjuvant therapy', 'cardiac injury biomarkers', 'real-world data', 'mapk', 'darbepoetin', 'human epidermal growth factor', 'interstitial fluid', 'her-2positivebreastcancer', 'exposure-response', 'review', 'prognosis', 'early-stage breast cancer', 'esophageal cancer', 'human epidermal growth factor receptor 2 positive', 'feline mammary carcinoma', 'blockades', 'mlr', 'drug delivery', 'adriamycin', 'biosimilars', 'mrna', 'her-2', 'antibody-dependent cellular cytotoxicity (adcc)', 'gastric cancer', 'affordability', 'extrapolation', 'pericardial effusion', 'china', 'pharmacoeconomics', 'a10', 'cardiac tumor', 't-dm1', 'fish', 'her2-positive gastric cancer', 'cancer', 'metronomic chemotherapy', 'treatment resistance', 'pd1 immunological synapse', 'a19', 'superoxide (o2•−)', 'immune checkpoints', 'case report', 'clinical development', 'stability', 'her2-positive', 'healthcare utilization', 'microparticles', 'canakinumab', 'topoisomerase i inhibitor', 'concurrent mutations', 'aspergillosis', 'pd1 blockade', 'monoclonal antibodies', 'neratinib', 'surgery', 'monoclonal antibody (mab)', 'belgium', 'targeted therapies', 'gestation', 'feline her2 mutations', 'treatment.', 'combination therapy', 'thrombocytopenia', 'neoadjuvant systemic treatment', 'omalizumab', 'metastatic breast cancer', 'trastuzumab emtansine', 'efficacy', 'biological activity', 'manufacturing change', 'immunotherapy', 'dual her2', 'disease-free-survivaldfs', 'market access', 'her2 gene', 'calcium handling', 'a1', 'triple-positive', 'metastatic disease', 'trastuzumab cardiotoxicity', 'piv', 'relapse-free survival', 'myl-1401o', 'oxidative stress markers', 'healthcare costs', 'drug multipurposing', 'pancreatic cancer', 'rituximab', 'aggregation', 'microdialysis', 'monotherapy', 'physicochemical', 'antibody–drug conjugate', 'peripheral neuropathy', 'epidermal growth factor receptor', 'epidermal growth factor receptor (egfr)', 'arrhythmia', 'pathologicalcompleteresponsepcr', 'safety', 'immunohistochemistry', 'brain metastases', 'response', 'ado-trastuzumabemtansine/t-dm1', 'doxorubicin', 'absolute quantification', 'network meta-analysis', 'nsclc', 'lapatinib', 'breast cancer biomarker assays', 'cardiotoxicity', 'trastuzumab-resistance', 'her2-positive metastatic breast cancer', 'invasive growth', 'plr', 'single cell sequencing', 'trastuzumab (tz)', 'charge heterogeneity', 'hepatocellular carcinoma', 'tumor spheroid', 'biological drugs', 'pi3k', 'ecm1', 'adenocarcinoma', 'docetaxel', 'non-metastatic', 'real world experience', 'tyrosine kinase inhibitors', 'platinum', 'tyrosine kinase inhibitor', 'open flow microperfusion', 'erbb2 gene', 'adverse drug reaction', 'adjuvant therapy', 'her2-positive breast cancer', 'esophagogastric adenocarcinoma', 'copositive', 'anti-her-2therapy', 'strat4', 'oligohydramnios', 'cost-efficiency', 'therapeutic window', 'antibody‐dependent cellular cytotoxicity (adcc)', 'melanoma', 'her2', 'payload', 'electrophysiology', 'aspergillus fumigatus', 'pleural effusions', 'complication', 'signalling pathway activation', 'brain metastasis', 'biologic', 'colorectal cancer', 'tumor organoid', 'pregnancy', 'neoadjuvantsystemictreatment', 'human epidermal growth factor receptor 2 (her/2)', 'combined therapies', 'resistance', 'core-shell nanoparticles', 'chemotherapy', 'breast neoplasms', 'bevacizumab', 'antibody-drug conjugate', 'gastroesophageal cancer', 'fixed-dose antihypertensive combinations', 'hormone receptor–positive', 'freeze-thaw', 'off-target toxicity', 'body mass index', 'trastuzumab-emtansine', 'surface plasmon resonance (spr)'}\n",
      "******************************\n",
      "\n",
      "\n",
      "polygenic risk score- {'biobank', 'the', 'disease:', 'uk', 'long-term', 'risk', 'polygenic', 'genetic', \"alzheimer's\", 'major'}\n",
      "polygenic risk score- {'prs', 'ad', 'the', 'uk', 'in', 'risk', '=', 'major', 'we', 'gwas'}\n",
      "\n",
      " all_keys: {'lpi', 'machine learning', 'fgf19', 'chronic kidney disease', 'optics and refraction', 'lipoproteínas', 'dementia', 'gout', 'therapy efficacy and safety', 'risk stratification', 'hcc', 'cardiovascular disease', 'genetic testing', 'dnl', 'antidepressants', 'gpr55', 'genetic variation', 'genome-wide interaction study', 'lynch syndrome', 'snp', 'gcn2/eif2ak4 gene', 'alspac', 'gge', 'stressful life events', 'coronary heart disease', 'phenotypes', 'ageing', 'radiotherapy', 'uk biobank', 'twin and family studies', 'polygenic hazard score', 'type 2 diabetes mellitus', 'late toxicity', 'short stature', 'genetics / genomics', 'psychosis', 'genetic interactions', 'hypercholesterolemia', 'diacylglycerol', 'beta power', 'homeostatic iron regulator', 'dietary habits', 'multifactorial inheritance', 'sterol response element binding protein', 'screening frequency', 'polygenic risk scores', 'social isolation', 'suicidal ideation', 'quilomicronemia familiar', 'mitochondrial amidoxime reducing component 1', 'triglycerides', 'lung cancer', 'free fatty acids', 'familial hypertriglyceridemia', 'anorectal disorders', 'obsessive-compulsive symptoms', 'triacylglycerol', 'gene–gene interaction', 'polygenic hypertriglyceridemia', 'comorbidity', 'children', 'lysophosphatidyl-inositol', 'public health', 'dyslipidaemia', 'apoe', 'hoxb13', 'early life events', 'adult height prediction', 'preventive medicine', 'hereditary cancer', 'clinical', 'serum', 'alcoholic steatohepatitis', 'hipercolesterolemia', 'catheter ablation', 'disease prediction', 'mild cognitive impairment', 'atrial fibrillation', 'lds', 'depressive disorders', 'triglicéridos', 'biobank', 'parental height', 'genetic risk score', 'steatohepatitis', 'patatin like phospholipase domain containing 3', 'neurodegenerative disease', 'health factors', 'hirschsprung disease', 'fxpoi', 'enteric nervous system', '\"parkinson\\'s disease\"', 'stable angina', 'breast tumours', 'heritability', 'diagnosis', 'pre-test probability', 'glucokinase regulator', 'alcohol use disorder', 'crystal arthropathies', 'epistasis', 'twins', 'lifespan', 'atherosclerosis', 'genetics', 'complex traits and diseases', 'health and retirement study (hrs)', 'precision medicine', 'inflammation', 'positive cores', 'rehabilomics', 'triage', 'molecular genetics', 'cancer syndrome', 'low-penetrance genes', 'fracture risk', 'farnesoid x receptor', 'sumo1', 'nutrition & dietetics', '\\\\napoe\\\\n', 'hfe', 'hipertrigliceridemia', 'response', 'association study', 'quilomicronemia poligénica', 'absolute risk', 'suicidal thoughts and behaviors', 'personalized medicine', 'white blood cell', 'audit-c', 'signaling pathway', 'cancer genetics', 'low-risk', 'nash', 'heroin', 'polygenic score', 'fluid intelligence', 'genetic biomarker', 'systems biology', 'common variants', 'tumour necrosis factor-α', 'high chd risk families', 'family chd history', 'bronchodilator response', 'gckr', 'srebp', 'sex differences', 'pufas', 'genetic predisposition', 'brazil', 'genetic risk factors', 'arachidonic acid', 'asthma', 'paediatric', 'interleukin 10', 'genome-wide association study', 'major depression', 'symptom dimensions', 'lipid droplets', 'polyunsaturated fatty acids', 'interleukin 6', 'body mass index', 'generalized epilepsy', 'high-penetrance genes', 'prediction model', 'healthcare professionals', 'depressive symptoms', 'quantitative radiomic features', 'healthspan', 'er', 'suicide attempt', 'arthritis', 'hypertriglyceridaemia', 'non-suicidal self-injury', 'ppar', 'mendelian randomization', 'alcohol', 'depression—epidemiology', 'zebrafish', 'personality', 'hsd17b13', 'anal canal histopathology', 'olfaction', 'chylomicronemia', 'pooled cohort equation', 'sick quitters', 'thyroid cancer', 'tag', 'aa', 'de novo lipogenesis', 'epidemiology', 'risk estimation', 'oscillations', 'network analysis', 'fxr', 'pparg', 'healthy-aging families', 'eeg', 'interleukin-32', 'sense of coherence', 'ffas', 'integrated stress response', 'genome wide association study', 'chd age-at-onset', 'pharmacogenetics', 'coronary artery disease', 'fld', 'il32', 'risk assessment', 'benzophenone-3', 'hsc', 'chylomicronemia syndrome', 'typology', 'major depressive disorder', 'mental health', 'pharmacogenomics', 'risk-stratified breast screening', 'primary ovarian insufficiency', 'endoplasmic reticulum', 'prediction', 'active surveillance', 'biomarker', 'odour identification', 'human genetics', 'adhd', 'peroxisome proliferator-activated receptor', 'obstetric complications', 'il-', 'childhood cancer survivors', 'alcoholic liver disease', 'alzheimer’s disease', 'fragile x-associated disorders', 'suicide', 'inflammaging', 'substance use disorders', 'genetic susceptibility', 'snps', 'cirrhosis', 'pnpla3', 'c-reactive protein', 'aging', 'craving', 'chronic post-surgical pain', 'genome-wide association studies', 'case-cohort study', 'genome-wide environmental interaction', 'antiarrhythmic drugs', 'prostatic neoplasms', 'polygenic risk score analysis', 'open science', 'sex-specific chd prs association', 'polygenic risk score', 'area under the curve', 'depression', 'cardiac aging', 'gene enrichment', 'biomarkers', 'multifactorial traits', 'polygenic traits', 'risk prediction', 'pancreatic cancer', 'life style', 'gender', 'dislipidemia', 'fatty liver disease', 'cardiovascular', 'app gene', 'mboat7', 'tnf-α', 'posttraumatic stress disorder', 'krr1', 'self-harm', 'latent class analysis', 'twin studies', 'hypertriglyceridemia', 'arrhythmias', 'familial combined hyperlipidaemia', 'military personnel', 'therapy', 'prs', 'non-alcoholic fatty liver disease', 'lifestyle', 'vascular', 'hepatocellular carcinoma', 'hepatic stellate cells', 'lipoproteins', 'hypertension', 'dag', 'gene environment interaction', ' cytochrome p450', 'non-alcoholic steatohepatitis', 'marc1', 'exome sequencing', 'hydroxysteroid 17-beta dehydrogenase 13', 'former drinkers', 'fibroblast growth factor 19', 'end-stage kidney disease', 'g protein-coupled receptor 55', 'prevention', 'gwas', 'hiperlipemia familiar combinada', 'ash', 'addiction', 'chronotype', 'sleep duration', 'colorectal cancer predisposition', 'genotype', 'dietary patterns', 'polygenic effects', 'prostate cancer', 'rare variants', 'genomics', 'genetic epidemiology', 'cancer therapies', 'interleukin-', 'osteoporosis', 'hypercholesterolaemia', 'obsessive-compulsive disorder', 'single nucleotide polymorphism', 'antidepressant response', 'membrane bound o-acyltransferase domain-containing 7', 'placenta biology', 'interaction'}\n",
      "******************************\n",
      "\n",
      "\n",
      "Breast Cancer- {'breast', 'cancer', 'using', 'cancer]', 'neoadjuvant', '2021', 'triple-negative', 'cancer:', 'm2'}\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Breast Cancer- {'breast', 'the', 'expression', 'kpna2', '95%', 'in', 'mri', 'wif1', '=', 'hormad1'}\n",
      "\n",
      " all_keys: {'pi3k/akt signaling pathway', 'neoadjuvant chemotherapy', 'pixelated semiconductor', 'déficit en testostérone', 'nucleus translocation', 'angiomotin‑like 2', 'advanced breast cancer', 'tumor microenvironment', 'enhancer of zeste homolog\\\\xa02 polycomb repressive complex subunit\\\\xa02', 'cancer registries', 'grip strength', 'marital status', 'ovarian clear cell carcinoma (occc)', 'brachial plexus', 'chemoradiotherapy', 'thyrotropin', 'irgd', 'traitement hormonal', 'activity', 'experimental study', 'mammograms', 'mitochondria', 'intracellular ph', 'ovarian', 'recurrence', 'lynch syndrome', 'sympathetic mediated pain', 'rac1', 'biomarker discovery', 'yes-associated protein 1', 'stat3', 'screening mammography', 'neurolysis', 'macrophage', 'risk-reducing surgery', 'thyroid autoimmunity', 'b3 lesions', 'decision aid', 'immune checkpoint inhibitors', 'hormone receptor', 'finite element method', 'covid-19 pandemic', 'breast mri', 'evolutionary algorithm', 'bioinformatics', 'collision tumor', 'sonodynamic therapy', 'pain', 'fatty acid composition', 'chemosensitivity', 'breast cancer self-examination', 'contralateral prophylactic mastectomy', 'sentinel lymph node', 'pathologic complete response', 'wnt inhibitor factor-1', 'cancer metabolism', 'oncology', 'nhe1', 'drug response', 'metastasis', 'prostate imaging', 'breast cancer screening', 'beta4 integrin', 'dual-colour silver in-situ hybridisation (dish)', 'glioblastoma', 'antitumor', 'ros', 'cancer stem cells', 'white', 'breast cancer', 'postprandial metabolism', 'tumour microenvironment', 'triple‑negative breast cancer', 'libido', 'heterogeneity', 'cancer systems biology', 'mirnas', 'ldrbt', 'cervical cancer', 'human epidermal growth factor receptor 2', 'triple-negative breast carcinoma', 'auricular acupressure', 'non-small cell lung cancer', 'double cancer', 'patient management', 'magnetic resonance imaging', 'targeted metabolomics', 'pseudogynecomastia', 'mir-10b', 'cancer therapeutics', 'sport', 'oral vinorelbine', 'tomosynthesis', 'thyroxine', 'neoadjuvant therapy', 'nor-β-lapachone', 'carcinoma', 'chinese', 'endometrial cancer', 'prognosis', 'cd9', 'tetrahedral framework nucleic acid', 'immunoregulation', 'incontinence', 'risk factor', 'factor', 'kif4a', 'poorly differentiated cancer', 'bromodomain-containing protein 7', 'hospice', 'digital medicine', 'dynamic change', 'stellate ganglion', 'breast', 'untargeted metabolomics', 'glioma', 'mammography', 'wait-list controlled', 'nqo1-directed antitumor agents', 'cancer immunotherapy', 'dna damage', 'gastric cancer', 'bilateral primary tumor', 'chemotherapy-associated insomnia', 'mir-1', 'syrian refugee women', 'external environment', 'covid-19', 'hereditary breast and ovarian cancer', 'oral squamous cell carcinoma', 'next-generation sequencing (ngs)', '3d thermal tomography', 'taurine upregulated gene\\\\xa01', 'cancer', 'breast imaging', 'hormone replacement therapy (hrt)', 'ovarian cancer', 'cell communication', 'omics', 'oncotype', 'cell proliferation', 'progesterone', 'early breast cancer', 'ap-2γ', 'testosterone deficiency', 'axillary lymph node dissection', 'cell adhesion', 'case report', 'implementation', 'epidemic disease', 'circular rna', 'hereditary tumor', 'ultrasound', 'prior chemotherapy', 'cancer pain', 'lung squamous carcinoma', 'neratinib', 'estrogen', 'invasion', 'surgery', 'xbp1v1', 'palliative systemic chemotherapy', 'canine mammary tumor', '\\\\nbrca\\\\n', '3d surface scan', 'migration', 'xbp1', 'erianin', 'mir-99a-5p', 'metastatic breast cancer', 'kpna2', 'cell apoptosis', 'pi3k‑p85', 'tubulin', 'palbociclib', 'neoplasm metastasis', 'high-risk lesions', 'early diagnosis', 'bio heat transfer equation', 'immunotherapy', 'mri', 'genomic profiling', 'tumor-associated lymphocytes', 'biomarkers', 'thyroid neoplasms', 'survey', 'fucosyltransferase 8', 'brca mutation', 'cancer cell survival', 'vitamin d 3 receptor', 'ovol2', 'molecular breast imaging', 'hr+/her2- abc', 'affective experiences', 'comparative oncology', 'healthcare delivery', 'containment', 'gynecomastia', 'population-based study', 'isoprenylcysteine carboxylmethyltransferase', 'xv1', 'long-term tumor vascular normalization', 'treatment', 'triple-negative breast cancer', 'angiogenesis', 'sonosensitizer', 'quadruple-modality therapy', 'temozolomide‑resistant', 'cancer de la prostate', 'immunohistochemistry', 'pd-l1', 'delta-like 1', 'radical mastectomy', 'metabolomics', 'cancer precision medicine', 'syria', 'breast volume', 'pi3k/akt pathway', 'therapeutic efficacy', 'autophagy', 'high lymph node burden', 'glycemia', 'breast cancer;', 'cannabinoids', 'hypothyroidism', 'tp53 c.475g>c', 'overall survival', 'therapy', 'indocyanine green', 'electroacupuncture', 'computational systems biology', 'major pathologic response', 'immunohistochemistry (ihc)', 'wnt/β‑catenin signaling', 'intervertebral disc degeneration', 'patient travel time', 'dysphagia', 'cell-free dna', 'glycolysis', 'ctdna', 'health beliefs model', 'omega-3 pufas', 'diet history questionnaire', 'tumor penetrating peptide', 'methylation', 'benzotriazole', 'apatinib', 'b‑lineage acute lymphoblastic leukemia', 'refugee', 'fish oil', 'perceived social support', 'hormone treatment', 'sup‑b15 cells', 'horma domain‑\\\\xadcontaining protein 1', '\"chuang\\'s prognostic scale\"', 'palliative care', 'prevention', 'prognostic marker', 'apoptosis', 'dox', 'erectile dysfunction', 'phosphatidylinositol 3-kinase', 'thyroidectomy', 'm2 macrophage', 'parp inhibitor', 'pathogenic germline variant', 'health disparity', 'prostate cancer', 'in-situ hybridisation (ish)', 'lean mass', 'dysfonction érectile', 'breast cancer microenvironment', 'exosome', 'visceral disease', 'nf-κb signalling', 'monte carlo simulation', 'breast neoplasms', 'human epidermal growth factor 2 (her2)', 'proliferation', 'lipids', 'chemo resistance', 'tyrer-cuzick model', 'cytotoxic t cells', 'life satisfaction', 'tumor metastasis', 'dog', 'high spatial resolution'}\n",
      "******************************\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "for k in kk:\n",
    "    \n",
    "    df = pd.read_csv(f'/home/amansinha/extractpubmed/papers/key_meta_all/{k}')\n",
    "    df['keywords'] = df['keywords'].str.strip('[]').str.split(',')\n",
    "    df['keywords'] = df['keywords'].apply(lambda x: [xx.strip().strip(\"''\") for xx in x])\n",
    "    \n",
    "    \n",
    "    name = k.split('_')[0]\n",
    "\n",
    "    akeys, amkeysdict, all_text = set(),[], []\n",
    "    for t in ['title', 'abstract']:\n",
    "        text = []\n",
    "        for i, (key, abst) in enumerate(zip(df['keywords'], df[t])):\n",
    "            if len(key)>1  and (not pd.isna(abst)):\n",
    "                    keylist = set(list(map(str.lower, key)))\n",
    "\n",
    "                    amkeysdict.append(d)\n",
    "                    text.append(abst)\n",
    "                    akeys |= keylist\n",
    "            if i == 100:\n",
    "                break\n",
    "                \n",
    "        all_text.append(' '.join(text))\n",
    "        mkd,d =  get_keywords(' '.join(all_text), 10)\n",
    "        manual_keylist = set(list(map(str.lower,mkd.keys() )))\n",
    "        \n",
    "        print(f'{name}- {manual_keylist}')\n",
    "        \n",
    "    print(f'\\n all_keys: {akeys}')\n",
    "        \n",
    "    print('*'*30)\n",
    "    print('\\n')\n",
    "            \n",
    "        \n",
    "    #break\n",
    "        \n",
    "                \n",
    "            \n",
    "            \n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 69,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'=': 0.015858450632270954,\n",
       " 'HER2-positive': 0.008156027624015315,\n",
       " 'trastuzumab': 0.00802735669239421,\n",
       " 'We': 0.007689004519923447,\n",
       " '<': 0.006317138540394327,\n",
       " 'eGDR': 0.005317759102235327,\n",
       " 'TDM1': 0.004644990300307977,\n",
       " 'The': 0.004398970261438498,\n",
       " 'HER2': 0.004127846754747094,\n",
       " 'trastuzumab/pertuzumab': 0.004104793021368067}"
      ]
     },
     "execution_count": 69,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ans, _ = get_keywords(' '.join(all_text), k=10)\n",
    "ans"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'=': 0.05529651285702302,\n",
       " '<': 0.038659677203126394,\n",
       " 'eGDR': 0.03342207033132504,\n",
       " 'ISS),': 0.027407525598688507,\n",
       " '%': 0.02263337732440638,\n",
       " 'number': 0.021164799406410542,\n",
       " 'milk': 0.019185454978530896,\n",
       " 'sequential': 0.016975032993304783,\n",
       " 'Conjugates,': 0.016447036378528897,\n",
       " '8': 0.01639166043239291,\n",
       " 'DGAT1': 0.01598787914877575,\n",
       " 'options,': 0.015873599554807907,\n",
       " 'effective': 0.015873599554807907,\n",
       " 'particularly': 0.015873599554807907,\n",
       " 'Historically,': 0.015873599554807907,\n",
       " 'considerations': 0.015873599554807907,\n",
       " 'evaluating': 0.015873599554807907,\n",
       " 'receptor-positive': 0.015873599554807907,\n",
       " 'endocrine': 0.015873599554807907,\n",
       " 'CDK4/6': 0.015873599554807907}"
      ]
     },
     "execution_count": 61,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "global_d = dict()\n",
    "for dd in amkeysdict:\n",
    "    global_d.update(**dd)\n",
    "    \n",
    "result = dict(sorted(global_d.items(), key = itemgetter(1), reverse = True)[:20]) \n",
    "result"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "metadata": {
    "collapsed": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'Third-line': 0.0,\n",
       " 'treatment': 0.009679054179100139,\n",
       " 'of': 0.0,\n",
       " 'HER2-positive': 0.015184402281593685,\n",
       " 'advanced': 0.015184402281593685,\n",
       " 'breast': 0.0,\n",
       " 'cancer:': 0.0,\n",
       " 'From': 0.0,\n",
       " 'no': 0.0,\n",
       " 'standard': 0.010268847119406597,\n",
       " 'to': 0.0,\n",
       " 'a': 0.0,\n",
       " \"Pandora's\": 0.0,\n",
       " 'box': 0.0,\n",
       " 'Margetuximab': 0.010134948692996422,\n",
       " 'for': 0.0,\n",
       " 'the': 0.0,\n",
       " 'metastatic': 0.008223518189264449,\n",
       " 'cancer': 0.015184402281593685,\n",
       " 'Post-neoadjuvant': 0.0,\n",
       " 'with': 0.0,\n",
       " 'capecitabine': 0.009467281837847648,\n",
       " 'and': 0.0,\n",
       " 'trastuzumab': 0.011153424250437662,\n",
       " 'emtansine': 0.013371339322597426,\n",
       " 'in': 0.0,\n",
       " 'patients-sequentially,': 0.0,\n",
       " 'or': 0.0,\n",
       " 'better': 0.015184402281593685,\n",
       " 'simultaneously?': 0.0,\n",
       " 'Comparison': 0.0,\n",
       " 'outcomes': 0.009679054179100139,\n",
       " 'population-based': 0.005689544716191807,\n",
       " 'cohort': 0.003915330109292958,\n",
       " 'patients': 0.0025809735750759004,\n",
       " 'receiving': 0.0,\n",
       " 'anti-HER2': 0.012890355893727015,\n",
       " 'therapy': 0.0,\n",
       " 'clinical': 0.0009193908019709801,\n",
       " 'trial': 0.001497900974017938,\n",
       " 'Safety': 0.0,\n",
       " 'after': 0.0,\n",
       " 'emtansine-induced': 0.010218921742874648,\n",
       " 'nodular': 0.002232266747867548,\n",
       " 'regenerative': 0.005324432977312071,\n",
       " 'hyperplasia:': 0.0,\n",
       " 'A': 0.010963010239475404,\n",
       " 'case': 0.010268847119406597,\n",
       " 'report': 0.010268847119406597,\n",
       " 'Analysis': 0.0,\n",
       " 'Cost-Effectiveness': 0.0,\n",
       " 'Liquid': 0.008718970701010527,\n",
       " 'Biopsy': 0.0,\n",
       " 'Determine': 0.0,\n",
       " 'Treatment': 0.014747812352339261,\n",
       " 'Change': 0.0,\n",
       " 'Patients': 0.01334326410952807,\n",
       " 'Her2-Positive': 0.0,\n",
       " 'Advanced': 0.0,\n",
       " 'Breast': 0.01327229236465226,\n",
       " 'Cancer': 0.011060243637210216,\n",
       " 'Colombia': 0.009215460393198946,\n",
       " 'Recent': 0.0,\n",
       " 'advances': 0.011625526864212801,\n",
       " 'optimal': 0.0,\n",
       " 'management': 0.015184402281593685,\n",
       " 'human': 0.007617001984175222,\n",
       " 'epidermal': 0.009467281837847648,\n",
       " 'growth': 0.0025514155155421945,\n",
       " 'factor': 0.011153424250437662,\n",
       " 'receptor-2-positive': 0.0,\n",
       " 'early-stage': 0.011625526864212801,\n",
       " 'When': 0.0,\n",
       " 'Add': 0.0,\n",
       " 'Additional': 0.0,\n",
       " 'Anti-HER2': 0.0,\n",
       " 'Therapy': 0.0,\n",
       " 'Adjuvant': 0.014145860827753985,\n",
       " 'Trastuzumab': 0.011153424250437662,\n",
       " 'The': 0.005119834905442678,\n",
       " 'evolving': 0.010134948692996422,\n",
       " 'role': 0.011153424250437662,\n",
       " '(T-DM1)': 0.013371339322597426,\n",
       " 'brain': 0.004081825898372118,\n",
       " 'metastases': 0.0,\n",
       " 'Investigational': 0.0,\n",
       " 'drugs': 0.010268847119406597,\n",
       " 'early': 0.007710274189062285,\n",
       " 'stage': 0.008195830216196454,\n",
       " 'trials': 0.011153424250437662,\n",
       " 'HER2+': 0.013563114674914934,\n",
       " 'Systemic': 0.013563114674914934,\n",
       " 'Central': 0.013371339322597426,\n",
       " 'Nervous': 0.0,\n",
       " 'System': 0.008718970701010527,\n",
       " 'Metastases': 0.0,\n",
       " 'residual': 0.0,\n",
       " 'disease': 0.009679054179100139,\n",
       " 'state': 0.0,\n",
       " 'art': 0.0,\n",
       " 'perspectives': 0.009467281837847648,\n",
       " 'ASCO': 0.009729550745276566,\n",
       " '2018:': 0.0,\n",
       " 'highlights': 0.0,\n",
       " 'Exceptional': 0.0,\n",
       " 'Durable': 0.0,\n",
       " 'Responses': 0.0,\n",
       " 'TDM-1': 0.0,\n",
       " 'After': 0.014914758381685987,\n",
       " 'Failure': 0.0,\n",
       " 'Skin': 0.0,\n",
       " 'Metastases:': 0.0,\n",
       " 'Potential': 0.0,\n",
       " 'Implications': 0.0,\n",
       " 'an': 0.0,\n",
       " 'Immunological': 0.0,\n",
       " 'Sanctuary': 0.0,\n",
       " 'Dual': 0.0,\n",
       " 'targeting': 0.0,\n",
       " 'pertuzumab:': 0.0,\n",
       " 'understanding': 0.015184402281593685,\n",
       " 'results': 0.0009193908019709801,\n",
       " 'Emtansine': 0.0,\n",
       " 'HER-2': 0.013371339322597426,\n",
       " 'Positive': 0.0,\n",
       " 'Carcinoma': 0.0,\n",
       " 'Ex-pleomorphic': 0.0,\n",
       " 'Adenoma': 0.0,\n",
       " 'Metastatic': 0.014747812352339261,\n",
       " 'Brain:': 0.0,\n",
       " 'Case': 0.0,\n",
       " 'Report': 0.0,\n",
       " 'Practical': 0.0,\n",
       " 'consensus': 0.013371339322597426,\n",
       " 'recommendations': 0.01327229236465226,\n",
       " 'regarding': 0.009467281837847648,\n",
       " 'HER2': 0.015184402281593685,\n",
       " 'neu': 0.0,\n",
       " 'positive': 0.013371339322597426,\n",
       " 'on': 0.0,\n",
       " 'Her2': 0.0,\n",
       " '+ve': 0.0,\n",
       " 'solitary': 0.0,\n",
       " 'mets': 0.0,\n",
       " 'Cardiotoxic': 0.0,\n",
       " 'effects': 0.0009574576386786233,\n",
       " 'novel': 0.006872289967934989,\n",
       " 'approved': 0.015184402281593685,\n",
       " 'anti-ErbB2': 0.0,\n",
       " 'agents': 0.008223518189264449,\n",
       " 'reverse': 0.0,\n",
       " 'cardioprotective': 0.007617001984175222,\n",
       " 'ranolazine': 0.005078001322783482,\n",
       " 'High': 0.0,\n",
       " 'irisin': 0.0,\n",
       " 'levels': 0.011716184031330063,\n",
       " 'are': 0.0,\n",
       " 'associated': 0.015184402281593685,\n",
       " 'glycemic': 0.0,\n",
       " 'control': 0.0009666102353929023,\n",
       " 'bone': 0.005117971360417656,\n",
       " 'health': 0.01056231694033966,\n",
       " 'children': 0.0032722471920984624,\n",
       " 'Type': 0.0,\n",
       " '1': 0.007710274189062285,\n",
       " 'diabetes': 0.0009193908019709801,\n",
       " 'Preliminary': 0.0,\n",
       " 'experience': 0.01327229236465226,\n",
       " 'concurrent': 0.002976678478268647,\n",
       " 'use': 0.010268847119406597,\n",
       " 'radiosurgery': 0.004399971434552547,\n",
       " 'T-DM1': 0.010268847119406597,\n",
       " 'radiotherapy': 0.0,\n",
       " 'Human': 0.011153424250437662,\n",
       " 'antagonists': 0.0,\n",
       " 'cardiotoxicity-A': 0.0,\n",
       " 'short': 0.0,\n",
       " 'review': 0.015184402281593685,\n",
       " 'problem': 0.0,\n",
       " 'preventative': 0.0,\n",
       " 'measures': 0.007710274189062285,\n",
       " 'Effects': 0.0,\n",
       " 'DGAT1': 0.01598787914877575,\n",
       " 'K232A': 0.011671704675422685,\n",
       " 'polymorphism': 0.008195830216196454,\n",
       " 'milking': 0.009592727489265448,\n",
       " 'frequency': 0.008195830216196454,\n",
       " 'milk': 0.019185454978530896,\n",
       " 'composition': 0.0020898896684547383,\n",
       " 'spontaneous': 0.001497900974017938,\n",
       " 'lipolysis': 0.008195830216196454,\n",
       " 'dairy': 0.0,\n",
       " 'cows': 0.005224724171136846,\n",
       " 'ACTIVITY': 0.0,\n",
       " 'OF': 0.0,\n",
       " 'TRASTUZUMAB-EMTANSINE': 0.0,\n",
       " '(TDM1)': 0.011153424250437662,\n",
       " 'IN': 0.0,\n",
       " 'HER2-POSITIVE': 0.0,\n",
       " 'BREAST': 0.0,\n",
       " 'CANCER': 0.0,\n",
       " 'BRAIN': 0.0,\n",
       " 'METASTASES:': 0.0,\n",
       " 'CASE': 0.0,\n",
       " 'SERIES': 0.0,\n",
       " 'Marked': 0.0,\n",
       " 'enhancement': 0.0,\n",
       " 'lysosomal': 0.0011288626677624252,\n",
       " 'efficacy': 0.010268847119406597,\n",
       " 'ErbB2-targeted': 0.008223518189264449,\n",
       " 'drug': 0.0,\n",
       " 'delivery': 0.003984706273468031,\n",
       " 'by': 0.0,\n",
       " 'HSP90': 0.013089867598202215,\n",
       " 'inhibition': 0.015184402281593685,\n",
       " 'combination': 0.010268847119406597,\n",
       " 'central': 0.010268847119406597,\n",
       " 'nervous': 0.010268847119406597,\n",
       " 'system': 0.010268847119406597,\n",
       " 'patient': 0.010268847119406597,\n",
       " 'study': 0.0012904867875379502,\n",
       " 'literature': 0.010268847119406597,\n",
       " 'Mechanisms': 0.0,\n",
       " 'lapatinib': 0.0030901958778636373,\n",
       " 'resistance': 0.007710274189062285,\n",
       " 'HER2-driven': 0.0,\n",
       " 'Long-term': 0.0,\n",
       " 'prognosis': 0.009679054179100139,\n",
       " 'type': 0.007710274189062285,\n",
       " '2': 0.009679054179100139,\n",
       " 'mellitus': 0.009679054179100139,\n",
       " 'coronary': 0.009679054179100139,\n",
       " 'artery': 0.009679054179100139,\n",
       " 'bypass': 0.009679054179100139,\n",
       " 'grafting': 0.009679054179100139,\n",
       " 'Insulin': 0.0,\n",
       " 'factors': 0.0,\n",
       " 'Diabetes': 0.009679054179100139,\n",
       " 'receptor': 0.0015051502236832336,\n",
       " '(HER2+)': 0.011412480695720095,\n",
       " '(ABC)': 0.011412480695720095,\n",
       " 'accounts': 0.011412480695720095,\n",
       " 'about': 0.0,\n",
       " '15-20%': 0.011412480695720095,\n",
       " 'all': 0.0,\n",
       " 'ABC': 0.013995061002141526,\n",
       " 'cases': 0.0014883392391343234,\n",
       " 'Large': 0.011412480695720095,\n",
       " 'randomized': 0.010019333427584128,\n",
       " 'have': 0.0,\n",
       " 'determined': 0.007710274189062285,\n",
       " 'first-': 0.011412480695720095,\n",
       " 'second-line': 0.011412480695720095,\n",
       " 'treatments': 0.010268847119406597,\n",
       " 'this': 0.0,\n",
       " 'subgroup': 0.011412480695720095,\n",
       " 'patients,': 0.007710274189062285,\n",
       " 'namely': 0.011412480695720095,\n",
       " 'dual': 0.012890355893727015,\n",
       " 'blockade': 0.014145860827753985,\n",
       " 'plus': 0.009729550745276566,\n",
       " 'chemotherapy': 0.0,\n",
       " 'TDM1': 0.007710274189062285,\n",
       " 'However,': 0.013371339322597426,\n",
       " 'is': 0.0,\n",
       " 'specifically': 0.008223518189264449,\n",
       " 'recommended': 0.010134948692996422,\n",
       " 'TDM1,': 0.005078001322783482,\n",
       " 'most': 0.0,\n",
       " 'subsequent': 0.013563114674914934,\n",
       " 'therapeutic': 0.015184402281593685,\n",
       " 'choices': 0.011412480695720095,\n",
       " 'commonly': 0.011412480695720095,\n",
       " 'rely': 0.011412480695720095,\n",
       " 'old': 0.010019333427584128,\n",
       " 'not': 0.0,\n",
       " 'optimally': 0.011412480695720095,\n",
       " 'reflecting': 0.011412480695720095,\n",
       " 'current': 0.009467281837847648,\n",
       " 'population': 0.013371339322597426,\n",
       " 'recent': 0.008223518189264449,\n",
       " 'FDA-approval': 0.011412480695720095,\n",
       " 'three': 0.011412480695720095,\n",
       " 'compounds': 0.011412480695720095,\n",
       " 'revolutionizing': 0.010134948692996422,\n",
       " 'field': 0.009729550745276566,\n",
       " 'In': 0.009679054179100139,\n",
       " 'particular,': 0.011412480695720095,\n",
       " 'deruxtecan': 0.010134948692996422,\n",
       " 'was': 0.0,\n",
       " 'showing': 0.011060243637210216,\n",
       " 'unprecedented': 0.011412480695720095,\n",
       " 'activity': 0.0015938825093872126,\n",
       " 'phase': 0.009729550745276566,\n",
       " 'highly': 0.007617001984175222,\n",
       " 'pretreated': 0.007617001984175222,\n",
       " 'patients;': 0.009729550745276566,\n",
       " 'tucatinib': 0.009729550745276566,\n",
       " 'neratinib': 0.009729550745276566,\n",
       " 'were': 0.0,\n",
       " 'based': 0.009201068768494849,\n",
       " 'HER2CLIMB': 0.011412480695720095,\n",
       " 'NALA': 0.011412480695720095,\n",
       " 'trial,': 0.011412480695720095,\n",
       " 'respectively': 0.009679054179100139,\n",
       " 'With': 0.011153424250437662,\n",
       " 'increasing': 0.010268847119406597,\n",
       " 'arsenal': 0.011412480695720095,\n",
       " 'options,': 0.015873599554807907,\n",
       " 'decision-making': 0.011412480695720095,\n",
       " 'will': 0.0,\n",
       " 'need': 0.008223518189264449,\n",
       " 'take': 0.011412480695720095,\n",
       " 'into': 0.0,\n",
       " 'account': 0.011412480695720095,\n",
       " 'variety': 0.011412480695720095,\n",
       " 'aspects,': 0.011412480695720095,\n",
       " 'including': 0.014747812352339261,\n",
       " 'differences': 0.011412480695720095,\n",
       " 'designs,': 0.011412480695720095,\n",
       " 'toxicity': 0.004261956628915272,\n",
       " 'profile': 0.011412480695720095,\n",
       " 'each': 0.0,\n",
       " 'drug,': 0.011412480695720095,\n",
       " \"patient's\": 0.014747812352339261,\n",
       " 'characteristics': 0.007710274189062285,\n",
       " 'preferences': 0.011412480695720095,\n",
       " 'No': 0.012086398441337349,\n",
       " 'specific': 0.010134948692996422,\n",
       " 'currently': 0.013371339322597426,\n",
       " '(BC)': 0.010142476121583676,\n",
       " 'progressing': 0.011060243637210216,\n",
       " '(TDM-1)': 0.010134948692996422,\n",
       " 'several': 0.014747812352339261,\n",
       " 'emerging': 0.008223518189264449,\n",
       " 'rapidly': 0.0,\n",
       " 'setting': 0.013371339322597426,\n",
       " 'Among': 0.009679054179100139,\n",
       " 'these,': 0.013643347646072003,\n",
       " 'FC-engineered': 0.010134948692996422,\n",
       " 'monoclonal': 0.0015938825093872126,\n",
       " 'antibody': 0.009729550745276566,\n",
       " 'margetuximab': 0.0052573786972064515,\n",
       " 'has': 0.0,\n",
       " 'recently': 0.007617001984175222,\n",
       " 'demonstrated': 0.013371339322597426,\n",
       " 'slightly': 0.009679054179100139,\n",
       " 'improve': 0.008223518189264449,\n",
       " 'progression-free': 0.010134948692996422,\n",
       " 'survival': 0.009679054179100139,\n",
       " '(PFS)': 0.013371339322597426,\n",
       " 'compared': 0.0036642099304279308,\n",
       " 'trastuzumab,': 0.013371339322597426,\n",
       " 'when': 0.0,\n",
       " 'combined': 0.009729550745276566,\n",
       " 'BC': 0.010142476121583676,\n",
       " 'present': 0.011060243637210216,\n",
       " 'article': 0.013371339322597426,\n",
       " 'recapitulates': 0.010134948692996422,\n",
       " 'development': 0.011153424250437662,\n",
       " 'margetuximab,': 0.010134948692996422,\n",
       " 'critically': 0.010134948692996422,\n",
       " 'discussing': 0.010134948692996422,\n",
       " 'its': 0.0,\n",
       " 'implications': 0.010134948692996422,\n",
       " 'landscape': 0.0016057362482006078,\n",
       " 'algorithms': 0.010134948692996422,\n",
       " 'can': 0.0,\n",
       " 'only': 0.0,\n",
       " 'be': 0.0,\n",
       " 'interpreted': 0.010134948692996422,\n",
       " 'view': 0.010134948692996422,\n",
       " 'Indeed,': 0.010134948692996422,\n",
       " 'represent': 0.0,\n",
       " 'appealing': 0.010134948692996422,\n",
       " 'options': 0.014747812352339261,\n",
       " 'post-TDM1': 0.010134948692996422,\n",
       " 'setting,': 0.012890355893727015,\n",
       " 'while': 0.0,\n",
       " 'may': 0.007710274189062285,\n",
       " 'progression': 0.010268847119406597,\n",
       " 'abovementioned': 0.010134948692996422,\n",
       " 'agents,': 0.011153424250437662,\n",
       " 'future': 0.007710274189062285,\n",
       " 'approval': 0.008223518189264449,\n",
       " 'Regardless': 0.010134948692996422,\n",
       " 'uptake,': 0.010134948692996422,\n",
       " 'it': 0.0,\n",
       " 'should': 0.0,\n",
       " 'noted': 0.008195830216196454,\n",
       " 'that': 0.0,\n",
       " 'relevantly': 0.010134948692996422,\n",
       " 'improved': 0.0025476781709909456,\n",
       " 'our': 0.0,\n",
       " 'biological': 0.013371339322597426,\n",
       " 'BC,': 0.010134948692996422,\n",
       " 'highlighting': 0.010134948692996422,\n",
       " 'implication': 0.010134948692996422,\n",
       " 'genotype': 0.006457892986583342,\n",
       " 'determining': 0.010134948692996422,\n",
       " 'outcomes,': 0.010134948692996422,\n",
       " 'as': 0.0,\n",
       " 'well': 0.008195830216196454,\n",
       " 'relevance': 0.010134948692996422,\n",
       " 'antibody-dependent': 0.010134948692996422,\n",
       " 'cellular': 0.011153424250437662,\n",
       " 'cytotoxicity': 0.010134948692996422,\n",
       " '(ADCC)': 0.010134948692996422,\n",
       " 'context': 0.011060243637210216,\n",
       " 'HER2-blockade': 0.010134948692996422,\n",
       " 'Following': 0.013643347646072003,\n",
       " 'neoadjuvant': 0.012890355893727015,\n",
       " 'cancer,': 0.010268847119406597,\n",
       " 'postoperative': 0.006585523493683228,\n",
       " 'systemic': 0.013371339322597426,\n",
       " 'therapy,': 0.01327229236465226,\n",
       " 'also': 0.001956503921238426,\n",
       " 'called': 0.013643347646072003,\n",
       " 'post-neoadjuvant': 0.009014569831164542,\n",
       " 'treatment,': 0.009467281837847648,\n",
       " 'been': 0.0,\n",
       " 'established': 0.013643347646072003,\n",
       " 'defined': 0.013643347646072003,\n",
       " 'risk': 0.01334326410952807,\n",
       " 'settings': 0.005164976763635115,\n",
       " 'We': 0.007710274189062285,\n",
       " 'reviewed': 0.013643347646072003,\n",
       " 'evidence': 0.013371339322597426,\n",
       " 'sequencing': 0.009467281837847648,\n",
       " 'radiation': 0.0007102969550173854,\n",
       " 'chemotherapy,': 0.011153424250437662,\n",
       " 'focus': 0.013371339322597426,\n",
       " '(T-DM1)-based': 0.013643347646072003,\n",
       " 'regimen': 0.013643347646072003,\n",
       " 'systematic': 0.013643347646072003,\n",
       " 'search': 0.011625526864212801,\n",
       " 'using': 0.007710274189062285,\n",
       " 'PubMed/MEDLINE/Web': 0.013643347646072003,\n",
       " 'Science': 0.013643347646072003,\n",
       " 'database': 0.013643347646072003,\n",
       " 'performed': 0.008718970701010527,\n",
       " 'included': 0.009679054179100139,\n",
       " 'prospective': 0.010142476121583676,\n",
       " 'retrospective': 0.010019333427584128,\n",
       " 'reports': 0.0,\n",
       " 'published': 0.01327229236465226,\n",
       " 'since': 0.013643347646072003,\n",
       " '2015': 0.013643347646072003,\n",
       " 'provided': 0.013643347646072003,\n",
       " 'data': 0.007710274189062285,\n",
       " 'effectiveness': 0.0006106061543131909,\n",
       " 'Six': 0.013643347646072003,\n",
       " 'studies': 0.009679054179100139,\n",
       " 'included,': 0.009679054179100139,\n",
       " 'five': 0.013643347646072003,\n",
       " 'which': 0.0,\n",
       " 'investigated': 0.009679054179100139,\n",
       " 'capecitabine-containing': 0.013643347646072003,\n",
       " 'regimens': 0.012890355893727015,\n",
       " 'Of': 0.013643347646072003,\n",
       " 'four': 0.013643347646072003,\n",
       " 'investigations': 0.013643347646072003,\n",
       " 'one': 0.011153424250437662,\n",
       " 'matched': 0.013643347646072003,\n",
       " 'comparative': 0.013643347646072003,\n",
       " 'analysis': 0.009729550745276566,\n",
       " 'One': 0.014145860827753985,\n",
       " 'found': 0.0006129272013139867,\n",
       " 'T‑DM1': 0.009729550745276566,\n",
       " 'majority': 0.013643347646072003,\n",
       " 'these': 0.0,\n",
       " 'reports,': 0.013643347646072003,\n",
       " 'radiation-associated': 0.013643347646072003,\n",
       " 'toxicities': 0.011153424250437662,\n",
       " 'addressed': 0.013643347646072003,\n",
       " 'Regarding': 0.013643347646072003,\n",
       " 'oncologic': 0.013643347646072003,\n",
       " 'outcome,': 0.013643347646072003,\n",
       " 'influence': 0.013643347646072003,\n",
       " 'maintenance': 0.013643347646072003,\n",
       " 'unclear': 0.010218921742874648,\n",
       " 'Synchronous': 0.013643347646072003,\n",
       " 'administration': 0.013643347646072003,\n",
       " 'feasible,': 0.013643347646072003,\n",
       " 'but': 0.0,\n",
       " 'possible': 0.008195830216196454,\n",
       " 'excess': 0.013643347646072003,\n",
       " 'partially': 0.011060243637210216,\n",
       " 'conflicting': 0.013643347646072003,\n",
       " 'Dose': 0.013643347646072003,\n",
       " 'reduction': 0.013643347646072003,\n",
       " 'considered,': 0.013643347646072003,\n",
       " 'especially': 0.014145860827753985,\n",
       " 'if': 0.0,\n",
       " 'normofractionated': 0.013643347646072003,\n",
       " 'used': 0.010268847119406597,\n",
       " 'terms': 0.0008515181667397484,\n",
       " 'tolerance,': 0.013643347646072003,\n",
       " 'hypofractionated': 0.013643347646072003,\n",
       " 'schedules': 0.013643347646072003,\n",
       " 'seem': 0.013643347646072003,\n",
       " 'superior': 0.013643347646072003,\n",
       " 'safely': 0.013643347646072003,\n",
       " 'administered': 0.013643347646072003,\n",
       " 'concurrently': 0.013643347646072003,\n",
       " 'Little': 0.010019333427584128,\n",
       " 'exist': 0.010019333427584128,\n",
       " 'comparing': 0.010019333427584128,\n",
       " 'cardiac': 0.0,\n",
       " 'safety': 0.010142476121583676,\n",
       " 'trastuzumab/pertuzumab': 0.013275604337780881,\n",
       " 'ado-T': 0.010019333427584128,\n",
       " '(MBC)': 0.014747812352339261,\n",
       " 'enrolled': 0.010019333427584128,\n",
       " '(RCT)': 0.010019333427584128,\n",
       " 'vs': 0.007007991038561021,\n",
       " 'real-world': 0.004309274767093562,\n",
       " 'This': 0.009679054179100139,\n",
       " 'MBC': 0.014747812352339261,\n",
       " 'treated': 0.010142476121583676,\n",
       " '(2012-2017)': 0.010019333427584128,\n",
       " 'Ontario,': 0.010019333427584128,\n",
       " 'Canada': 0.010019333427584128,\n",
       " 'Outcomes': 0.010019333427584128,\n",
       " 'incident': 0.010019333427584128,\n",
       " 'heart': 0.011153424250437662,\n",
       " 'failure': 0.011060243637210216,\n",
       " '(HF)': 0.010019333427584128,\n",
       " 'overall': 0.011153424250437662,\n",
       " '(OS)': 0.010019333427584128,\n",
       " 'RCT': 0.0060405460018240755,\n",
       " 'obtained': 0.008718970701010527,\n",
       " 'from': 0.0,\n",
       " 'digitizing': 0.010019333427584128,\n",
       " 'curves': 0.010019333427584128,\n",
       " 'Kaplan-Meier': 0.010019333427584128,\n",
       " 'Age-based': 0.010019333427584128,\n",
       " 'comparison': 0.010019333427584128,\n",
       " 'conducted': 0.010019333427584128,\n",
       " '≥': 0.010019333427584128,\n",
       " '65': 0.0074649331642768465,\n",
       " 'years': 0.009679054179100139,\n",
       " 'younger': 0.009679054179100139,\n",
       " 'than': 0.0,\n",
       " 'two': 0.007710274189062285,\n",
       " 'cohorts': 0.010019333427584128,\n",
       " 'composed': 0.010019333427584128,\n",
       " '833': 0.010019333427584128,\n",
       " '397': 0.010019333427584128,\n",
       " 'whom': 0.0,\n",
       " '55%': 0.010019333427584128,\n",
       " '76%': 0.010019333427584128,\n",
       " 'had': 0.0,\n",
       " 'baseline': 0.010019333427584128,\n",
       " 'HF,': 0.010019333427584128,\n",
       " 'Incident': 0.010019333427584128,\n",
       " 'HF': 0.00920824215891911,\n",
       " 'following': 0.009679054179100139,\n",
       " 'low': 0.009729550745276566,\n",
       " '(trastuzumab/pertuzumab': 0.0074649331642768465,\n",
       " '18': 0.010019333427584128,\n",
       " 'events/100': 0.014623454507043682,\n",
       " 'person': 0.0006253336536995028,\n",
       " 'years;': 0.010019333427584128,\n",
       " '002': 0.010019333427584128,\n",
       " 'years)': 0.010019333427584128,\n",
       " 'median': 0.0006253336536995028,\n",
       " 'OS': 0.01327229236465226,\n",
       " '392': 0.010019333427584128,\n",
       " '564': 0.010019333427584128,\n",
       " 'months': 0.0,\n",
       " 'CLEOPATRA,': 0.010019333427584128,\n",
       " '154': 0.010019333427584128,\n",
       " '309': 0.010019333427584128,\n",
       " 'EMILIA,': 0.010019333427584128,\n",
       " 'Cohort': 0.010019333427584128,\n",
       " 'significantly': 0.010268847119406597,\n",
       " 'worse': 0.014145860827753985,\n",
       " 'HR': 0.014623454507043682,\n",
       " '167,': 0.010019333427584128,\n",
       " '95%': 0.007710274189062285,\n",
       " 'CI': 0.007710274189062285,\n",
       " '137-203,': 0.010019333427584128,\n",
       " 'p': 0.009816741576295387,\n",
       " '<': 0.038659677203126394,\n",
       " '00001;': 0.010019333427584128,\n",
       " '280,': 0.010019333427584128,\n",
       " '227-344,': 0.010019333427584128,\n",
       " '00001)': 0.010019333427584128,\n",
       " 'Older': 0.010019333427584128,\n",
       " '(HR': 0.014623454507043682,\n",
       " '160,': 0.010019333427584128,\n",
       " '119-216,': 0.010019333427584128,\n",
       " '=': 0.05529651285702302,\n",
       " '00018),': 0.010019333427584128,\n",
       " '116,': 0.010019333427584128,\n",
       " '081-166,': 0.010019333427584128,\n",
       " '043)': 0.010019333427584128,\n",
       " 'incidence': 0.013371339322597426,\n",
       " 'during': 0.0,\n",
       " 'Survival': 0.010019333427584128,\n",
       " 'RCT,': 0.010019333427584128,\n",
       " 'suggesting': 0.010019333427584128,\n",
       " 'recruitment': 0.010019333427584128,\n",
       " 'similar': 0.010142476121583676,\n",
       " 'required': 0.008718970701010527,\n",
       " 'antibody-drug': 0.007617001984175222,\n",
       " 'conjugate': 0.007617001984175222,\n",
       " 'recurrent': 0.0006377904993907279,\n",
       " 'Cases': 0.010218921742874648,\n",
       " 'hyperplasia': 0.0025511619975629118,\n",
       " 'often': 0.009679054179100139,\n",
       " 'reported': 0.009679054179100139,\n",
       " 'overt': 0.010218921742874648,\n",
       " 'noncirrhotic': 0.010218921742874648,\n",
       " 'portal': 0.0006377904993907279,\n",
       " 'hypertension': 0.0006377904993907279,\n",
       " 'ascites': 0.010218921742874648,\n",
       " 'variceal': 0.010218921742874648,\n",
       " 'bleeding': 0.010218921742874648,\n",
       " '61-year-old': 0.010218921742874648,\n",
       " 'woman': 0.010218921742874648,\n",
       " 'who': 0.0,\n",
       " 'multiple': 0.01056231694033966,\n",
       " 'stellate': 0.0006377904993907279,\n",
       " 'angiomas': 0.0,\n",
       " 'gradual': 0.0006377904993907279,\n",
       " 'increased': 0.0036642099304279308,\n",
       " 'liver': 0.0013311082443280178,\n",
       " 'transaminases': 0.010218921742874648,\n",
       " 'reduced': 0.009679054179100139,\n",
       " 'platelet': 0.0006377904993907279,\n",
       " 'count': 0.0006377904993907279,\n",
       " '27-months': 0.010218921742874648,\n",
       " 'course': 0.013371339322597426,\n",
       " 'histologically': 0.010218921742874648,\n",
       " 'confirmed,': 0.010218921742874648,\n",
       " 'stopped': 0.010218921742874648,\n",
       " 'months,': 0.010218921742874648,\n",
       " 'restarted': 0.010218921742874648,\n",
       " 'together': 0.012890355893727015,\n",
       " 'exemestane': 0.010218921742874648,\n",
       " 'During': 0.009679054179100139,\n",
       " 'normalization': 0.010218921742874648,\n",
       " 'transaminases,': 0.010218921742874648,\n",
       " 'improvement': 0.013371339322597426,\n",
       " 'her': 0.0,\n",
       " 'continued': 0.009729550745276566,\n",
       " '15': 0.010218921742874648,\n",
       " 'without': 0.004162922039154536,\n",
       " 'any': 0.0,\n",
       " 'reoccurrence': 0.010218921742874648,\n",
       " 'Nodular': 0.010218921742874648,\n",
       " 'suspected': 0.010218921742874648,\n",
       " 'year': 0.014145860827753985,\n",
       " 'signs': 0.010218921742874648,\n",
       " 'cirrhosis': 0.010218921742874648,\n",
       " 'Definitive': 0.010218921742874648,\n",
       " 'cessation': 0.010218921742874648,\n",
       " 'diagnosis': 0.010142476121583676,\n",
       " 'complete': 0.0071466835702359175,\n",
       " 'resolution': 0.010218921742874648,\n",
       " 'symptoms': 0.010218921742874648,\n",
       " 'generally': 0.014747812352339261,\n",
       " 'takes': 0.010218921742874648,\n",
       " 'Based': 0.010218921742874648,\n",
       " 'fundamental': 0.010218921742874648,\n",
       " 'studies,': 0.010218921742874648,\n",
       " 'probably': 0.011625526864212801,\n",
       " 'caused': 0.011153424250437662,\n",
       " '(DM1)': 0.010218921742874648,\n",
       " 'part': 0.013371339322597426,\n",
       " 'It': 0.011153424250437662,\n",
       " 'still': 0.011625526864212801,\n",
       " 'reintroduced': 0.0006377904993907279,\n",
       " 'induced': 0.008195830216196454,\n",
       " 'emtansine,': 0.010218921742874648,\n",
       " 'depriving': 0.010218921742874648,\n",
       " 'HER2-targeted': 0.010218921742874648,\n",
       " 'Only': 0.010218921742874648,\n",
       " 'having': 0.0,\n",
       " 'given': 0.010218921742874648,\n",
       " 'situation': 0.010218921742874648,\n",
       " 'over': 0.0,\n",
       " 'month': 0.010218921742874648,\n",
       " 'case,': 0.010218921742874648,\n",
       " 'complications': 0.007710274189062285,\n",
       " 'long': 0.010218921742874648,\n",
       " 'extent': 0.010218921742874648,\n",
       " 'TDM1-associated': 0.010218921742874648,\n",
       " 'prevalent': 0.008718970701010527,\n",
       " 'worldwide': 0.008718970701010527,\n",
       " 'leads': 0.008195830216196454,\n",
       " 'high': 0.008195830216196454,\n",
       " 'health-care': 0.008718970701010527,\n",
       " 'costs': 0.0,\n",
       " 'subtype': 0.008718970701010527,\n",
       " 'represents': 0.008718970701010527,\n",
       " '30%': 0.008718970701010527,\n",
       " 'cancers': 0.0,\n",
       " 'poor': 0.015184402281593685,\n",
       " 'therapies': 0.0,\n",
       " 'frequently': 0.008718970701010527,\n",
       " 'develop': 0.011625526864212801,\n",
       " 'require': 0.008718970701010527,\n",
       " 'pharmacological': 0.008718970701010527,\n",
       " 'change': 0.001279449521361085,\n",
       " 'biopsy': 0.0038383485640832546,\n",
       " 'minimally': 0.008718970701010527,\n",
       " 'invasive': 0.009467281837847648,\n",
       " 'easily': 0.008718970701010527,\n",
       " 'accessible': 0.008718970701010527,\n",
       " 'technique,': 0.008718970701010527,\n",
       " 'sensitivity': 0.007710274189062285,\n",
       " 'specificity,': 0.008718970701010527,\n",
       " 'detect': 0.008718970701010527,\n",
       " 'molecular': 0.008223518189264449,\n",
       " 'even': 0.008718970701010527,\n",
       " 'before': 0.0,\n",
       " 'onset': 0.007617001984175222,\n",
       " 'manifestations': 0.008718970701010527,\n",
       " 'thus': 0.008718970701010527,\n",
       " 'reduce': 0.008718970701010527,\n",
       " 'unnecessary': 0.008718970701010527,\n",
       " 'To': 0.007710274189062285,\n",
       " 'evaluate': 0.008195830216196454,\n",
       " 'cost-effectiveness': 0.008718970701010527,\n",
       " 'liquid': 0.007113422949266041,\n",
       " '(ctDNA': 0.012573750661249508,\n",
       " 'detection)': 0.007709559920477963,\n",
       " 'determine': 0.008718970701010527,\n",
       " 'women': 0.008718970701010527,\n",
       " 'economic': 0.008718970701010527,\n",
       " 'evaluation': 0.008718970701010527,\n",
       " 'decision': 0.008718970701010527,\n",
       " 'tree': 0.008718970701010527,\n",
       " 'modeling': 0.008718970701010527,\n",
       " 'deterministic': 0.008718970701010527,\n",
       " 'analyses': 0.008718970701010527,\n",
       " 'first': 0.008195830216196454,\n",
       " 'second': 0.008195830216196454,\n",
       " 'lines': 0.007617001984175222,\n",
       " '(trastuzumab,': 0.015184402281593685,\n",
       " 'pertuzumab,': 0.015184402281593685,\n",
       " 'docetaxel,': 0.008718970701010527,\n",
       " 'TDM1);': 0.008718970701010527,\n",
       " 'resistance;': 0.008718970701010527,\n",
       " 'outcomes;': 0.008718970701010527,\n",
       " 'specificity': 0.008718970701010527,\n",
       " 'tests': 0.008718970701010527,\n",
       " 'detecting': 0.008718970701010527,\n",
       " 'measured': 0.008718970701010527,\n",
       " 'quality-adjusted': 0.008718970701010527,\n",
       " 'life': 0.01327229236465226,\n",
       " '(QALY)': 0.008718970701010527,\n",
       " 'score,': 0.008718970701010527,\n",
       " 'databases': 0.008718970701010527,\n",
       " 'national': 0.008718970701010527,\n",
       " 'validity,': 0.008718970701010527,\n",
       " 'suppliers,': 0.008718970701010527,\n",
       " 'Colombian': 0.008718970701010527,\n",
       " 'Drug': 0.007617001984175222,\n",
       " 'Price': 0.008718970701010527,\n",
       " 'Information': 0.008718970701010527,\n",
       " '(SISMED),': 0.008718970701010527,\n",
       " 'local': 0.0033099192498625665,\n",
       " 'conventional': 0.009201068768494849,\n",
       " 'more': 0.0,\n",
       " 'expensive': 0.008718970701010527,\n",
       " 'less': 0.008718970701010527,\n",
       " 'effective': 0.015873599554807907,\n",
       " '(US': 0.008718970701010527,\n",
       " '$177,98535': 0.008718970701010527,\n",
       " '0533889206': 0.008718970701010527,\n",
       " 'QALY,': 0.008718970701010527,\n",
       " 'respectively)': 0.01056231694033966,\n",
       " 'incremental': 0.001279449521361085,\n",
       " 'cost': 0.0,\n",
       " 'US': 0.007617001984175222,\n",
       " '$7,33317': 0.008718970701010527,\n",
       " '000042256': 0.008718970701010527,\n",
       " 'QALY': 0.008718970701010527,\n",
       " 'relative': 0.008718970701010527,\n",
       " 'method': 0.008718970701010527,\n",
       " 'Including': 0.008718970701010527,\n",
       " 'considered': 0.010268847119406597,\n",
       " 'inapplicable': 0.008718970701010527,\n",
       " 'because': 0.0,\n",
       " 'Our': 0.008718970701010527,\n",
       " 'open': 0.008718970701010527,\n",
       " 'window': 0.008718970701010527,\n",
       " 'opportunity': 0.008718970701010527,\n",
       " 'implementation': 0.008718970701010527,\n",
       " 'ctDNA': 0.008718970701010527,\n",
       " 'testing': 0.009201068768494849,\n",
       " 'Colombia,': 0.008718970701010527,\n",
       " 'potentially': 0.008718970701010527,\n",
       " 'reducing': 0.007617001984175222,\n",
       " 'More': 0.008718970701010527,\n",
       " 'utility': 0.008718970701010527,\n",
       " 'test,': 0.008718970701010527,\n",
       " 'depending': 0.008718970701010527,\n",
       " 'financial': 0.008718970701010527,\n",
       " 'capacity': 0.008718970701010527,\n",
       " 'other': 0.0,\n",
       " 'countries': 0.008718970701010527,\n",
       " 'introduction': 0.009201068768494849,\n",
       " 'anthracycline-based': 0.0,\n",
       " 'regimens,': 0.009201068768494849,\n",
       " '5-year': 0.009201068768494849,\n",
       " 'rates': 0.013371339322597426,\n",
       " 'addition': 0.012890355893727015,\n",
       " 'receptor-2': 0.009201068768494849,\n",
       " '(HER2),': 0.009201068768494849,\n",
       " 'improvements': 0.011625526864212801,\n",
       " 'observed': 0.007710274189062285,\n",
       " 'among': 0.009679054179100139,\n",
       " 'Subsequently,': 0.009201068768494849,\n",
       " 'lapatinib,': 0.009201068768494849,\n",
       " 'orally': 0.009201068768494849,\n",
       " 'bioavailable': 0.009201068768494849,\n",
       " 'small': 0.009729550745276566,\n",
       " 'molecule': 0.009201068768494849,\n",
       " 'HER2-': 0.009201068768494849,\n",
       " 'EGFR/HER1-specific': 0.009201068768494849,\n",
       " 'tyrosine': 0.011625526864212801,\n",
       " 'kinase': 0.009467281837847648,\n",
       " 'inhibitor,': 0.009201068768494849,\n",
       " 'received': 0.009201068768494849,\n",
       " 'Food': 0.007617001984175222,\n",
       " 'Administration': 0.007617001984175222,\n",
       " '(FDA)': 0.009201068768494849,\n",
       " 'Then,': 0.009201068768494849,\n",
       " 'pertuzumab': 0.013371339322597426,\n",
       " '2012': 0.009201068768494849,\n",
       " 'ado-trastuzumab': 0.013371339322597426,\n",
       " '2013': 0.009679054179100139,\n",
       " 'elsewhere': 0.009201068768494849,\n",
       " 'mostly': 0.009201068768494849,\n",
       " 'naïve': 0.009201068768494849,\n",
       " 'trastuzumab-exposed': 0.009201068768494849,\n",
       " 'FDA': 0.008223518189264449,\n",
       " 'extended': 0.009201068768494849,\n",
       " 'adjuvant': 0.012890355893727015,\n",
       " 'basis': 0.009201068768494849,\n",
       " 'ExteNET': 0.009201068768494849,\n",
       " 'benefit': 0.01327229236465226,\n",
       " 'those': 0.0,\n",
       " 'triggered': 0.009201068768494849,\n",
       " 'them': 0.0,\n",
       " 'single': 0.009201068768494849,\n",
       " 'HER2-targeting': 0.015184402281593685,\n",
       " 'article,': 0.010268847119406597,\n",
       " 'we': 0.0,\n",
       " 'nonanthracycline-based': 0.009201068768494849,\n",
       " 'optimum': 0.009201068768494849,\n",
       " 'tumors': 0.011153424250437662,\n",
       " 'dramatically': 0.014145860827753985,\n",
       " 'improves': 0.0018167536411499668,\n",
       " 'irrespective': 0.0018167536411499668,\n",
       " 'anatomic': 0.014145860827753985,\n",
       " 'stage,': 0.014145860827753985,\n",
       " 'status': 0.014145860827753985,\n",
       " 'backbone': 0.006394607200622253,\n",
       " 'up': 0.0,\n",
       " '25%': 0.014145860827753985,\n",
       " 'recur': 0.014145860827753985,\n",
       " 'Here,': 0.014145860827753985,\n",
       " 'additional': 0.012890355893727015,\n",
       " 'modestly': 0.014145860827753985,\n",
       " 'disease-free': 0.011153424250437662,\n",
       " 'particularly': 0.015873599554807907,\n",
       " 'at': 0.0,\n",
       " 'highest': 0.006359148445504085,\n",
       " 'recurrence': 0.011060243637210216,\n",
       " 'Lack': 0.014145860827753985,\n",
       " 'pathologic': 0.012890355893727015,\n",
       " 'response': 0.015184402281593685,\n",
       " 'preoperative': 0.014145860827753985,\n",
       " 'targeted': 0.0,\n",
       " 'lack': 0.014145860827753985,\n",
       " 'pCR,': 0.014145860827753985,\n",
       " 'outcome': 0.011153424250437662,\n",
       " 'Preoperative': 0.014145860827753985,\n",
       " 'discussed': 0.01327229236465226,\n",
       " 'cm': 0.014145860827753985,\n",
       " 'Future': 0.014145860827753985,\n",
       " 'must': 0.014145860827753985,\n",
       " 'de-escalation': 0.014145860827753985,\n",
       " 'biomarkers': 0.014145860827753985,\n",
       " 'further': 0.0,\n",
       " 'tailored': 0.014145860827753985,\n",
       " 'Approximately': 0.010268847119406597,\n",
       " '30-50%': 0.013371339322597426,\n",
       " '(HER2)': 0.011153424250437662,\n",
       " '(BMs)': 0.013371339322597426,\n",
       " 'Brain': 0.013371339322597426,\n",
       " 'become': 0.011625526864212801,\n",
       " 'main': 0.013371339322597426,\n",
       " 'limitation': 0.013371339322597426,\n",
       " 'expectancy': 0.013371339322597426,\n",
       " 'half': 0.013371339322597426,\n",
       " 'die': 0.013371339322597426,\n",
       " 'Even': 0.008223518189264449,\n",
       " 'managed': 0.013371339322597426,\n",
       " 'curative': 0.013371339322597426,\n",
       " '(CNS)': 0.010268847119406597,\n",
       " 'usually': 0.011060243637210216,\n",
       " 'site': 0.008195830216196454,\n",
       " 'Local': 0.013371339322597426,\n",
       " 'surgery': 0.013371339322597426,\n",
       " 'essential': 0.013371339322597426,\n",
       " 'new': 0.008223518189264449,\n",
       " 'appear': 0.013371339322597426,\n",
       " 'contribute': 0.013371339322597426,\n",
       " 'significant': 0.015184402281593685,\n",
       " 'CNS': 0.010268847119406597,\n",
       " 'progresses': 0.013371339322597426,\n",
       " 'BM,': 0.013371339322597426,\n",
       " 'agents-trastuzumab': 0.013371339322597426,\n",
       " 'Despite': 0.013371339322597426,\n",
       " 'fatal': 0.011625526864212801,\n",
       " 'Usually,': 0.011625526864212801,\n",
       " 'receive': 0.011625526864212801,\n",
       " 'Most': 0.011625526864212801,\n",
       " 'innovative': 0.0,\n",
       " 'approaches': 0.009467281837847648,\n",
       " 'positioning': 0.011625526864212801,\n",
       " 'themselves': 0.0,\n",
       " 'resistant': 0.0,\n",
       " 'describe': 0.010268847119406597,\n",
       " 'aim,': 0.011625526864212801,\n",
       " 'via': 0.011625526864212801,\n",
       " 'Pubmed': 0.011625526864212801,\n",
       " 'made': 0.007617001984175222,\n",
       " 'inventory': 0.011625526864212801,\n",
       " 'abstracts': 0.011625526864212801,\n",
       " 'last': 0.011625526864212801,\n",
       " 'major': 0.011153424250437662,\n",
       " 'oncology': 0.011625526864212801,\n",
       " 'conferences': 0.011625526864212801,\n",
       " 'Further': 0.011625526864212801,\n",
       " 'changes': 0.011625526864212801,\n",
       " 'occur': 0.011625526864212801,\n",
       " 'next': 0.011625526864212801,\n",
       " 'decade': 0.011625526864212801,\n",
       " 'mainly': 0.01056231694033966,\n",
       " 'driven': 0.011625526864212801,\n",
       " 'fact': 0.011625526864212801,\n",
       " 'mainstay': 0.011625526864212801,\n",
       " '(pertuzumab': 0.011625526864212801,\n",
       " 'TDM-1)': 0.011625526864212801,\n",
       " 'confer': 0.011625526864212801,\n",
       " 'prolonged': 0.013371339322597426,\n",
       " '(56': 0.011625526864212801,\n",
       " 'months)': 0.011625526864212801,\n",
       " 'being': 0.0,\n",
       " 'subset': 0.011625526864212801,\n",
       " 'Thus,': 0.008195830216196454,\n",
       " 'there': 0.0,\n",
       " 'urgent': 0.011625526864212801,\n",
       " 'new,': 0.011625526864212801,\n",
       " 'whose': 0.011625526864212801,\n",
       " 'potent': 0.011153424250437662,\n",
       " 'Several': 0.011625526864212801,\n",
       " 'conjugates,': 0.011625526864212801,\n",
       " 'bispecific': 0.009729550745276566,\n",
       " 'antibodies': 0.0011288626677624252,\n",
       " 'generation': 0.011625526864212801,\n",
       " 'inhibitor': 0.009729550745276566,\n",
       " '(TKIs)': 0.011625526864212801,\n",
       " 'hold': 0.011625526864212801,\n",
       " 'promise': 0.011625526864212801,\n",
       " 'assessed': 0.011625526864212801,\n",
       " 'Historically,': 0.015873599554807907,\n",
       " 'very': 0.0,\n",
       " 'limited': 0.013371339322597426,\n",
       " 'focuses': 0.015184402281593685,\n",
       " 'important': 0.008195830216196454,\n",
       " 'considerations': 0.015873599554807907,\n",
       " 'ongoing': 0.012890355893727015,\n",
       " 'evaluating': 0.015873599554807907,\n",
       " 'For': 0.008223518189264449,\n",
       " 'hormone': 0.014747812352339261,\n",
       " 'receptor-positive': 0.015873599554807907,\n",
       " 'metastases,': 0.013371339322597426,\n",
       " 'endocrine': 0.015873599554807907,\n",
       " 'CDK4/6': 0.015873599554807907,\n",
       " 'inhibitors': 0.008223518189264449,\n",
       " 'explored': 0.012890355893727015,\n",
       " 'number': 0.021164799406410542,\n",
       " 'lapatinib-capecitabine,': 0.015873599554807907,\n",
       " 'neratinib-': 0.015873599554807907,\n",
       " 'tucatinib-based': 0.015873599554807907,\n",
       " 'combinations': 0.015873599554807907,\n",
       " 'Triple-negative': 0.015873599554807907,\n",
       " 'respond': 0.015873599554807907,\n",
       " 'Although': 0.011153424250437662,\n",
       " 'much': 0.015873599554807907,\n",
       " 'progress': 0.015184402281593685,\n",
       " ...}"
      ]
     },
     "execution_count": 59,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "global_d"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "metadata": {
    "collapsed": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'Third-line': 0.0, 'treatment': 0.0, 'HER2-positive': 0.0, 'advanced': 0.0, 'breast': 0.0, 'cancer:': 0.0, 'From': 0.0, 'standard': 0.0, \"Pandora's\": 0.0, 'box': 0.0}\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "({'Third-line': 0.0,\n",
       "  'treatment': 0.0,\n",
       "  'of': 0.0,\n",
       "  'HER2-positive': 0.0,\n",
       "  'advanced': 0.0,\n",
       "  'breast': 0.0,\n",
       "  'cancer:': 0.0,\n",
       "  'From': 0.0,\n",
       "  'no': 0.0,\n",
       "  'standard': 0.0},\n",
       " {'Third-line': 0.0,\n",
       "  'treatment': 0.0,\n",
       "  'of': 0.0,\n",
       "  'HER2-positive': 0.0,\n",
       "  'advanced': 0.0,\n",
       "  'breast': 0.0,\n",
       "  'cancer:': 0.0,\n",
       "  'From': 0.0,\n",
       "  'no': 0.0,\n",
       "  'standard': 0.0,\n",
       "  'to': 0.0,\n",
       "  'a': 0.0,\n",
       "  \"Pandora's\": 0.0,\n",
       "  'box': 0.0})"
      ]
     },
     "execution_count": 55,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "get_keywords(\"Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box.\", k=10)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "metadata": {
    "collapsed": true
   },
   "outputs": [
    {
     "ename": "NameError",
     "evalue": "name 'tt3' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mNameError\u001b[0m                                 Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-50-833d5bdcc38c>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m\u001b[0m\n\u001b[1;32m      3\u001b[0m \u001b[0mresult\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'keywordVtitle_b'\u001b[0m\u001b[0;34m]\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mtt1\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      4\u001b[0m \u001b[0mresult\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'keywordVtitle_sbs'\u001b[0m\u001b[0;34m]\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mtt2\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m----> 5\u001b[0;31m \u001b[0mresult\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'keywordVtitle_sem'\u001b[0m\u001b[0;34m]\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mtt3\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m      6\u001b[0m \u001b[0mresult\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'keywordVabstract_b'\u001b[0m\u001b[0;34m]\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mtabst1\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m      7\u001b[0m \u001b[0mresult\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'keywordVabstract_sbs'\u001b[0m\u001b[0;34m]\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mtabst2\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;31mNameError\u001b[0m: name 'tt3' is not defined"
     ]
    }
   ],
   "source": [
    "result = pd.DataFrame(columns = ['key', 'keywordVtitle_b','keywordVtitle_sbs', 'keywordVtitle_sem', 'keywordVabstract_b','keywordVabstract_sbs', 'keywordVabstract_sem', 'nsamples'])\n",
    "result['key']  = tn\n",
    "result['keywordVtitle_b'] = tt1\n",
    "result['keywordVtitle_sbs'] = tt2\n",
    "result['keywordVtitle_sem'] = tt3\n",
    "result['keywordVabstract_b'] = tabst1\n",
    "result['keywordVabstract_sbs'] = tabst2\n",
    "result['keywordVabstract_sem'] = tabst3\n",
    "result['nsamples'] = tc"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>key</th>\n",
       "      <th>keywordVtitle_b</th>\n",
       "      <th>keywordVtitle_sbs</th>\n",
       "      <th>keywordVabstract_b</th>\n",
       "      <th>keywordVabstract_sbs</th>\n",
       "      <th>nsamples</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>tdm1</td>\n",
       "      <td>0.112037</td>\n",
       "      <td>0.669167</td>\n",
       "      <td>0.055952</td>\n",
       "      <td>0.377976</td>\n",
       "      <td>28</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>genome wide association study</td>\n",
       "      <td>0.071084</td>\n",
       "      <td>0.761368</td>\n",
       "      <td>0.046135</td>\n",
       "      <td>0.355531</td>\n",
       "      <td>3184</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>progression free survival</td>\n",
       "      <td>0.120741</td>\n",
       "      <td>0.882582</td>\n",
       "      <td>0.067391</td>\n",
       "      <td>0.445179</td>\n",
       "      <td>3607</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>hormone therapy</td>\n",
       "      <td>0.103923</td>\n",
       "      <td>0.853283</td>\n",
       "      <td>0.059205</td>\n",
       "      <td>0.378839</td>\n",
       "      <td>3280</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>overall survival</td>\n",
       "      <td>0.107009</td>\n",
       "      <td>0.880749</td>\n",
       "      <td>0.062405</td>\n",
       "      <td>0.399481</td>\n",
       "      <td>3557</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>disease free survival</td>\n",
       "      <td>0.101470</td>\n",
       "      <td>0.926997</td>\n",
       "      <td>0.055107</td>\n",
       "      <td>0.442631</td>\n",
       "      <td>3551</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>radiation</td>\n",
       "      <td>0.089672</td>\n",
       "      <td>0.881630</td>\n",
       "      <td>0.051175</td>\n",
       "      <td>0.389246</td>\n",
       "      <td>3335</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>chemotherapy</td>\n",
       "      <td>0.107750</td>\n",
       "      <td>0.892227</td>\n",
       "      <td>0.060680</td>\n",
       "      <td>0.414168</td>\n",
       "      <td>3626</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>neratinib</td>\n",
       "      <td>0.128151</td>\n",
       "      <td>0.735046</td>\n",
       "      <td>0.074891</td>\n",
       "      <td>0.383719</td>\n",
       "      <td>201</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>pertuzumab</td>\n",
       "      <td>0.115225</td>\n",
       "      <td>0.787713</td>\n",
       "      <td>0.104231</td>\n",
       "      <td>0.391004</td>\n",
       "      <td>555</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>pathologic complete response</td>\n",
       "      <td>0.078563</td>\n",
       "      <td>0.907833</td>\n",
       "      <td>0.056481</td>\n",
       "      <td>0.485851</td>\n",
       "      <td>1545</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>surgery</td>\n",
       "      <td>0.096846</td>\n",
       "      <td>0.986873</td>\n",
       "      <td>0.053983</td>\n",
       "      <td>0.436597</td>\n",
       "      <td>3170</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>polymorphism</td>\n",
       "      <td>0.092430</td>\n",
       "      <td>0.722382</td>\n",
       "      <td>0.065082</td>\n",
       "      <td>0.396130</td>\n",
       "      <td>3615</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>neoadjuvant</td>\n",
       "      <td>0.087158</td>\n",
       "      <td>0.967743</td>\n",
       "      <td>0.049471</td>\n",
       "      <td>0.477578</td>\n",
       "      <td>3214</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>adjuvant</td>\n",
       "      <td>0.100213</td>\n",
       "      <td>0.908498</td>\n",
       "      <td>0.056118</td>\n",
       "      <td>0.405715</td>\n",
       "      <td>3662</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>trastuzumab</td>\n",
       "      <td>0.118542</td>\n",
       "      <td>0.811807</td>\n",
       "      <td>0.092071</td>\n",
       "      <td>0.397680</td>\n",
       "      <td>3048</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>polygenic risk score</td>\n",
       "      <td>0.078099</td>\n",
       "      <td>0.733832</td>\n",
       "      <td>0.049238</td>\n",
       "      <td>0.345385</td>\n",
       "      <td>1350</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>0.098544</td>\n",
       "      <td>0.908281</td>\n",
       "      <td>0.053532</td>\n",
       "      <td>0.385232</td>\n",
       "      <td>3480</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                              key  keywordVtitle_b  keywordVtitle_sbs  \\\n",
       "0                            tdm1         0.112037           0.669167   \n",
       "1   genome wide association study         0.071084           0.761368   \n",
       "2       progression free survival         0.120741           0.882582   \n",
       "3                 hormone therapy         0.103923           0.853283   \n",
       "4                overall survival         0.107009           0.880749   \n",
       "5           disease free survival         0.101470           0.926997   \n",
       "6                       radiation         0.089672           0.881630   \n",
       "7                    chemotherapy         0.107750           0.892227   \n",
       "8                       neratinib         0.128151           0.735046   \n",
       "9                      pertuzumab         0.115225           0.787713   \n",
       "10   pathologic complete response         0.078563           0.907833   \n",
       "11                        surgery         0.096846           0.986873   \n",
       "12                   polymorphism         0.092430           0.722382   \n",
       "13                    neoadjuvant         0.087158           0.967743   \n",
       "14                       adjuvant         0.100213           0.908498   \n",
       "15                    trastuzumab         0.118542           0.811807   \n",
       "16           polygenic risk score         0.078099           0.733832   \n",
       "17                  Breast Cancer         0.098544           0.908281   \n",
       "\n",
       "    keywordVabstract_b  keywordVabstract_sbs  nsamples  \n",
       "0             0.055952              0.377976        28  \n",
       "1             0.046135              0.355531      3184  \n",
       "2             0.067391              0.445179      3607  \n",
       "3             0.059205              0.378839      3280  \n",
       "4             0.062405              0.399481      3557  \n",
       "5             0.055107              0.442631      3551  \n",
       "6             0.051175              0.389246      3335  \n",
       "7             0.060680              0.414168      3626  \n",
       "8             0.074891              0.383719       201  \n",
       "9             0.104231              0.391004       555  \n",
       "10            0.056481              0.485851      1545  \n",
       "11            0.053983              0.436597      3170  \n",
       "12            0.065082              0.396130      3615  \n",
       "13            0.049471              0.477578      3214  \n",
       "14            0.056118              0.405715      3662  \n",
       "15            0.092071              0.397680      3048  \n",
       "16            0.049238              0.345385      1350  \n",
       "17            0.053532              0.385232      3480  "
      ]
     },
     "execution_count": 49,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "result"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Correlation is defined the average of count of intersection of number of keywords between the actual keywords provided by the authors over complete number of samples."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "def simple_match(authorkeys, manualkeys):\n",
    "    return (len(authorkeys & manualkeys)/len(authorkeys))\n",
    "\n",
    "def substring_match(authorkeys, manualkeys):\n",
    "    c = 0\n",
    "    for ak in authorkeys:\n",
    "        for mk in manualkeys:\n",
    "            print(ak,mk,int(ak.find(mk)!= -1))\n",
    "            c += int(ak.find(mk)!= -1)\n",
    "            '''\n",
    "            if (ak.find(mk)!= -1):\n",
    "                if mk not in ak.split(' '):\n",
    "                    c -= 1\n",
    "            #print(ak,mk, int(ak.find(mk)!= -1))\n",
    "            '''\n",
    "    \n",
    "    return c/len(authorkeys)\n",
    "    \n",
    "def semantic_match(authorkeys, manualkeys, tokenizer, model):\n",
    "    embdict = dict()\n",
    "    \n",
    "    for k in authorkeys | manualkeys:\n",
    "        inputs = tokenizer.encode_plus(k)\n",
    "        ids = torch.tensor(inputs['input_ids']).unsqueeze(0)\n",
    "        mask = torch.tensor(inputs['attention_mask']).unsqueeze(0)\n",
    "        with torch.no_grad():\n",
    "            embed = model(ids)[0]\n",
    "        #print(embed.shape)\n",
    "        final = torch.mean(embed[:, 1:-1], dim=1).squeeze().detach().numpy()\n",
    "        \n",
    "        embdict[k] = final, np.linalg.norm(final)\n",
    "    \n",
    "    c= 0\n",
    "    for ak in authorkeys:\n",
    "        a = 0\n",
    "        for mk in manualkeys:\n",
    "            iak, imk = embdict[ak], embdict[mk]\n",
    "            a += iak[0].dot(imk[0])/(iak[1]*imk[1])\n",
    "            #print(ak,mk,  iak[0].dot(imk[0])/(iak[1]*imk[1]))\n",
    "        c += a/len(manualkeys)\n",
    "        \n",
    "        \n",
    "    \n",
    "    return c/len(authorkeys)\n",
    "    \n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Some weights of the model checkpoint at allenai/scibert_scivocab_cased were not used when initializing BertModel: ['cls.predictions.transform.LayerNorm.weight', 'cls.seq_relationship.weight', 'cls.predictions.decoder.weight', 'cls.predictions.decoder.bias', 'cls.predictions.transform.dense.weight', 'cls.predictions.transform.LayerNorm.bias', 'cls.predictions.bias', 'cls.seq_relationship.bias', 'cls.predictions.transform.dense.bias']\n",
      "- This IS expected if you are initializing BertModel from the checkpoint of a model trained on another task or with another architecture (e.g. initializing a BertForSequenceClassification model from a BertForPreTraining model).\n",
      "- This IS NOT expected if you are initializing BertModel from the checkpoint of a model that you expect to be exactly identical (initializing a BertForSequenceClassification model from a BertForSequenceClassification model).\n"
     ]
    }
   ],
   "source": [
    "import torch\n",
    "import numpy as np\n",
    "from transformers import *\n",
    "\n",
    "tokenizer = AutoTokenizer.from_pretrained('allenai/scibert_scivocab_cased')\n",
    "model = AutoModel.from_pretrained('allenai/scibert_scivocab_cased')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 102,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['post', '-', 'neo', '##adjuvant']"
      ]
     },
     "execution_count": 102,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "tokenizer.tokenize('post-neoadjuvant')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "#authorkeys =  {'trastuzumab deruxtecan', 'tucatinib', 'ds8201a', 'her2\\\\xa0+', 'breast cancer', 'third line'} \n",
    "#manualkeys = {'from', 'of', 'breast', 'cancer:', 'standard', 'her2-positive', 'third-line', 'no', 'advanced', 'treatment'}\n",
    "\n",
    "authorkeys= {'t‑dm1', 'radiochemotherapy', 'radiotherapy', 'capecitabine', 'breast cancer'} \n",
    "manualkeys= {'with', 'emtansine', 'and', 'trastuzumab', 'post-neoadjuvant', 'treatment', 'in', 'breast', 'cancer', 'capecitabine'}\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "capecitabine in 1\n",
      "capecitabine treatment 0\n",
      "capecitabine capecitabine 1\n",
      "capecitabine breast 0\n",
      "capecitabine with 0\n",
      "capecitabine and 0\n",
      "capecitabine trastuzumab 0\n",
      "capecitabine cancer 0\n",
      "capecitabine emtansine 0\n",
      "capecitabine post-neoadjuvant 0\n",
      "radiotherapy in 0\n",
      "radiotherapy treatment 0\n",
      "radiotherapy capecitabine 0\n",
      "radiotherapy breast 0\n",
      "radiotherapy with 0\n",
      "radiotherapy and 0\n",
      "radiotherapy trastuzumab 0\n",
      "radiotherapy cancer 0\n",
      "radiotherapy emtansine 0\n",
      "radiotherapy post-neoadjuvant 0\n",
      "radiochemotherapy in 0\n",
      "radiochemotherapy treatment 0\n",
      "radiochemotherapy capecitabine 0\n",
      "radiochemotherapy breast 0\n",
      "radiochemotherapy with 0\n",
      "radiochemotherapy and 0\n",
      "radiochemotherapy trastuzumab 0\n",
      "radiochemotherapy cancer 0\n",
      "radiochemotherapy emtansine 0\n",
      "radiochemotherapy post-neoadjuvant 0\n",
      "breast cancer in 0\n",
      "breast cancer treatment 0\n",
      "breast cancer capecitabine 0\n",
      "breast cancer breast 1\n",
      "breast cancer with 0\n",
      "breast cancer and 0\n",
      "breast cancer trastuzumab 0\n",
      "breast cancer cancer 1\n",
      "breast cancer emtansine 0\n",
      "breast cancer post-neoadjuvant 0\n",
      "t‑dm1 in 0\n",
      "t‑dm1 treatment 0\n",
      "t‑dm1 capecitabine 0\n",
      "t‑dm1 breast 0\n",
      "t‑dm1 with 0\n",
      "t‑dm1 and 0\n",
      "t‑dm1 trastuzumab 0\n",
      "t‑dm1 cancer 0\n",
      "t‑dm1 emtansine 0\n",
      "t‑dm1 post-neoadjuvant 0\n",
      "subs: 0.8\n"
     ]
    }
   ],
   "source": [
    "#print(f'simple: {simple_match(authorkeys, manualkeys)}')\n",
    "print(f'subs: {substring_match(authorkeys, manualkeys)}')\n",
    "#print(f'semantic: {semantic_match(authorkeys, manualkeys, tokenizer, model)}')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 108,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "capecitabine post-neoadjuvant 0\n",
      "capecitabine breast 0\n",
      "capecitabine cancer 0\n",
      "capecitabine trastuzumab 0\n",
      "capecitabine capecitabine 1\n",
      "capecitabine and 0\n",
      "capecitabine in 1\n",
      "capecitabine with 0\n",
      "capecitabine emtansine 0\n",
      "capecitabine treatment 0\n",
      "breast cancer post-neoadjuvant 0\n",
      "breast cancer breast 1\n",
      "breast cancer cancer 1\n",
      "breast cancer trastuzumab 0\n",
      "breast cancer capecitabine 0\n",
      "breast cancer and 0\n",
      "breast cancer in 0\n",
      "breast cancer with 0\n",
      "breast cancer emtansine 0\n",
      "breast cancer treatment 0\n",
      "radiochemotherapy post-neoadjuvant 0\n",
      "radiochemotherapy breast 0\n",
      "radiochemotherapy cancer 0\n",
      "radiochemotherapy trastuzumab 0\n",
      "radiochemotherapy capecitabine 0\n",
      "radiochemotherapy and 0\n",
      "radiochemotherapy in 0\n",
      "radiochemotherapy with 0\n",
      "radiochemotherapy emtansine 0\n",
      "radiochemotherapy treatment 0\n",
      "radiotherapy post-neoadjuvant 0\n",
      "radiotherapy breast 0\n",
      "radiotherapy cancer 0\n",
      "radiotherapy trastuzumab 0\n",
      "radiotherapy capecitabine 0\n",
      "radiotherapy and 0\n",
      "radiotherapy in 0\n",
      "radiotherapy with 0\n",
      "radiotherapy emtansine 0\n",
      "radiotherapy treatment 0\n",
      "t‑dm1 post-neoadjuvant 0\n",
      "t‑dm1 breast 0\n",
      "t‑dm1 cancer 0\n",
      "t‑dm1 trastuzumab 0\n",
      "t‑dm1 capecitabine 0\n",
      "t‑dm1 and 0\n",
      "t‑dm1 in 0\n",
      "t‑dm1 with 0\n",
      "t‑dm1 emtansine 0\n",
      "t‑dm1 treatment 0\n",
      "subs: 0.6\n"
     ]
    }
   ],
   "source": [
    "print(f'subs: {substring_match(authorkeys, manualkeys)}')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.10"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
